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ABSTRACT 
The formation of granulomas at the site of antigen presentation in both tuberculosis and 
sarcoidosis is an essential component of host immunity for controlling inflammation. 
Granuloma formation is a complex process that also requires recruitment and activation of 
lymphocytes and macrophages to the site of infection and arrangement into a granuloma. It 
is dependant on the activation of especially IFNγ secreting CD4+ T cells, resulting in a Th1 
profile. However, it is suggested that a persistently high IFNγ is responsible for the damage 
caused by granulomatous disease and that moderating cytokines, resulting in a Th0 profile, 
are necessary to down-regulate the IFNγ response to more appropriate levels later in the 
disease process, after the antigen has been effectively contained. 
I propose that:  “Cytokine profiles determine clinical and histopathological phenotypes of 
disease. This thesis tests the hypothesis that it will be reflected by cytokine expression 
profiles in granulomas in different forms of tuberculosis and in sarcoidosis.” To examine 
this, biopsy tissue was obtained from patients with pulmonary cavitary tuberculosis, pleural 
tuberculosis in HIV sero-negative and sero-positive patients, and sarcoidosis. The diagnosis 
of tuberculosis or sarcoidosis was confirmed, granulomas were characterised as necrotic or 
non-necrotic, sarcoidosis cases were graded histologically and in situ hybridisation was 
performed for IL-12-, IFNγ-, TNFα- and IL-4-mRNA. 
  
In all patients with pleural tuberculosis, a Th0 profile was noted, while necrotic granulomas 
were more evident in HIV positive than HIV negative patients.  There was a clear 
association between TNFα and necrosis in tuberculous granulomas that may be ascribed to 
the increased apoptotic activity of TNFα.  An increase in IFNγ correlated with an increase 
in necrosis, supporting the theory that high IFNγ levels later in disease is detrimental. This 
effect may be enhanced by a strong presence of TNFα positive cells. An increase in both 
Th1 and Th2 cytokine mRNA in HIV positive patients supports the theory that an 
overproduction of cytokines may be a mechanism to compensate for the failure of another 
immune effector mechanism. Findings in pulmonary tuberculosis were similar to those in 
pleural tuberculosis.   
In all sarcoidosis cases the presence of a very strong Th1 and TNFα, but no Th0 response 
was confirmed. None of the differences in either the histological grading, or the clinical 
outcome of patients were reflected in the cytokine profile. It is possible that this profile 
does not reflect the histological grade of disease or that it may reflect various stages of 
disease. These findings support the theory that a strong Th1 presence later in disease, in 
conjunction with TNFα may induce fibrosis, as most of these cases showed signs of at least 
focal fibrosis.  
Numerous aspects, including a T helper response are involved in granulomatous 
inflammation. The earlier dogma of good, beneficial (Th1) versus evil, detrimental (Th2), 
is an oversimplification of a very complex process. It is clear that the effect of a cytokine 
depends at least partially on the stage of disease. The balance between the various 
cytokines, and the levels of these cytokines contribute to their role in resolution or disease 
progression.  An early, pure Th1 response may be beneficial if effectively clearing the 
granuloma-inducing antigen. At this stage, a Th2 presence will be harmful as clearing of 
the antigen will not be as effective. In chronic disease where failure to remove the antigen 
results in progression of granulomas with subsequent necrosis and/or fibrosis, a pro-
inflammatory Th1 response may be detrimental and minimising of this effect is needed. An 
overly strong presence of the various cytokines may also be detrimental, while lower levels 
will be beneficial.   
  4 
ABSTRAK 
Die vorming van granulome by die plek waar die antigeen presenteer word in beide 
tuberkulose en sarkoïedose is ‘n noodsaaklike komponent van die gasheer immuniteit in die 
beheer van inflammasie. Granuloomvorming is ‘n komplekse proses wat onder andere 
werwing en aktivering van limfosiete en makrofae na die plek van infeksie en rangskikking 
in ‘n granuloom insluit. Dit is afhanklik van aktivering van veral IFNγ sekreterende CD4+ 
T selle, wat lei tot ‘n Th1 respons. Dit is egter moontlik dat persisterende hoë IFNγ 
verantwoordelik is vir die skade veroorsaak deur granulomateuse siekte en dat 
modererende sitokiene, wat lei tot ‘n Th0 profiel, nodig is om IFNγ af te reguleer na 
aanvaarbare vlakke later in die siekteproses, sodra die antigeen onder beheer is.  
Ek postuleer dat: “sitokien profiele die kliniese en histopatologiese fenotipes van siekte 
bepaal. Hierdie tesis toets die hipotese dat dit reflekteer sal word deur die sitokien profiele 
in granulome in verskillende vorms van tuberkulose en sarkoïedose”. Om dit te ondersoek 
is weefsel biopsies verkry van pasiënte met holtevormende long tuberkulose, pleurale 
tuberkulose in HIV sero-negatiewe en positiewe pasiënte en sarkoïedose. Die diagnose van 
tuberkulose of sarkoïedose is bevestig, granulome is geklassifiseer as nekroties of nie-
nekroties, sarkoïedose gevalle is histologies gegradeer en in situ hibridisasie is gedoen vir 
IL-12-, IFNγ-, TNFα- en IL-4-mRNA.    
‘n Th0 profiel is bespeur in alle pleurale tuberkulose pasiënte en daar is meer nekrotiese 
granulome in HIV positiewe as HIV negatiewe pasiënte. Daar is ‘n duidelike assosiasie 
tussen TNFα en nekrose in tuberkuleuse granulome, wat toegeskryf mag word aan 
verhoogde apoptotiese aktiwiteit van TNFα. ‘n Toename in IFNγ korreleer met ‘n toename 
in nekrose, wat die teorie ondersteun dat hoë vlakke van IFNγ later in die siekteproses 
nadelig kan wees. Hierdie effek mag versterk word deur die sterk teenwoordigheid van 
TNFα positiewe selle. ‘n Toename in Th1 en Th2 sitokien mRNA in HIV positiewe 
pasiënte ondersteun die teorie dat die oorproduksie van sitokiene ‘n meganisme is om te 
kompenseer vir die versaking van ‘n ander immuun effektor meganisme. Soortgelyke 
bevindings word in die long tuberkulose gevalle gesien.  
‘n Sterk Th1 en TNFα respons, met ‘n afwesige Th0 respons is in al die sarkoïedose 
gevalle gesien. Geen van die verskille in histologiese gradering of kliniese uitkoms is 
gereflekteer in die sitokien profiel nie. Dit is moontlik dat hierdie profiel nie die 
histologiese graad reflekteer nie, of dat verskillende fases van die siekte gereflekteer word. 
Hierdie bevindinge ondersteun die teorie dat ‘n sterk Th1 profiel, later in siekte, tesame 
met TNFα fibrose kan induseer, aangesien meeste van die gevalle ten minste fokale fibrose 
getoon het.  
Verkeie aspekte, insluitende ‘n T helper respons, is betrokke in granulomateuse 
inflammasie. Die vroeëre dogma van goed, voordelig (Th1) teenoor kwaad, nadelig (Th2) 
is ‘n oorvereenvoudiging van ‘n baie komplekse proses. Dit is duidelik dat die effek van ‘n 
sitokien ten minste deels berus op die stadium van siekte. Die balans tussen die 
verskillende sitokiene en die vlakke van hierdie sitokiene dra by tot hulle rol in resolusie of 
progressie van siekte. ‘n Suiwer Th1 respons vroeg in siekte is waarskynlik voordelig 
indien die granuloom-induserende antigeen verwyder word. Op hierdie stadium sal ‘n Th2 
teenwoordigheid nadelig wees en antigeen verwydering sal nie so effektief wees nie. In 
chroniese siekte, waar die onvermoë om die antigeen te verwyder lei tot progressie van 
granulome met gevolglike nekrose en/of fibrose, mag ‘n pro-inflammatoriese Th1 respons 
nadelig wees en die verlangde effek verdun. ‘n Oormatige sterk teenwoordigheid van die 
spektrum van sitokiene mag ook nadelig wees, terwyl laer vlakke voordelig kan wees. 
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Our imagination loves to be filled with an object or to grasp at 
anything that is too big for it's capacity. We are flung into a pleasing 
astonishment at such unbounded views and feel a delightful stillness 
and amazement in the soul at the apprehension of them.  
Joseph Addison (1672 - 1719), 1712 
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CYTOKINES AND TUBERCULOSIS: 
An Investigation of Tuberculous Lung Tissue and a Comparison with Sarcoidosis 
 
1. Literature Review 
1.1 Introduction 
Defense against micro-organisms is mediated by the early reactions of innate immunity 
in a previously unexposed/unsensitised individual, or the later response of adaptive 
immunity in a previously sensitised individual. Innate immunity is not specific and 
consists of cellular and biochemical defenses that exist even before infection and are 
ready to respond rapidly to infections3,4.    
 
In contrast, adaptive immunity is acquired by exposure to infective agents and increases 
with each successive exposure to the same antigen. Adaptive immunity is exquisitely 
specific and has the ability to remember and respond more vigorously to subsequent 
exposures4. There are two types of adaptive immunity, called humoral immunity and 
cell-mediated immunity5.  Cell-mediated immunity (CMI) is mediated by T 
lymphocytes and aimed at intra-cellular micro-organisms, such as viruses and 
mycobacteria that survive within phagocytic cells, like macrophages, or infect non-
phagocytic cells.  The function of macrophages is to ingest and kill micro-organisms.  
Many organisms have developed defense mechanisms that help them survive and even 
replicate in macrophages and the function of CMI is to enhance the microbiocidal 
effect of macrophages and eradicate the organism.  
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Adaptive immunity has a number of fundamental properties that reflect the properties 
of the lymphocytes that mediate the responses. These are6,7: 
 
1.  Specificity – distinct antigens elicit specific responses. 
2.  Diversity – enables the immune system to respond to a large variety of antigens. 
3.  Memory – leads to enhanced responses to repeated exposures to the same antigens. 
4.  Specialisation – generates responses that are optimal for defense against different 
types of micro-organisms.  
5.  Self-limitation – after eliminating the antigen, the immune system returns to a 
resting state until the next exposure.  
6.  Non-reactivity to self – prevents injury to the host during these responses.  
Abnormalities in this process for instance lead to the so-called auto-immune diseases, 
allergies infections and tumours.  
 
Granulomatous inflammation is a distinctive pattern of chronic inflammation and 
adaptive immunity, and the granuloma is the hallmark of many human diseases of great 
significance, the most important of which must be tuberculosis8,9. Its formation is 
firmly linked to the type IV (delayed type) hypersensitivity reaction (DTH), which is a 
form of adaptive cell- mediated immunity that is mediated by activated T lymphocytes 
and their products, called cytokines.  Recognition of granulomatous inflammation on 
histology is very important because of the fairly limited number of conditions (table 1) 
that give rise to granulomas and the clinical significance of these diagnoses.  
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Table 1: Examples of granulomatous inflammation10 
Infectious Mycobacteria 
 
Other bacteria 
 
Fungi 
 
Spirochetes 
Parasites, larvae, eggs, worms 
Tuberculosis, leprosy, atypical 
mycobacteria 
Cat-scratch disease, brucellosis, 
meliodosis 
Cryptococcosis, candidiasis, 
aspergillosis 
Syphilis 
Foreign 
bodies/particles 
Endogenous 
 
Exogenous  
 
Keratin, necrotic bone, cholesterol 
crystals, sodium urate 
Tattoos, talc, silica, suture 
material, oils, silicone, thorns, 
splinters 
Hypersensitivity pneumonitis 
Chemicals   Beryllium 
Drugs   Allopurinol, phenylbutazone, 
sulphonamides 
Idiopathic 
 
 Sarcoidosis  
Wegener’s granulomatosis 
Crohn’s disease  
Neoplasia Lymphomas Hodgkin’s lymphoma 
 
 
1.1.1 Definition of a Granuloma 
A granuloma is defined morphologically as follows: a microscopic aggregation of 
epithelioid (activated) macrophages, usually surrounded by a collar of lymphocytes 
(fig. 1)11.  Despite the fact that granulomas in specific diseases occasionally have a 
specific histological appearance, this is usually not pathognomonic of a particular 
disease and additional investigations are required to determine the exact cause of the 
granulomatous disease12.    
 
 
1.1.2 The Cells Involved in Granuloma Formation 
Two main cell types are involved in an immunogenic granuloma, namely antigen 
presenting cells and T lymphocytes. 
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1.1.2.1 Antigen presenting cells (APCs) 
Antigen presenting cells are specialised to capture and process microbial and other 
antigens, present them to lymphocytes, and provide signals that stimulate proliferation 
and differentiation of lymphocytes13. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: An example of a classical granuloma.  
 The granulomas contain all the cellular components required, as described in the text. Epithelioid 
macrophages are present in the centre and some multi-nucleated giant cells can be seen. The central area 
is surrounded by lymphocytes. Granuloma circled in black. Haematoxylin and eosin (H + E) stain14.  
X200 magnification  
 
1.1.2.1.1  Macrophages 
The macrophage is central in chronic inflammation because of the vast number of 
substances an activated macrophage can produce13.  It forms part of the mononuclear 
phagocyte system (MNPS), arising from a common bone marrow precursor.  The 
MNPS consists of blood monocytes and tissue macrophages. Tissue macrophages are 
scattered in connective tissue or clustered in organs such as the liver (Kupffer cells), 
spleen, lymph nodes (sinus histiocytes) and lungs (alveolar macrophages) and results 
Epithelioid 
macrophages 
Multi-nucleated 
giant cells 
Lymphocytes 
  20 
from blood monocytes (with a half-life of about one day) migrating into various tissues 
to transform into macrophages with a half-life of months.  This whole process is 
regulated by a variety of growth and differentiation factors, cytokines, adhesion 
molecules and cellular interactions13,15.  
 
Macrophages are primarily phagocytic cells, but have the potential to be activated, 
resulting in increased cell size, resulting in an epithelioid appearance. Lysosomal 
enzyme levels and metabolism are increased and the cells can then more effectively 
phagocytose and kill ingested organisms. In addition, more MHC class II molecules are 
expressed on the surface. This facilitates antigen presentation as CD4+ lymphocytes 
only recognise antigens in the presence of MHC class II expression. Several growth 
factors are also secreted, that stimulate fibroblast proliferation and collagen synthesis.  
Activation signals include cytokines, produced by T lymphocytes, bacterial endotoxins, 
other chemical mediators and certain extra-cellular matrix proteins.  After activation 
the macrophage secretes a wide variety of biologically active products8,15.  
 
In an H + E stained slide epithelioid cells have abundant pale pink cytoplasm with 
indistinct cell borders, giving the impression of merging into one another.  The cell has 
a vesicular nucleus, often with a distinct nucleolus.  Epithelioid cells frequently fuse to 
form multi-nucleated giant cells of various configurations.  They are usually seen on 
the periphery of a granuloma, but can be present anywhere in the granuloma. 
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1.1.2.1.2  Dendritic cells 
Dendritic cells play an important role in antigen capture and the induction of T cell 
responses, especially in naïve T cells16.  They are present in lymphoid organs, the skin, 
the gastro-intestinal and respiratory tracts and most parenchymal organs. Dendritic cells 
have spine-or finger like projections of their cell membranes, resulting in a vastly 
increased surface area of each cell.  These cells capture protein antigens and transport 
them to the draining lymph nodes.  During this journey the dendritic cells mature and 
become extremely efficient in presenting antigens to naïve T cells17.    
 
1.1.2.2 Lymphocytes 
Lymphocytes are the only cells in the body capable of specifically recognising and 
distinguishing different antigens18.  They are therefore responsible for both the 
specificity and memory that are the defining characteristics of the adaptive immune 
response.  Lymphocytes that have not been stimulated by antigens are called naïve 
lymphocytes and are small cells, measuring 8-10µ in diameter, which are in the G0 
stage of the cell cycle. Once stimulated they become larger, with more cytoplasm, 
organelles and cytoplasmic RNA. The lymphocytes involved in the cell mediated 
adaptive immune response are CD3+ T cells, usually of the T helper type (CD4+). Once 
activated they differentiate into effector and memory cells.  This activation follows a 
series of steps7,15,17,18.  
 
1. Early after antigen presentation (the stimulus), the lymphocytes start transcribing 
previously silent genes, to synthesize new proteins, including:  
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1.1.  Cytokines, to stimulate growth and differentiation of lymphocytes and other 
cells 
1.2.  Cytokine receptors 
1.3.  Other proteins involved in gene transcription and cell division 
2.  Cellular proliferation 
The antigen specific lymphocytes undergo mitotic division in response to antigen and 
growth factors, resulting in clonal expansion. 
3.  Differentiation into effector cells. These cells express surface proteins that interact 
with other cells, and secrete cytokines. 
4.  Differentiation into memory cells.  The function of these cells is to mediate rapid 
and enhanced responses to second and subsequent exposure to antigens.  
 
Most T cells recognise only peptides and are specific for amino acid sequences of 
peptides.  Therefore, if an animal is immunised with native protein, the antigen specific 
T cells that are stimulated will respond to denatured or even digested forms of that 
protein.  Different T cells can distinguish peptides that differ at single amino acid 
residues. T cells recognise and respond only to foreign peptide antigens when they are 
attached to the surface of APCs, and only in the presence of that individual’s own 
MHC molecules17,19.   
 
1.1.3 Cytokines in Granulomatous Disease 
Cytokines are small protein molecules that regulate immunological responses at a 
cellular level.  This response helps the body to defend itself against invasion by micro-
organisms and particularly those organisms that localise intra-cellularly to escape tissue 
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defences situated in the blood and interstitial fluid compartments.  Different cytokines 
stimulate varied responses of the cells involved in immunity and inflammation20. In the 
activation phase they stimulate the proliferation and differentiation of lymphocytes and 
in the effector phase they activate effector cells to eliminate micro-organisms and other 
antigens.  Cytokines can prime and either divert or target various effector cells to 
produce other mediators or toxic substances, such as oxygen radicals produced in the 
macrophages in response to IFNγ stimulation, which will kill intracellular organisms20.   
 
1.1.3.1 General properties of cytokines 
Cytokine secretion is a transitory, self-limiting event.  Cytokines are not stored as pre-
produced products, but their synthesis is stimulated by cellular activation, via new gene 
transcription21. To identify the presence of a specific cytokine in situ in a specific cell, 
it is often necessary to perform messenger-RNA (m-RNA) in situ hybridisation (ISH) 
due to the rapid secretion and degeneration of cytokine protein22. The mRNA can also 
be identified for only a brief period, as the particular gene is switched off again and the 
mRNA is unstable21.  
 
The actions of cytokines are often pleiotropic and redundant.  One cytokine has the 
ability to act on different cell types, which allows a cytokine to mediate diverse 
biological effects.  Multiple cytokines also have the same functional effect21. Cytokines 
manipulate the manufacture and actions of other cytokines.  This ability leads to a 
cascade effect and often cytokines that stimulate the production of others are affected 
by these cytokines.  They may also have opposing, additive or synergistic effects21.  
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Effects are local or systemic.  Most cytokines act in an autocrine or paracrine fashion, 
but when produced in large amounts cytokines may enter the systemic circulation and 
act from a distance in an endocrine fashion21. Cytokines initiate their actions by binding 
to specific membrane receptors on target cells.  They often bind their ligands with high 
affinities, consequently often only small quantities of cytokines are needed to elicit 
biological effects21.   
 
External signals regulate the expression of cytokine receptors and therefore the 
responsiveness of cells to cytokines.  This mechanism maintains the specificity of 
immune responses as only antigen stimulated cells express increased numbers of 
cytokine receptors.  Receptor expression is also controlled by cytokines themselves, 
either by positive amplification or negative feedback21.  
 
1.1.3.2 Specific cytokines  
1.1.3.2.1 Interleukin-12 (IL-12) 
IL-12 is a principal mediator of the early innate immune response to intra-cellular 
bacteria and is a key player in the induction of cell-mediated immunity.  Its most 
important function is to stimulate IFNγ production by T cells and NK cells. IL-12 is 
produced by macrophages and dendritic cells. A recent publication by Fenhalls et al1 
also demonstrated the presence of IL-12p40 mRNA in CD8+ lymphocytes, indicating 
that these lymphocytes produce IL-12. IL-12 is critical for the induction of the Th1 
response and the subsequent DTH reaction23,24,25,26.  On initial encounter with an 
organism, resting macrophages attempt to phagocytose and kill the organism, but are 
often not successful. This encounter, however, leads to the production and secretion of 
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IL-12 by the macrophage.  IL-12 is produced in response to many stimuli, including 
intra-cellular bacteria and viruses.   
 
Antigen stimulated T cells also induce IL-12 production, via the CD40 ligand on T 
cells engaging the CD40 receptor on producing cells.  T cells and NK cells also 
produce IFNγ that stimulates IL-12 production.  IL-12 is therefore produced during the 
induction and effector phases of the cell-mediated immune response23,24,25,26.   
 
IL-12 is crucial in initiating the responses resulting in the eradication of intra-cellular 
bacteria23,24,25,26:  
• IL-12 induces the production of IFNγ by T cells and NK cells.  IFNγ activates 
the macrophages to kill phagocytosed organisms.  
• IL-12 stimulates the differentiation of CD4 T helper cells into Th1 cells.  These 
cells then activate phagocytes in cell-mediated immunity.  
• IL-12 enhances the cytolytic activity of activated CD8 cytolytic T cells and NK 
cells.  
• IL-12 induces autocrine stimulation of macrophages, leading to additional IL-12 
secretion by macrophages.  
• IL-12 suppresses IgG1 and IgE production. 
 
1.1.3.2.2 IL-2 
IL-2 is a growth factor for antigen-stimulated T lymphocytes and is responsible for the 
clonal expansion of T cells after antigen recognition.  IL-2 is produced by CD4+T cells 
and sometimes also by CD8+ T cells. IL-2 production is transient, with a peak 8-12 
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hours after stimulation.  Antigen stimulation enhances IL-2 receptor expression on T 
cells, thereby augmenting the preferential proliferation of antigen stimulated T 
cells20,27.  
IL-2 plays several important roles in the adaptive immune response: 
• IL-2 is the most important T cell growth factor, and specifically for antigen 
stimulated T cell proliferation.  This is achieved by promotion of cell cycle 
progression. 
• IL-2 promotes survival of cells by inducing bcl-2, an anti-apoptotic protein, 
thereby preventing cell death.    
• IL-2 increases production of IL-4 and IFNγ by T cells. 
• IL-2 promotes the proliferation and differentiation of other immune cells, 
including NK cells. It stimulates growth and enhances cytolytic function.  It also 
stimulates B cell growth and antibody synthesis.  
• Repeated activation of CD4+ T cells in the presence of IL-2 makes these cells 
sensitive to apoptosis via the Fas pathway.  This functions as a control to switch 
off the immune response.     
 
1.1.3.2.3 Interferon-gamma (IFNγ) 
IFNγ is the principal activator of macrophages and plays a role in both innate and 
adaptive cell-mediated immunity. In innate immunity, natural killer (NK) cells secrete 
IFNγ, stimulated by IL-12, in response to recognition of unknown organisms. In 
adaptive immunity, T cells secrete IFNγ in response to antigen stimulation, as well as 
IL-12 and IL-18 secretion28,29.  
 
  27 
The functions of IFNγ are especially important in adaptive cell-mediated immunity: 
• IFNγ is a macrophage-activating cytokine, enhancing the microbiocidal 
activities of macrophages.  It stimulates the synthesis of reactive oxygen 
intermediates and nitric oxide.  These active molecules are produced in 
lysosomes and destroy organisms within the phagolysosome20,28,29,30.  
• IFNγ stimulates expression of class I and II MHC molecules and costimulators 
on APCs.  It also stimulates the expression of many antigen-processing proteins. 
In this way it enhances MHC-associated antigen presentation and amplifies the 
recognition phase of immune responses by increasing expression of the ligands 
that T cells recognise. 
• IFNγ activates vascular endothelial cells and potentiates some of the action of 
TNFα. These actions promote lymphocyte adhesion and extravasation to the site 
of infection.  
• IFNγ promotes the differentiation of naïve CD4+ T cells to the Th1 subset.  
• IFNγ inhibits the proliferation of Th2 cells.   
• In B cells, IFNγ promotes the switching of certain IgG subclasses.  
• IFNγ activates neutrophils and stimulates cytolytic activity of NK cells. 
• Although IFN production is induced by IL-12, IFNγ in turn initiates or augments 
IL-12 secretion.  
• IFNγ also enhances the number of IL-12 binding sites expressed on individual 
macrophages.  
 
The net effect of these activities is to promote a macrophage rich inflammatory 
environment, while inhibiting IgE-dependent reactions20,28,29,30.    
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1.1.3.2.4 Tumour necrosis factor-alpha (TNFα) 
TNFα is the principal mediator of the acute inflammatory response.  It is also, in an 
endocrine fashion, responsible for many of the systemic complications of severe 
infections.  TNFα is mainly produced by macrophages, but T cells, NK cells and mast 
cells can also produce TNFα.  
 
TNFα has important effects on endothelial and inflammatory cells9,15,20,31.  
• Increased secretion of prostacyclin, which leads to increased blood flow by 
vasodilation. 
• Increased expression of amongst others, E-selectin, an adhesion molecule that 
promotes attachment of lymphocytes and monocytes to the endothelium in the 
vicinity of the inflammatory process. 
• Induction and secretion of chemotactic factors such as IL-8. 
• Stimulation of mesenchymal cells such as fibroblasts and smooth muscle cells.  
• Suppresses IL-12 p40 transcription 32. 
• Induces IL-10 production 33 
 
These actions all facilitate extravasation of lymphocytes and macrophages at the site of 
reaction.  
 
1.1.3.2.5  IL-10 
IL-10 is an inhibitor of activated macrophages and dendritic cells.  It is produced by 
activated macrophages and therefore acts as a negative feedback regulator.  It is 
however, not clear what stimulates the production of IL-109,20,34.   
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• IL-10 inhibits the expression of costimulators and class II MHC molecules on                          
macrophages and dendritic cells.  This leads to inhibition of T cell activation and 
termination of cell-mediated immune reactions. 
• IL-10 inhibits the production of IL-12.  IL-10 consequently down-regulates the 
induction of innate and cell-mediated immune reactions. 
• On the other hand IL-10 promotes the differentiation of immature dendritic cells 
into macrophages.   
  
1.1.3.2.6  IL-4  
IL-4 is the major stimulus for the production of IgE antibodies and for the development 
of Th2 cells from naïve CD4 T cells.  IL-4 is, in turn, also produced by Th2 cells, 
activated mast cells and basophils, thereby stimulating Th2 differentiation and 
proliferation in an autocrine fashion20,35,36,37.  
 
• IL-4 stimulates B-cell Ig heavy chain class switching to the IgE isotype. 
• IL-4 mediates recruitment and activation of mast cells.    
• IL-4 stimulates the development of Th2 cells from naïve CD4 T cells and 
functions as an autocrine growth factor for differentiated Th2 cells.  Therefore 
IL-4 induces and expands this subset of T cells.  
• IL-4 suppresses macrophage-derived production of Il-12, thereby inhibiting 
differentiation of Th1 cells.  
• IL-4 antagonizes the macrophage activating effects of IFNγ and consequently 
inhibits cell-mediated immune reactions. 
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• IL-4 is able to block or suppress the monocyte derived cytokines, including IL-1, 
TNFα, IL-6, IL-8 and macrophage-inflammatory protein-1α38,39,40,41. 
• It has also been shown to suppress macrophage cytotoxic activity, parasite 
killing and macrophage-derived nitric oxide production42.    
• IL-4 can potentiate proliferation of vascular endothelium and skin fibroblasts, 
and decrease proliferation of human adult astrocytes and vascular smooth muscle 
cells38,43.  
• In addition IL-4 induces potent cytotoxic responses in tumours, possibly by 
stabilizing disease and modifying tumour growth rates44.  
 
 
1.2 Pathogenesis of DTH and Granuloma Formation 
There are 5 distinct phases of adaptive immunity4,7,45, namely 
• Recognition of antigens  
• Activation of lymphocytes 
• Effector phase (elimination of antigens) 
• Decline (return to resting state) 
• Memory 
 
The current model for granuloma formation is based on the delayed-type 
hypersensitivity (DTH) reaction, as epitomized by the tuberculin reaction46.  With the 
first exposure of a person to tubercle bacilli, naïve CD4+ T cells recognise captured 
peptides derived from these bacilli in association with class II molecules on antigen 
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presenting cells, namely dendritic or Langerhans cells. This initiates the differentiation 
of these T cells to sensitised Th1 cells.  Some of these Th1 cells enter the circulation 
and remain in the T cell memory pool for years18,19.  
 
On subsequent intracutaneous injection of tuberculin, the DTH process is initiated by 
these sensitised Th1 cells, following antigen presentation by macrophages47,48.  In a 
previously sensitised person, a response appears on site within 8-12 hours after 
injection, in the form of reddening and induration.  This reaches a peak within 24-72 
hours and thereafter recedes.  The redness and induration are due to vasodilation with 
perivascular cuffing of predominantly CD4 (helper) T lymphocytes around small veins 
and venules18,19.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A schematic illustration of granuloma formation during the DTH reaction.  
After capture of the antigen, antigen presenting cells present the antigen to the CD-4 lymphocytes, while 
producing IL-12 which stimulates Th1 differentiation. The pro-inflammatory cytokines TNFα and IFNγ 
drive the inflammation, resulting in granuloma formation.  
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An increase in vascular permeability results in the escape of plasma proteins and fluid, 
causing dermal oedema and fibrin deposition, leading to induration.  With persistence 
of the antigen, the lymphocytic infiltrate is largely replaced by macrophages over the 
next 2-3 weeks.  These macrophages undergo morphological transformation to 
epithelioid cells and thus a granuloma is formed9. 
 
 
1.2.1 Antigen Capture, Processing and Presentation 
Micro-organisms stimulate the innate immune response and induce the secretion of 
inflammatory cytokines in an effort to kill the organisms. Innate immunity against 
intra-cellular organisms may limit bacterial growth, but usually fails to eradicate the 
organisms and then requires adaptive CMI for eradication.  This process starts with the 
capturing of an antigen by an antigen presenting cell9,16,17. 
 
Once the protein antigen is captured and phagocytosed by the APC, it is converted to a 
peptide and then displayed as a peptide-MHC II complex on the surface of the APC, for 
recognition by T cells17.  The initial capturing is performed by immature dendritic cells 
(DCs), and occurs at the site of infection/exposure to the antigen, which is usually the 
skin, GIT, respiratory tract or other mucosal surfaces. These cells express membrane 
receptors like mannose and Toll-like receptors that capture micro-organisms, 
endocytose them and start processing the proteins into peptides that can bind to MHC II 
molecules for presentation to CD4+ T cells.  
 
This conversion is called antigen processing. These actions activate the DCs. The cells 
lose their adhesiveness for epithelium and start migrating to the draining lymph nodes 
of those areas via afferent lymphatics. During the migration the DCs mature and are 
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able to present antigens to naïve CD4+ T cells and activate these cells.  Mature DCs 
express high levels of Class II MHC molecules with bound peptides as well as the 
costimulators required for T cell activation21.  
 
1.2.2 Activation, Proliferation and Differentiation of Lymphocytes 
DCs present antigens to naïve CD4+ T cells in lymphoid tissue and during this process 
the naïve lymphocytes are activated.  This results in a clonal expansion of antigen-
specific lymphocytes and the differentiation of these cells into effector cells and 
memory cells.  Some of these cells re-enter the systemic circulation and migrate to the 
site of infection.  Here the cells again encounter the antigen and respond to eliminate 
the antigen49.  
 
The activation of T cells requires18,19,47,49: 
• Antigen recognition by the T cells.  
This is the first signal for activation and provides the ensuing specificity of the T cells.  
CD4+ T cells recognise MHC II specifically.  Adhesion molecules stabilise the 
attachment of T cells to DCs.  This ensures prolonged exposures to ensure that the 
functional responses of the T cells are triggered. T cell receptors for costimulators on 
DCs provide second signals for T cell activation.  During this process cytokines are 
produced that drive the proliferation and differentiation of the T cells18,19,47,49.    
• Costimulators and 
• Cytokines produced by DCs and T cells themselves.  
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1.2.3 Functional Responses of T Cells 
1.2.3.1 Cytokine production and secretion 
One of the earliest responses to antigen recognition by the T cells is cytokine 
production and secretion.  The principal cytokine produced by naïve T cells is IL-2.  
IL-2 functions as a growth factor for T cells.  Antigen stimulation also increases 
expression of receptors for various cytokines by T cells18,19,50,51.   
 
1.2.3.2 Proliferation 
This is mediated in a primarily autocrine manner via IL-2.  The T cells respond to their 
own secreted cytokines and also express surface receptors for these cytokines18,19,50,51.   
 
1.2.3.3 Differentiation  
On antigen stimulation some of the T cells differentiate into effector cells and others 
into memory cells. This is also dependant on antigen stimulation, costimulators and 
cytokines18,19,50,51. The offspring of CD4+ T cells can differentiate into two distinct 
subsets: called Th1 and Th219,47,52,53.  These cells are recognised by the principal 
cytokines they produce.  Th1 cells produce IFNγ and Th2 cells IL-4 and IL-5.   
 
Th1 and Th2 subsets develop from the same naïve T cells and the differentiation is 
determined by the stimuli, especially cytokines, present early in the immune response.  
IL-12 induces Th1 and IL-4 induces Th2 differentiation19,47,52,53,54,55.  Th1 
differentiation is the response to organisms that infect/activate macrophages or NK 
cells, while Th2 differentiation follows on helminth and allergen exposure.   
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1.2.3.3.1 Th1  
Following the innate immune response, macrophages activated by intra-cellular 
organisms secrete IL-1217.  The organisms may trigger this directly by binding Toll-like 
receptors on the macrophages or indirectly by stimulating NK cells to produce IFNγ, 
which then activates macrophages to secrete IL-127,15,17. T-cells further enhance this 
process via CD40L on T cells engaging CD40 on APCs, stimulating IL-12 gene 
transcription.  
 
IL-12 binds to receptors on activated CD4+ cells and activates the transcription of 
STAT4, a transcription factor that promotes the differentiation of Th1 cells.  IFNγ 
induces another TH1 transcription factor, called T-bet7,15.  Simultaneously, IFNγ 
stimulates IL-12 production by macrophages and IL-12 receptor expression on T 
lymphocytes.  In addition, IFNγ suppresses Th2 proliferation54,55. 
 
1.2.3.3.2 Th2  
Th2 differentiation is dependant on IL-4, which activates a transcription factor, STAT6, 
that stimulates Th2 development35.  Th2 cells are, however, the major source of IL-4 
during the immune response.  This poses the interesting question of where IL-4 comes 
from before the Th2 cells differentiate.  A possible explanation is that, from the point of 
activation, CD4+ T cells secrete small amounts of IL-4. If the antigen then persists and 
does not induce IL-12 secretion, Th2 differentiation will follow54,55.  Other factors that 
influence differentiation are the amount of antigen and costimulators expressed on 
APCs and the genetic structure of the host.  In mice some strains develop Th2 
responses to stimuli that elicit Th1 responses in most strains.  IL-10, also produced by 
Th2 cells, inhibits activation of Th1 cells20. 
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1.2.3.4 Migration of effector cells to site of antigen 
The migration of the effector cells is mediated by cytokines18,56. These cytokines 
induce the expression of adhesion molecules on endothelial cells and the chemotaxis of 
leukocytes.  
 
Cytokines are produced by macrophages and endothelial cells, stimulated by microbial 
products and later by activated T cells, responding to the antigen.  The most important 
cytokines involved are TNFα, IL-12 and chemokines. Both TNFα and IL-1 activate 
endothelial cells to express ligands for leukocyte adhesion molecules.   
 
Table 2:A comparison of the Th1 and Th2 subsets 
 Th1 subset Th2 subset 
Cytokines produced 
IFNγ 
IL-4, IL-5, IL-13 
IL-10 
IL-3, GM-CSF 
 
+++ 
- 
+/- 
++ 
 
- 
+++ 
++ 
++ 
 
Cytokine receptor expression 
IL-12R β chain 
IL-18R 
 
++ 
++ 
 
- 
- 
 
Chemokine receptor expression 
CCR4 
CXCR3, CCR5 
 
+/- 
++ 
 
 
++ 
+/- 
Ligands for E- and P-selectin ++ +/- 
Antibody isotypes stimulated IgG2a (mouse) IgE, IgG1 
(mouse) 
IgG4 (humans) 
Macrophage activation +++ - 
 
 
Cytokines are produced by macrophages and endothelial cells stimulated by microbial 
products and later by activated T cells, responding to the antigen.  The most important 
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cytokines involved are TNFα, IL-12 and chemokines. Both TNFα and IL-1 activate 
endothelial cells to express ligands for leukocyte adhesion molecules.   
 
Chemokines increase the affinity of leukocyte adhesion molecules for their ligands on 
endothelial cells and also promote trans-endothelial migration of leukocytes54,55.   
 
TNFα stimulates endothelial cells to produce prostacyclin, a vasodilatory substance 
that causes increased blood flow and increased delivery of leukocytes to the site of 
inflammation19.  
 
TNFα and IFNγ induce endothelial cells to change shape and remodel basement 
membrane, supporting extravasation of cells and leakage of macromolecules like 
fibrinogen19,30.  This leakage of macromolecules forms the basis of the induration seen 
in DTH reactions50,51.  Fibrinogen, and its product fibrin, provides the scaffolding that 
facilitates migration and retention of leukocytes in the extravascular tissue.   
 
The migration of effector T cells to the site of inflammation is not antigen 
specific18,50,51.  All activated T cells will migrate to this region, including effector and 
memory T cells that might be specific for the antigen in question. If these specific T 
cells recognise the antigen presented, the affinity of these cells’ adhesion molecules for 
their ligands is increased, resulting in the preferential retaining of antigen specific 
effector and memory cells.  T cells not specific for the antigen may return to the 
circulation via the lymphatic system.    
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1.2.3.5 Effector phase 
Effector T cells can respond to antigens presented by a wider variety of APCs than 
naïve cells.  Both effector and memory cells are less dependant on costimulators and 
require less antigen to be activated. Once the effector cells reach the site of antigen 
challenge, they are activated to perform their effector duties57.  In cell-mediated 
immunity, the main effector function of the CD4+ cells is to stimulate the microbiocidal 
activities of macrophages and other leukocytes.   
 
Monocytes are recruited from the blood and are then exposed to Th1 effector cells that 
activate them into macrophages, able to kill micro-organisms50,51.  Stimulated effector 
Th1 cells secrete IFNγ and express CD40L.  Macrophages are activated by the IFNγ 
and CD40L-CD40 (CD40 expressed on macrophages) interaction.  The requirement for 
CD40L-CD40 interaction ensures that the macrophages presenting antigen to T cells 
are also the macrophages activated by the T cells7.  
 
In chronic DTH reactions, activated macrophages also undergo changes in response to 
persistent cytokine signals.  They then acquire the morphological appearance of 
epithelioid cells.  These macrophages have an increase in cytoplasm and organelles and 
a collection of these forms a granuloma. They may also fuse to form multi-nucleated 
giant cells. 
 
1.2.3.5.1 Function of activated macrophages 
Killing of phagocytosed micro-organisms58 
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• Macrophage activation leads to increased synthesis of reactive oxygen 
intermediates and nitric oxide, which are potent microbiocidal agents, produced 
in the lysosomes of macrophages.  These substances kill phagocytosed 
organisms after fusion of phagosome with lysosome. They may also be released 
into the adjacent tissue, to kill extra-cellular organisms and may then cause 
tissue damage15.  
Stimulation of acute inflammation 
• Activated macrophages stimulate acute inflammation through the secretion of 
cytokines, chemokines and lipid mediators. This results in local inflammation 
rich in neutrophils, to phagocytose and destroy organisms.  
Repair 
• Activated macrophages remove dead tissue and therefore facilitate repair.   
• They also produce growth factors that stimulate formation of repair tissue. 
These include platelet derived growth factor (fibroblast stimulation), 
transforming growth factor-β (collagen synthesis) and fibroblast growth factor 
(angiogenesis) 15.  
 
1.2.3.6 Memory phase  
Memory T cells are an expanded population of T cells specific for an antigen that can 
respond rapidly to subsequent encounters with the same antigen, differentiate into 
effector cells and eliminate the antigen. The mechanisms of memory cell generation are 
not known.   
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1.3 Tuberculosis 
Tuberculosis (TB) is an important cause of serious pulmonary disease and mortality. 
Previous research into the pathogenesis has been neglected because of the low public 
health priority of tuberculosis, but the advent of HIV infection and the subsequent rise 
in the incidence of tuberculosis refocused attention on  this disease. Another important 
gap in current knowledge is an understanding of how host resistance to infection is 
mediated and how infection may be resisted or heals spontaneously.  
 
Tuberculosis is caused by the organism Mycobacterium tuberculosis (M.tb), which is 
an aerobic, non-spore forming, non-motile bacillus with a waxy coating that retains red 
dye when treated in acid-fast stains. M.tb is transmitted by inhalation of infective 
droplets.  The lungs are the usual sites of infection. The ensuing granuloma of TB has a 
very characteristic appearance. Early in the disease typical granulomas as previously 
described can be seen.  With progression of disease, however, central necrosis develops 
in these granulomas, bestowing these granulomas with the typical caseating centre seen 
in tuberculosis59,60.   
 
1.3.1 Pathogenesis 
Tuberculosis is divided into a primary and a post-primary (secondary) type.  
1.3.1.1 Primary tuberculosis 
This phase takes place in a previously unexposed host.  The organism is inhaled and in 
the lung, usually in the periphery, the organism is phagocytosed and innate immunity is 
initiated. The phagocytosed organism is transported to the hilar lymph nodes and  
 
  41 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Microscopic appearance of caseous necrosis.  
A well-formed granuloma containing epithelioid macrophages, with a rim of lymphocytes and several 
Langhans giant cells can be seen.  Centrally, caseous necrosis is apparent as amorphous pink material.  
 
 
presented to naïve T cells, stimulating the process of activation, proliferation and 
differentiation of these T cells.  If the organism is not killed, the process of adaptive 
immunity takes control and a DTH response commences.  This response occurs 
predominantly at the primary site of infection, i.e. the periphery of the lung and 
granuloma formation ensues, classically typified by central (caseating) necrosis. In 
most patients infected in this manner the infection is contained, usually by fibrosis, and 
a calcified scar in the periphery of the lung, also referred to as a Ghon focus, is all that 
remains.  Sometimes the hilar lymph nodes are also involved in this process and the 
lesion is the referred to as a Ghon complex59,60. In a small number of patients, usually 
due to some form of immune-suppression, active disease develops immediately 
following primary infection. This process is called progressive primary tuberculosis 
and is often a disseminated form of tuberculosis.     
Langhans 
giant cells 
Caseous 
necrosis 
Epithelioid 
macrophages 
Lymphocytes  
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1.3.1.2 Secondary tuberculosis 
Some patients become reinfected with mycobacteria or reactivate dormant disease.  M. 
tuberculosis infection is latently present in one third of the world population.  Less than 
10% however, develop active disease.  The remainder generate an effective immune 
response, which allows containment of the bacilli within granulomas. The bacteria 
persist for long periods of time in this dormant state, but fail to transmit infection. Re-
activation of the dormant infection and the onset of active disease will lead to the 
transmission of disease to a new host.   The clinical and morphological pictures of these 
events are similar.  
 
 Granulomas of secondary TB occur most often in the apices of the lungs, but may be 
widely disseminated, depending on a large variety of factors.  Again, the most 
prominent site affected is the lung and the granulomas, which fail to contain the 
bacteria, are a major cause of tissue destruction, due to the extensive caseous 
necrosis59,60.  Once these localised granulomas develop, the subsequent course is 
variable.  They may heal spontaneously or after therapy, resulting in a fibro-calcified 
nodule, or they may progress as follows: 
 
Caseating granulomas may erode into a bronchiole or a bronchus.  The result is 
cavitation and this facilitates organism growth due to the favourable oxygen tension.  In 
most cases the cavity is walled off by a fibrotic capsule and the lesion remains 
localised. However, in certain circumstances the infective material may 
disseminate59,60.   
This happens in one or more of the following ways:  
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• The infective caseous material may be coughed up and spread in the following 
manner: 
o It can spread along the airways and affect the trachea, larynx, and the 
rest of the upper respiratory and digestive tract. 
o The infective material can be inhaled, causing a bronchopneumonic 
picture.  
o It can be swallowed, leading to intestinal TB, usually in the region of the 
distal ileum or ileo-caecal junction, as this is where the lymphoid tissue 
of the GIT is present in the form of Peyer’s patches.  
• The granulomas may spread into a branch of the pulmonary artery, leading to: 
o Haemorrhage into the cavity, resulting in haemoptysis 
o Localised spread of the infective material to the area of the lung 
supplied by that section of the pulmonary artery, causing localised 
miliary TB. 
• The granulomas may spread through the lymphatics to lymph nodes: 
o Spreading retrogressively through other lymphatics to other areas of the 
lung, or other organs.  
o Spread to both lungs via the right heart back through the pulmonary 
arteries, causing diffuse miliary TB. 
• The granulomas may spread into the pulmonary veins, again resulting in: 
o Haemoptysis 
o Spreading to the systemic circulations via the pulmonary veins to the left 
heart and through the aorta.  
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In the progression of pulmonary disease, the pleura is often inevitably involved.  This 
can take on the form of serous effusions, tuberculous empyema or massive obliterative 
fibrous pleuritis61.  
 
Spread to the systemic circulation can lead either to individual organs being affected or 
to miliary TB, depending on the immune status of the patient and the virulence of the 
organism. Organs that are often affected include the kidneys, spleen, brain, adrenals, 
testes, etc. 
 
1.3.1.3 Miliary TB 
In the miliary type of TB, individual lesions vary from one to several millimetres in 
diameter and are distinct, yellow-white nodules. There is no visible central necrosis or 
cavitation present. Histologically, however, it has the characteristic necrotising 
granulomatous appearance. Organs often involved in miliary TB include the bone 
marrow, liver, spleen and eye. This is usually an aggressive form of the disease with a 
fulminant course62.  
 
1.3.1.4 Pleural tuberculosis 
Primary pleural effusion, as a presenting symptom of TB, usually occurs in adolescents 
and adults. It occurs on the same side as the primary (Ghon complex), suggesting that   
a sub-pleural tuberculous focus or lymph node has extended into the pleural space63. 
Bilateral or opposite effusion should raise the possibility of miliary TB64,65.  In primary 
pleural effusions granulomas are seen on both the visceral and the parietal pleural 
surfaces and have the typical appearance of TB granulomas.   
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Primary pleural TB usually resolves without treatment.  In young adults especially, it 
does, however, carry the risk of developing into other forms of TB, usually within 5-10 
years.  Full therapy is therefore justified.  Local complications that may ensue include 
focal or diffuse fibrosis, a large caseous lesion or cavity that may rupture into the 
pleura, creating a pulmonary-pleural fistula or spontaneous pneumothorax, para-
vertebral abscess and osteitis of the ribs. 
 
These manifestations of TB are caused by the balance between the virulence of the 
organism and the host immune response. Little is known about the virulence factors of 
M.tb, but current research, including the now completed sequencing of the organism’s 
genome will advance our understanding of the organism.    
 
Understanding the human host response is also important, as only a complete 
understanding of this process will assist in the development of new vaccines and 
possible immuno-modulatory adjuvants to the treatment of tuberculosis.  
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1.3.2 Cellular Immunity and Tuberculosis 
One of the examples of an organism of low virulence forcing a host response is that of 
Mycobacterium leprae that appears to be able to elicit two very different clinical 
manifestations of the disease leprosy, with a spectrum of changes between these two 
poles and has therefore been described as a polar disease66. Leprosy has been 
investigated extensively and has a vast spectrum of clinical manifestations, from 
lepromatous leprosy, which is the most severe form of leprosy, to tuberculoid leprosy, 
which is the mildest form of leprosy. Studies of lepra have yielded some insights into 
the cellular and molecular mechanisms of mycobacterial granulomatous inflammation 
and suggest that the Th1 cytokines such as IFNγ and TNFα may have an important role 
in resistance to infection as they are found in tuberculoid lepra66,67.  
 
Conversely, a predominance of Th2 cytokines (IL-4, IL-10) may be associated with 
spread of disease as can be observed in lepromatous lepra68,69.  Patients with 
tuberculoid leprosy exhibit paucibacillary disease with a well-developed Th1 response. 
The T cells in these patients proliferate vigorously in response to mycobacterial 
antigens and large amounts of IFNγ are present in these lesions. On the other hand, 
patients with lepromatous leprosy have a high bacillary load and a poor proliferative 
response to mycobacterial antigens. Whether this is due to a Th2 response or a lack of 
Th1 response is debatable. Attempts have been made to extrapolate these observations 
in leprosy to patients with TB.     
 
It is generally accepted that the cellular immune system plays the most important role 
in host defense against M.tb.  All the components in this immune system, from the 
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initial innate immunity, through to the late stages of granuloma formation may play an 
important role in this host defense. However, for the purposes of this study I will focus 
on the granuloma as such and specifically some of the cytokines involved in this 
process.  
 
Clinical studies are restricted by certain common features. Most studies involve post-
clinical observation of chronic infection, where the dose of the organism and the level 
of exposure are unknown. The patient also may have chronic infection-induced anergy, 
for instance when infected by helminths, in several stages of the parasite life cycle, 
each stage being able to stimulate different types of immune responses. In animal 
models, a more controlled environment for study exists. Despite the vast number of 
variables that have to be considered when studying human disease, it is clear that 
similarities exist between the immune response in humans and those in mouse models.   
  
It has become quite apparent that T cells play a major role in the host response against 
M.tb. This is clearly illustrated in HIV/AIDS where patients develop tuberculosis at a 
rate of 10% per year, rather than the norm of 10% per lifetime70. During the last few 
years a substantial case has been built to prove that IFNγ, the hallmark cytokine of the 
Th1 response, plays a key role in the defence against tuberculosis. IFNγ is a pro-
inflammatory cytokine promoting a macrophage rich inflammatory environment that is 
beneficial for the inhibition and killing of mycobacteria. It is clear from the literature 
that IFNγ is crucial in the defence against mycobacteria, as individuals with a genetic 
defect in IFNγ production or receptors, or who do not respond to IFNγ, develop severe 
systemic infection71,72. It has also been shown that patients with lymphocytic alveolitis 
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and significant local production of IFNγ develop mild disease, as opposed to patients 
without this response, who develop cavitary disease73.  In patients with multi-drug-
resistant (MDR) TB, who failed medical treatment, clinical and radiological 
improvement was noted after IFNγ aerosol treatment73.   
 
On the other hand it is suggested that a persistent high IFNγ is responsible for the 
damage caused by granulomatous disease and that moderating cytokines are necessary 
to down-regulate the IFNγ response to more appropriate levels later in the disease 
process, once the organisms have been effectively contained.  
 
Mouse models demonstrate the existence of a non-static, adaptive immune response 
that can change over time given the relevant stimulus. Longitudinal studies suggest that 
IL-4 has a controlling effect on IFNγ74. Thus, in tuberculosis a dual role for INFγ in 
both protection and immunopathology is suggested, where a proper CMI is responsible 
for containment, but an over-exuberant CMI is responsible for tissue destruction.  In 
cattle, the peak level of IFNγ production did not coincide with protection, and it is 
suggested that the over-production of IFNγ might lead to immune dysregulation and be 
damaging to the host75.  
 
An in vitro study of the production of cytokines by normal peripheral blood 
mononuclear cells (PBMC) in response to BCG described an evolving cytokine 
response, starting with the production of monokines, followed by a Th1 response and 
ending with a Th2 response76. In a cattle model, cattle were infected with virulent M. 
bovis and the cytokines monitored for 20 weeks. By this time lesions had formed in the 
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upper respiratory lymph nodes and lungs. A strong, sustained IFNγ response was 
present throughout the infection period. IL-4 was detected in a peak from 8-10 weeks. 
Before and after this peak IL-4 was undetectable77. In the same study a model with 
cattle infected by onchocerciasis demonstrated exactly the inverse cytokine profile. 
These observations suggest that a prolonged cytokine bias results in immunopathology 
and that a balanced immune response is necessary for host protection and the resolution 
of infection. 
 
Some studies suggest however, that an increase in IL-4 and IL-10 production is 
responsible for the immunopathology of tuberculosis. It is suggested that an increase in 
IL-4 suppresses IFNγ production, followed by reduced killing of organisms78. A study 
on PBMCs in patients with cavitary TB and normal controls demonstrated an increase 
in IL-4 producing cells in patients with cavitary TB, whereas IFNγ production was the 
same. Similar findings were also reported by Seah et al 79.        
                   
Another cytokine that is of key importance is IL-12. It has been demonstrated that IL-
12 production is essential to initiate the Th1-response and that persistent IL-12 
production is necessary to sustain it. This is due to the fact that IL-12 is a potent 
inducer of IFNγ production in many different cell types80 as well as the key inducer of 
Th1 differentiation.  
 
In mice, enhanced protection was noted in the group where IL-12 was used as an 
adjuvant to bacille Calmette-Guérin (BCG) immunisation81. Other studies performed in 
mice confirmed this. In IL-12p40-/- mice there was an inability to control bacterial 
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growth and IFNγ and TNFα mRNA levels as well as IL-4 are reduced82. There were 
also a lower number of lymphocytes in the granulomas.  After infection with BCG, IL-
12p40-/- mice demonstrated a lack of both Th1 and Th2 cytokines in the lung and blood.  
They also had an impaired inflammatory response, lacking macrophages, neutrophils, 
CD4, CD8 and NK cells in the lung 83.  There is also however, evidence for the 
destructive effect of IL-12. A study on mice84 demonstrated that granuloma 
disintegration and death was dependant on T cells and IL-12 production, while 
depletion of T cells subsets and IL-12 led to well formed compact granulomas and 
prolonged survival.                                                                                                                                 
 
TNFα has a central role to play both in the host immune response to M.tb and the 
immunopathology of tuberculosis85. The release of TNFα in response to M.tb has 
several beneficial effects. In-vitro studies have demonstrated that TNFα increases the 
ability of macrophages to phagocytose and kill mycobacteria86.  This cytokine is 
required for granuloma formation, which sequesters mycobacteria and prevents 
dissemination of the organism87. It is accepted that granuloma formation is protective 
and indicates a successful immune response.  
 
Several studies in mice have demonstrated the importance of TNFα. Roach et al88 
demonstrated that TNFα was required for the early expression of mRNA encoding 
chemokines and leucocyte recruitment. Lymphocytes and macrophages also failed to 
form granulomas and prevent progressive infection. In a study by Ehlers et al89, 
granulomas in TNFR1-deficient mice underwent progressive necrosis and resulted in 
death of the mice. Blocking of TNFα caused fatal reactivation of persistent 
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tuberculosis, as well as an increase in bacillary load and increased production of IL-
1090, while inhibition of TNFα synthesis increased macrophage degeneration and tissue 
destruction91. TNFα depletion in TNFR1-deficient mice also resulted in abnormal 
granuloma formation92. TNFα also assisted in containing mycobacterial growth by 
inducing apoptosis of ineffective macrophages93,94,95.  
 
Although enough evidence exists to support a protective role for TNFα, excessive 
production of TNFα and an increased sensitivity to the cytokine have been implicated 
in the immunopathology of tuberculosis, for example, caseous necrosis. A study on 
mice demonstrated the opposite effects of TNFα96. On the one hand TNFα is necessary 
for the accumulation of cells into well-organised granulomas, the activation of T-cells 
and the differentiation of dendritic cells to enhance IL-12 production. On the other 
hand, TNFα has detrimental effects. A high dose of TNFα resulted in damaging 
inflammation, due to the systemic effects of this cytokine. With a high dose of TNFα in 
this study there was an aggressive and rapid response in the lung, with extensive 
cellular recruitment in the lung, compromising lung function. While TNFα is an 
essential component of the host immune response against mycobacterial infection, high 
levels of the cytokine at the site of infection induce an excessive inflammatory response 
that overwhelms the beneficial effects of the cytokine.        
 
It is also possible that the type two cytokines may mediate local tissue inflammation 
and necrosis through their effect on TNFα mediated cytotoxicity97,98. This is supported 
by findings that the IFNγ:IL-4 mRNA copy number ratios were significantly lower in 
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patients with tuberculosis than in healthy controls.  This ratio was even lower in 
patients with more severe radiological disease79.     
 
The role of cytokines such as TNFα may be to modulate and fine-tune this process, 
depending on the spectrum of cytokines already present.  It may be of particular impor-
tance in TB where TNFα superimposed on a Th1 cytokine profile may lead to a 
protective granulomatous response, whereas a Th2 background may result in tissue 
necrosis and breakdown with cavitation, thus favouring spread of organisms.   
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1.4 Pleural Tuberculosis  
Primary pleural effusion, as a presenting symptom of TB, usually occurs in adolescents 
and adults, in up to 10% of recently infected persons. It occurs on the same side as the 
primary (Ghon complex), suggesting that disease in a sub-pleural tuberculous focus or 
lymph node spread into the pleural space63. Contralateral or bilateral effusions should 
raise the possibility of miliary TB64,65.  A tuberculous pleural effusion may also be the 
result of post primary/secondary tuberculosis, years after primary infection.   
 
Primary pleural TB usually resolves without treatment.  In young adults especially, it 
does however carry the risk of developing into other forms of TB, usually within 5-10 
years99.  Full therapy is therefore justified.  Local complications that may ensue include 
focal or diffuse fibrosis, occasionally a large caseous lesion or cavity may rupture into 
the pleura, creating pulmonary-pleural fistula or leading to spontaneous pneumothorax, 
para-vertebral abscess and osteitis of the ribs. 
 
The clinical importance of tuberculosis in general and of tuberculous pleural effusion in 
particular is not the same worldwide. Eight million people developed tuberculosis in 
1990 and 95% of these people lived in developing countries100. The frequency of 
pleural effusion in these tuberculous patients is currently approximately 31% 101,102. 
Fifty percent of all individuals infected with HIV worldwide are also infected with 
tuberculosis.  Of all HIV-related deaths, approximately 33% are ascribed to 
tuberculosis.  Furthermore, the lifetime risk of an HIV positive person of developing 
tuberculosis is 50%, compared to 5-10% in an uninfected person103.  There are 
contradictions regarding the frequency of pleurisy in HIV-positive and HIV-negative 
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patients with tuberculosis. A South African study reported a higher frequency in HIV-
positive patients 104, but some Central African studies could find no such differences, 
103, 105. Initial data suggest that HIV patients tend to develop tuberculous pleurisy in the 
early stages of immunosuppression, when the CD4+ T-lymphocyte (helper-inducer) 
count >200 cells·mL-1 (27%) as opposed to CD4+ T-lymphocyte count <200 cells·mL-
1 (10%)106. 
 
It is clear from these figures that co-infection by tuberculosis and HIV is a very 
dangerous combination. This problem is compounded in South Africa, with its high 
incidence of both HIV and tuberculosis.      
 
1.4.1 Pathogenesis 
The current hypothesis for the pathogenesis of primary tuberculous pleural effusion is 
that a subpleural caseous focus in the lung ruptures into the pleural space 6–12 weeks 
after a primary infection63,64. Mycobacterial antigens enter the pleural space and elicit a 
delayed hypersensitivity reaction and the accumulation of fluid. It appears that the DTH 
reaction results in an increased permeability of pleural capillaries to serum proteins65, 
leading to increased oncotic pressure in the pleural fluid and the development a pleural 
effusion. 
 
In primary pleural effusions, granulomas are seen on both the visceral and the parietal 
pleural surfaces and have the typical appearance of TB granulomas. These granulomas 
tend to follow the lymphatics on the visceral surface107 and focal or diffuse fibrosis 
may follow. The lymphatic system is probably also involved and may contribute to the 
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development of a pleural effusion. Impaired clearance of proteins from the pleural 
space has been reported in human tuberculous effusions65.  
 
Clearance of proteins and fluid from the pleural space is performed by lymphatics in 
the parietal pleura. Access to the lymphatics is through openings in the parietal pleura 
called stomata108. In tuberculous pleuritis, with diffuse involvement of the parietal 
pleura, damage to or obstruction of the stomata could be an important mechanism 
leading to accumulation of pleural fluid.  
 
It appears that tuberculous pleurisy is due to release of isolated mycobacterial antigens 
into the pleural space, eliciting a delayed hypersensitivity reaction rather than to a 
tuberculous infection by viable organisms109. This hypothesis is supported by several 
facts. Cultures of pleural specimens from patients with tuberculous pleurisy are positive 
in one-fifth to two thirds of patients110 who are HIV negative111.  On histological 
examination, acid-fast bacilli are demonstrated in 5- 18% of cases112. The yield is 
improved when a combination of fluid culture as well as culture and histology of tissue 
are performed. The diagnosis is then confirmed in more than 95% of patients113.  A 
lymphocytic pleurisy can be produced in sensitised guinea pigs by the intrapleural 
instillation of heat-killed bacilli Calmette- Guérin (BCG)114. Moreover, pleural effusion 
also develops in nonsensitised animals that have received cells from immunized 
animals115; and effusion does not develop in sensitised animals if they are given 
antilymphocyte serum116. 
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The same process of granuloma formation previously described takes place in the 
pleura. Some studies suggest that the mesothelial cell plays a role in the recruitment of 
the cells  participating in tuberculous pleuritis117. As expected, most of the lymphocytes 
in a tuberculous pleural effusion are CD4+ T-lymphocytes118, with a mean CD4:CD8 
(helper:suppressor) ratio of about 4.3 in pleural fluid, and 1.6 in peripheral blood119. 
Pleural tuberculosis in HIV-negative subjects has been taken to represent a protective 
immune response to Mycobacterium tuberculosis because a high proportion of 
individuals can recover without antibiotic therapy120. A tuberculous pleural effusion in 
HIV-negative subjects is usually associated with a prominent cell-mediated immune 
response, represented by an infiltration of CD4+ T cells 121 and high levels of pro-
inflammatory cytokines, including IFNγ and TNFα122.  This appears to indicate a key 
role for these responses in protective immunity against tuberculosis in humans, in 
keeping with evidence that IFNγ and TNFα are necessary for protective immunity to 
tuberculosis in animals123,124,125, and that abnormalities of the IFNγ receptor are 
associated with susceptibility to mycobacterial disease in humans126,127. 
 
1.4.2 The Effect of HIV on TB 
Increased nosocomial128,129 and community130 exposure to M.tb may play a role in the 
increased risk of contracting tuberculosis in HIV infected patients, but HIV-associated 
impairment of one or more immunological mechanisms plays an important role131. 
These mechanisms include impairment of pulmonary innate immune defences, 
impairment of cellular recruitment and establishment of the cell-mediated 
granulomatous response to recent M.tb infection, and functional impairment of 
established granulomas containing latent M.tb infection. 
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There are no epidemiological data that clearly demonstrate a higher rate of initial M.tb 
infection among HIV-1- infected individuals than among non-infected individuals 
following a similar exposure132. It therefore appears that the risk of infection by M.tb is 
similar for both HIV positive and HIV negative persons.   
The risk of developing progressive primary TB following M.tb infection is however 
higher among HIV- 1-infected persons than among immunocompetent persons128,133.  
In addition, the estimated lifetime risk of developing active TB among 
immunocompetent individuals with latent M.tb infection is only 2–23%134. However, in 
HIV-infected persons this number is much higher and is estimated to be approximately 
10% per year132,135. Therefore, the risk of developing active TB among HIV-1-infected 
persons with latent M.tb infection appears to be very high.  
 
These data suggest that HIV-1 infection affects the ability of established granulomas to 
contain M.tb, resulting in increased reactivation of latent mycobacteria. The relative 
contribution of endogenous reactivation and recently acquired exogenous TB to the 
overall increased risk of TB among HIV-1-infected persons is not clear and is likely to 
vary depending on the prevalence of TB and M.tb infection in a given community. 
 
HIV-1 replication is closely regulated by the host cell transcriptional machinery, and is 
therefore under the influence of a complex network of pro-inflammatory and 
immunoregulatory cytokines136,137,138. TNFα plays a pivotal role in HIV-1 
pathogenesis139 by inducing HIV-1 transcription in both macrophages and T 
lymphocytes via the NF-κB pathway138,139, 140,141.  Other proinflammatory cytokines 
(IL-1, IL-2, and IL-6) also induce HIV-1 replication142. IL-6 synergizes with TNFα to 
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enhance HIV-1 replication at transcriptional and posttranscriptional levels in monocytic 
cells but not lymphocytes143. IL-1 increases HIV-1 replication in promonocytic cell 
lines by enhancing TNFα mediated induction of NF-κB144. In addition to these 
proinflammatory cytokines, it is possible that other host-encoded immune mediators 
may play a role in the induction of HIV-1 transcription during the inflammatory 
response145,146. 
 
It has been hypothesized that qualitative T-helper-type responses may also impact 
AIDS pathogenesis. A switch in the predominant response from a Th1 to a Th2 
response and the production of associated cytokines may facilitate disease 
progression147,148,149. Some studies indicate that HIV-1 disease progression is associated 
with increasing secretion of IL-10150,151. However, these findings and the supposed role 
of modulation of T helper responses in HIV pathogenesis remain controversial152,153.  
 
This controversy concerning the role of T helper-type responses in HIV-1 pathogenesis 
raised the question whether coinfections that modulate these Th responses 
might also impact on the natural history of HIV-1 in vivo154,155. Parasitic diseases 
typically induce a dominant Th2 response and also modulate subsequent responses. For 
example, mice with schistosomiasis mount Th2 responses to nonparasite antigens that 
normally induce Th1 responses156,157,158. An example in humans is that of 
schistosomiasis that impairs Th1 responses to tetanus toxoid immunization159. It is 
therefore possible that Th2 modulation of the immune system resulting from 
coinfections with parasitic diseases may facilitate HIV-1 replication in coinfected 
persons154,160, although data to support this are lacking. 
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In 1994 Lucas et al described 3 histological stages of cellular immune response that 
correlate with depletion of the peripheral blood CD4+ lymphocyte count161, namely:  
• in immunocompetent individuals with HIV-1 infection, TB granulomas are 
characterised by abundant epithelioid macrophages, Langhans giant cells, 
peripherally located CD4+ lymphocytes, and a paucity of bacteria 
• in individuals with moderate HIV-associated immunodeficiency, Langhans giant 
cells are not seen, epithelioid differentiation and activation of macrophages are 
absent, there is CD4+ lymphocytopaenia, and acid-fast bacilli (AFB) are more 
numerous 
• in individuals with advanced HIV associated immunosuppression and AIDS, there 
is a striking paucity of granuloma formation with little cellular recruitment, very 
few CD4+ lymphocytes, and even larger numbers of AFB.  
It is therefore apparent that HIV-1 coinfection weakens the granulomatous host 
response to M.tb. 
 
HIV-1 infects macrophages and CD4+ T cells that are essential in granuloma formation 
in tuberculosis. Co-infection will therefore impair cell-mediated immune responses to 
M.tb infection.  Several possible levels of impairment exist.    
 
Macrophages are central to the pathogenesis of both TB and HIV-1 infection. They are 
the initial effector cells against M.tb and serve as reservoirs for the intracellular growth 
of both organisms. Several studies indicate that HIV-1 impairs intrinsic macrophage-
mediated defences against a variety of intracellular pathogens,162,163,164,165,166,167 
including increased intra-cellular growth of M.tb 166 and suppression of IL-12 
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production32.  TB and HIV-1 coinfection are also likely to be associated with extensive 
virus-induced and activation-induced cell loss and with the suppression of lymphocyte 
regeneration and maturation168,169. HIV may also block the ability of the host to mount 
an effective proliferative T- lymphocyte response to M.tb170. It is well recognized that 
CD4+ lymphocytes in HIV-infected persons are functionally impaired171,172,173,174,175,176. 
 
According to the dogma, effective cell-mediated immunity to M.tb is characterised by a 
strong Th1 response. This is supported by the susceptibility to tuberculosis among 
individuals with IL-12- receptor or IFNγ- receptor deficiencies177. Numerous studies 
have shown that during the progression of HIV-1 disease, mononuclear cells lose their 
ability to secrete Th1 cytokines and instead produce increased levels of the Th2 
cytokines178.  
 
1.4.2.1 The effect of HIV on the granuloma 
The several changes already described above, as well as the progressive 
immunosuppression associated with the development of AIDS result in failure of 
epithelioid differentiation of macrophages, no formation of Langhans giant cells, and 
no caseous necrosis161. Tuberculous hypersensitivity-type granulomas are thought not 
to be immunologically quiescent structures but rather to have a continual level of 
mononuclear cell-death and cell replacement by active recruitment179. Very little is 
known, however, about the mechanisms whereby HIV-1 coinfection 
actually causes dysfunction of established granulomas and leads to the reactivation of 
latent TB. 
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It is possible that HIV-1 infection might affect granuloma function via two processes:  
• Systemic depletion of the mononuclear cells required for the ongoing maintenance 
and functioning of granulomas and  
• The effects of HIV-1-infected cells (either lymphocytes or macrophages) trafficking 
into the granuloma itself. 
 
It is clearly documented that tuberculosis is an early occurrence in HIV, before any 
reduction in CD4+ count180. The effect of HIV infected cells trafficking into the 
granuloma is therefore probably the more important pathway for granuloma disruption.  
 
There are many areas in which concomitant HIV infection may tip the balance in 
tuberculous infection towards progressive disease. Individuals with both infections 
have reduced T cell lymphoproliferative responses and less production of IFNγ and IL-
2 in vitro when stimulated with tuberculous antigen in comparison to patients infected 
only with TB. Thus, Th1 type cytokines are reduced. However, there is little evidence 
for an enhanced Th2 response as IL-4 production appears to be the same in co-infected 
and tuberculous-only individuals103.  
 
CD4+ T lymphocyte depletion is crucial for the pathogenesis of HIV infection. It has 
been demonstrated that M.tb infection enhances HIV replication and CD4+ T 
lymphocyte depletion. High CD4+ T lymphocyte decline rate was observed in patients 
with active tuberculosis disease, whereas M.tb -infected asymptomatic patients showed 
similar rates of decline and similar levels of HIV load as patients without latent 
tuberculosis infection181,182.  
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M.tb can also modulate HIV replication by generating a cytokine microenvironment 
favouring viral infection and spread in local mononuclear cells. In fact, in the context 
of the specific anti- MTB immune response, a number of cytokines are produced in 
large amounts in the infected organs183,184,185,186,187,188. Several of these cytokines have 
in vitro upregulating (TNFα, IL-6, GM-CSF), or bifunctional activities on HIV 
replication (IL-10, IFNγ, TGFβ)189,190. In support of these data, Garrait et al. found that 
pleural fluid obtained from tuberculosis patients, but not from subjects with congestive 
heart failure, induced in vitro HIV replication and this effect was mediated by TNFα  
and IL-6191.  
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1.5 Sarcoidosis 
Sarcoidosis is a multi-system granulomatous disease of unknown aetiology, although 
several organisms have been investigated as possible causes, amongst these M. 
tb192,193,194,195.  It is characterised by enhanced cellular hypersensitivity at sites of 
involvement.  Elsewhere in the body, cellular hypersensitivity is depressed so that 
reactions to common allergens such as tuberculin are negative.  The disease is 
characterised by non-caseating granulomas, which either resolve or progress to fibrosis.  
The severity of disease varies and there are individuals whose disease is asymptomatic 
or sub-clinical196.  
 
Sarcoidosis occurs worldwide, but appears to be more prevalent in higher altitudes, 
especially Scandinavia, other northern European countries and North America. 
However, Black Americans, and West Indian and Asian immigrants in the United 
Kingdom have a much higher incidence than any other racial group197. Amongst some 
races the disease is extremely rare. Most cases occur between the ages of 20 and 40 
years and are often discovered during evaluation for other conditions198. Symptoms are 
worst in older women. Approximately 90% of patients have signs of involvement on 
chest X-ray, with/without lymphadenopathy199.  
 
The radiological picture of pulmonary sarcoidosis may vary considerably, but the 
histological picture is always that of granulomatous disease, with or without 
accompanying fibrosis. Ninety percent of patients present with hilar lymphadenopathy 
or pulmonary involvement on chest X-ray (CXR).  Skin and eye lesions are also fairly 
common.   Patients present with a variety of symptoms, often respiratory, but in 10% of 
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cases this disease is discovered during evaluation for other conditions. Respiratory 
symptoms include shortness of breath, cough, chest pain and haemoptysis, which can 
be massive.  Although the CXR findings may vary enormously, the classical finding is 
that of a reticulonodular infiltrate, implying delicate alveolar septum involvement 
(reticular) as well as aggregates of granulomas (nodular)200.  Radiological staging 
systems for sarcoidosis have been in use for many years and the system described by 
Berkmen is as follows: 
 
Stage 0:  Normal CXR (5-10%) 
Stage I:  Lymphadenopathy only (50%) 
Stage II:  Lymphadenopathy associated with pulmonary infiltrates (25-30%) 
Stage III:  Pulmonary infiltrates without lymphadenopathy (15%) 
Stage IV:  Fibrosis and end stage lung disease -  ± 20% progress to this stage 
 
The macroscopic size and distribution of the granulomas differ significantly and 
explains the variation in radiological findings.    
 
In a study by Möllers et al201, patients were divided into two groups according to the 
duration of symptoms.  Patients with symptoms lasting < 2 years at presentation were 
regarded as having acute disease and patients with symptoms > 2 years were regarded 
as having chronic disease.  All patients with acute disease had a stage I CXR and all 
patients with chronic disease had either a stage II or III CXR.   
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Since other diseases, including mycobacterial and fungal infections, can also produce 
noncaseating granulomas, the diagnosis of sarcoidosis is one of clinicopathological 
correlation.  However, the granulomas in sarcoidosis do have a characteristic 
appearance, suggestive of the diagnosis on histology202.  The granulomas are well 
formed, consisting of tightly clustered epithelioid macrophages, usually with Langhans 
or foreign body-type giant cells, and often lacking significant surrounding 
inflammation.  Concentric fibrosis, surrounding the granuloma, is often a feature (fig. 
4). A variety of changes may be seen in the granulomas, but none are specific to this 
disease. These include small foci of fibrinoid necrosis and giant cells with inclusions 
like Schaumann bodies, asteroid bodies and calcium oxalate crystals.  
 
The granulomas are distributed along the pulmonary lymphatics in the pleura and septa 
and along pulmonary arteries, veins and bronchi, often involving these structures.   An 
interstitial infiltrate of lymphocytes and plasma cells often occurs in the alveoli 
adjacent to granulomas.  The lymphatic distribution is classical of sarcoidosis and 
assists in distinguishing sarcoidosis from other granulomatous diseases. More than 50% 
of cases show histological involvement of pulmonary arteries and/or veins (fig. 4). This 
can probably be explained by the lymphatic distribution of this disease. Both small and 
large airways are frequently involved by granulomas and are often visible as small 
submucosal nodules on bronchoscopy. An interstitial infiltrate of lymphocytes and 
plasma cells are frequently present in sarcoidosis, especially around the granulomas. 
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Figure 4: Concentric fibrosis around granulomata evident (x100 magnification, Verhoef van 
Giesson stain). The concentic fibrosis surrounding the granulomas can be seen staining red in this 
section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Brochocentric distribution of the granulomata (x100 magnification). Numerous 
granulomata can be seen, invading the bronchial wall.  
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Figure 6: Granulomatous angiitis (x200 Verhoef van Giesson stain). A granuloma can be seen clearly 
invading the blood vessel wall, with destruction of the wall.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Lymphocytic pneumonitis in sarcoidosis (x200 magnification).  An interstitial lymphocytic 
infiltrate is present in the alveolar interstitium, removed from the granulomata.  
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This infiltrate varies from very mild, to sometimes quite severe. Apart from interstitial 
inflammation, interstitial fibrosis can also be seen and is a precursor of honeycombing.   
Although the clinical and radiological features are often so typical that a presumptive 
diagnosis of sarcoidosis can be made without histological confirmation, histological 
confirmation should be obtained before treatment.  
 
A histological grading system exists to determine the severity of pulmonary 
involvement, based on the extent of specific pathological changes, including 
granulomas, interstitial pneumonitis, fibrosis and overall change.   The extent of airway 
involvement can also be determined histologically203. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY INVOLVEMENT203 
a. Extent of specific pathological change  
i. Granulomas 
1. Minimal: a few scattered granulomas 
2. Moderate: more than a few, but occupying less than two 
thirds of the  area 
3. Extensive: numerous granulomas, often conglomerated and 
occupying more than two thirds of the area 
ii. Interstitial pneumonitis (nongranulomatous inflammation of the 
alveolar walls, predominately lymphocytic) 
1. Minimal: lesions occupying less than one third of the area 
2. Moderate: lesions occupying one to two thirds of the areas 
3. Extensive: lesions occupying more than two thirds of the 
area 
iii. Granulomatous angiitis (granulomas within the walls of veins 
and/or arteries)   
1. Absent: no granulomatous angiitis 
2. Minimal: one to two foci 
3. Moderate: more than two foci 
iv. Fibrosis (fibrosis of alveolar wall or interstitium) 
1. Absent: no fibrosis 
2. Focal: focal and scattered fibrosis 
3. Diffuse: diffuse and extensive fibrosis 
b. Evaluation of overall pathologic change 
i. Mild:  no fibrosis, granulomas and interstitial pneumonitis minimal 
and granulomatous angiitis absent or minimal 
ii. Moderate:  by exclusion from mild and severe categories 
iii. Severe:  diffuse fibrosis, granulomatous and interstitial 
pneumonitis both extensive, granulomatous angiitis moderate 
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1.5.1 Pathogenesis 
In patients with sarcoidosis, the hypersensitivity reaction is viewed as the consequence 
of a chronic, exaggerated Th1 immunological response against an unidentified antigen 
that persists at the sites of disease involvement204. Initial granuloma formation has the 
same pathogenesis as previously described. The accumulation of CD4+ Th1 cells and 
macrophages at the site of inflammation is the earliest step in the events that lead to 
granuloma formation. This accumulation is followed by granuloma formation.  
 
Many of the immunological studies performed on the cells involved in sarcoidosis are 
based on cells present in broncho-alveolar lavage or cell suspensions, while very little 
is known about the in situ profile of these cells.  
 
In general, there is a depression of DTH, an imbalance of CD4/CD8 T cell subsets, an 
influx of Th1 cells to the site of activity, hyper-reactivity of B cells and circulation on 
immune complexes. In the early phases of the disease, T cells in the granulomatous 
areas show a predominantly Th1 profile, expressing elevated mRNA and protein levels 
of IFNγ, IL-2 and IL-12205,206,207. According to these studies the net effect of the Th1 
response is the organization of the local inflammatory process into the granuloma and 
the inhibition of the fibrogenetic process208,209,210. 
 
TNFα is thought to play a key role as mediator of inflammation and cellular response, 
due to its pivotal role in granuloma formation211,212,213. As TNFα also stimulates 
fibroblast proliferation and collagen synthesis it may be regarded as a key mediator for 
the induction of pulmonary fibrosis in sarcoidosis214,215,216.    
  70 
 Some studies suggest that a switch to Th2 cells occurs in patients with progressive 
disease who evolve towards lung fibrosis207. According to these studies the T cells in 
the lungs release Th2 cytokines, including IL-4, which stimulate the production of 
extra-cellular matrix proteins and is chemo-attractant for fibroblasts, as has been 
demonstrated in cryptogenic fibrosing alveolitis217,218. This results in hyperplasia of 
fibroblasts in granulomas, as well as the expansion of the mesenchymal cell population 
and subsequent increased deposition of extra-cellular matrix components in the 
environment surrounding the granulomas.  
 
On the other hand, it has been demonstrated that in newly diagnosed sarcoidosis 
patients with progressive disease, cells in their broncho-alveolar lavage specimens are 
characterised by significantly higher release of the pro-inflammatory cytokines TNFα, 
IL-8 and macrophage inflammatory protein 1 (MIP-1), compared to patients with stable 
disease204,219. Furthermore patients with high levels of spontaneous TNFα release by 
alveolar macrophages at time of diagnosis had a significantly higher risk of disease 
progression (in patients not yet on systemic steroid therapy), or a higher rate of relapse 
(in patients on systemic steroid therapy)220,221. In support of these findings, two studies 
demonstrated a significant fall in alveolar macrophage TNFα release in patients who 
responded to corticosteroid or immuno-suppressive treatment222,223. Another study also 
demonstrated that in patients with long-standing sarcoidosis and progressive disease 
(not on treatment) and patients with corticosteroid resistant disease, TNFα was 
significantly elevated.   
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A number of studies have indicated the relationship between raised TNFα levels and 
steroid therapy resistance. As soon as anti-TNFα treatment is applied, a positive 
response to steroid treatment is noticed224,225,226,227,228,229.  Increased levels of IL-12 
have also been demonstrated in untreated sarcoid patients with disease progression, 
indicating a potential prognostic role for this parameter230. Möllers et al demonstrated 
that patients with acute onset of disease expressed more Th1 cytokines than patients 
with chronic disease. However, Th2 expression was similar in both groups and the 
expected Th2 shift was not observed.   
 
1.5.2 Causal Agent of Sarcoidosis 
Numerous studies have been performed in patients with sarcoidosis to determine the 
cause of this disease. Varying results point towards several organisms, including M.tb, 
Propionibacterium acnes, Rickettsia helvetica and Human herpesvirus 8 192,193,194,1957.  
These results were never conclusive, but there are many indications that an infective 
agent may be responsible for the development of sarcoidosis. Unpublished data by 
Fenhalls demonstrated the presence of M.tb DNA, RNA and protein  in the granulomas 
of patients diagnosed with sarcoidosis (personal communication).    
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1.6 Apoptosis  
Cell death in living organisms presents either as necrosis or apoptosis, also known as 
programmed cell death (PCD). Each has distinctive morphological and biochemical 
characteristics. Necrosis is unregulated, resulting in disintegration of the cell membrane 
and its organelles231. Apoptosis on the other hand, results from the activation of an 
internally encoded suicide program induced by a variety of extrinsic and intrinsic 
signals. It is a form of cell death that serves to eliminate cells that are no longer 
needed232. Differences between apoptosis and necrosis are listed in table 3.  
 
Table 3: Differences between apoptosis and necrosis 
 Apoptosis Necrosis 
Cellular role  Active Passive 
Cellular membrane Preserved Loss of integrity 
Cellular architecture Preserved Interrupted 
Induction Slow (hours) Rapid (seconds) 
Chromatin condensation Present Absent 
Cell removal Rapid  Slow  
Inflammatory response Absent Present 
Regulation Gene regulated Not regulated 
 
 
 It was first identified as a distinct form of cell death on the basis of its morphology, 
where tissue architecture is preserved and inflammation is minimal231.  Subsequent 
studies of its incidence, biochemistry and genetics have upheld predictions of its 
general role in controlled cell deletion and its genetically determined nature. The 
classic example of the role of apoptosis in embryogenesis is the programmed cell death 
of various human embryonic tissues, such as deletion of the finger webs. Apoptosis 
also plays a very important role in the development of T cells, by selecting self-tolerant 
T cells.  
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The earliest morphological changes in apoptotic cells include cell shrinkage and 
condensation of the cytoplasm. The nuclei become pyknotic and basophilic chromatin 
marginates to the periphery. Endonucleases cleave the nuclear DNA at 180-200-base 
pair intervals.  The DNA and cell content do not spill into the extra-cellular space and 
therefore do not provoke an inflammatory response. Eventually cells break into 
fragments, forming apoptotic bodies that are phagocytosed and removed232.  
 
Apoptosis is the net result of the balance between pro-apoptotic and anti-apoptotic 
stimuli, including cytokines, death receptors, caspases, mitochondria bcl-2 proto-
oncogenes and certain tumour-suppressor genes.  
 
Understanding apoptosis is important because it can potentially be controlled or 
manipulated to gain therapeutic advantage in certain disease states.   A delicate balance 
between apoptosis and survival of activated inflammatory cells is a fundamental 
mechanism for the homeostasis of the immune system.  
 
1.6.1 Pro-Apoptotic Factors 
Apoptosis is the endpoint of an energy-dependent cascade of molecular events, initiated 
by certain stimuli and consisting of 4 separable but overlapping events, namely:  
 
• Initiation of apoptosis via signalling pathways 
• Control and integration 
• Execution 
• Removal of dead cells  
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Apoptotic stimuli generate signals that are either transmitted across the cell membrane 
to intra-cellular regulatory molecules or directly affect targets within the cell. Death 
receptors are situated on the surface of certain cells and act as sensors to extra-cellular 
apoptotic signals. These include Fas (CD95) and TNFreceptorI and TNF-RII, and their 
corresponding ligands Fas ligand (FasL) and TNFα. 
  
TNFα is an established pro-apoptotic cytokine, released during the inflammatory 
process.  TNFα stimulation does not necessarily lead to apoptosis, but also to activation 
and proliferation, depending on the cell type, the receptor and other regulators.  Fas 
ligand is released by activated T cells, neutrophils and monocytes. Following 
activation, the signal for apoptosis is mediated by cleavage of caspases.  
 
In tuberculosis the first step in host defence is the ingestion and uptake of M. tb 
organisms by alveolar macrophages and other cells.  Apoptosis is an important host 
defence mechanism to contain mycobacterial survival and growth233.  By inducing 
apoptosis of macrophages containing organisms, the organism is deprived of its 
intracellular sanctuary and the process of apoptosis therefore favours the host233,234. It is 
possible that dissemination in tuberculosis depends at least in part on a paucity of 
apoptosis.  Insufficient T cell apoptosis may also interfere with clonal deletion and 
maintenance of tolerance, resulting in inappropriate T cell accumulation, contributing 
to chronic inflammation. This may lead to maintenance of the granulomas and to 
consequent fibrosis235.  
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Several factors control apoptosis. Dysregulation of the TNF-receptor and TNF-ligand 
superfamilies are involved in T-cell apoptosis, which occur in a number of fibrotic lung 
diseases235. The ratio of Th1/Th2 cells is also an important factor in regulating 
apoptosis through cytokine release. Th1 cytokines inhibit apoptosis, while Th2 
cytokines enhance apoptosis.  
 
1.7 Hypothesis  
Cytokine profiles determine clinical and histopathological phenotypes of disease. This 
thesis tests the hypothesis that this will be reflected by cytokine expression profiles in 
granulomas in different forms of tuberculous and in sarcoidosis.  
 
Sarcoidosis has been described as the prototype of a Th1 disease and one of the 
organisms considered as the aetiology in sarcoidosis is M.tb and is, apart from the 
overwhelming incidence of tuberculosis in the Western Cape, one of the relatively 
common granulomatous lung diseases diagnosed in the Western Cape.  On the other 
hand, in pulmonary tuberculosis, it is suggested that defective Th1 reactions result in 
immunopathology and caseous necrosis. Furthermore, pleural tuberculosis is often self-
healing, and may offer insights into more appropriate antimycobacterial immune 
responses.      
 
An in situ assessment of the cytokine profile of each of these diseases as well as a 
comparison between the various profiles will add to the understanding of the 
pathogenesis of these diseases.  
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2. Aims 
 
• To describe the Th1 and Th2 cytokine profile in patients with:  
o pleural tuberculosis,  
o sarcoidosis and 
o pulmonary tuberculosis 
by in situ hybridisation (ISH) and/or immunohistochemical techniques. 
The roles of the following cytokines will be investigated:  
IL-12 
IFNγ 
IL-4  
TNFα 
 
• To compare the cytokine profile of necrotic and non-necrotic granulomas in each of 
the diseases 
 
• To compare the cytokine profile in patients with tuberculosis and patients with 
sarcoidosis 
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3. Materials and Methods 
In situ hybridisation is a valuable tool in investigating tissue sections as the 
preservation of tissue morphology permits patterns of specific nucleic acid sequences to 
be localised in their cellular environment.  Immunohistochemistry, on the other hand, is 
a technique that applies immunological principles to tissue to identify cellular or tissue 
antigens through antigen-antibody interactions.  The site of antibody binding is 
identified either by direct labelling of the antibody, or by use of a secondary labelling 
method.  Excellent descriptions of the principles of both these techniques, as well as the 
advantages, disadvantages, pitfalls and false positive or negative results exist in the 
literature236,237,238.   
 
3.1 Pleural Tuberculosis 
To investigate the cytokine profile of patients with pleural tuberculosis, two groups of 
patients were examined. The one group consisted of 6 patients presenting with 
tuberculous pleural effusion and sero-negative for human immunodeficiency virus.  
The second group consisted of 6 patients presenting with tuberculous pleural effusions 
and sero-positive for human immunodeficiency virus. The clinical information 
available on these patients are summarised in Table 4.   
 
3.1.1 Tissue Specimens 
Pleural biopsy tissue was obtained from 12 patients presenting with pleural effusions at 
Tygerberg Hospital.  The biopsies were performed for diagnostic purposes.  After the 
diagnosis of tuberculosis was confirmed, the patients were put on standard, fixed-dose 
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anti-tuberculous treatment and referred back to their respective clinics. No follow-up 
data on these patients were available.   
 
Table 4: Clinical information on patients with pleural tuberculosis 
Patient Age /sex previous TB  Current RX Clinical presentation HIV serology 
1 39 / F No None (L) pleural effusion positive 
2 21 / F No None (R) pleural effusion positive 
3 31 / M No None (R) pleural effusion positive 
4 39 / F No None (R) pleural effusion positive 
5 43 / F No None (L) pleural effusion positive 
6 34 / M No None (L) pleural effusion positive 
7 71 / M No None (L) pleural effusion negative 
8 38 / M No None Bilateral pleural effusions negative 
9 41 / F No None (L) pleural effusion negative 
10 40 / M No None (L) pleural effusion negative 
11 42 / M No None (R) pleural effusion negative 
12 23 / M No None Bilateral pleural effusions negative 
Age in years F = female, M = Male RX = treatment (L) = left, (R) = right     
 
 
There were seven male and five female patients.  Tissue biopsies were routinely 
processed in the department of anatomical pathology and the diagnosis of tuberculosis 
was made, based on the presence of granulomatous inflammation and Ziehl-Neelsen 
positive bacilli239. All patients were subsequently culture positive for drug-sensitive M. 
tuberculosis. HIV serology was performed on all 12 patients by ELISA. 
 
3.1.2 Preparation of Riboprobes 
Peripheral mononuclear blood cells (PBMCs) were isolated from 10 ml of blood 
collected from a healthy volunteer. These cells were stimulated with 
phytohemagglutinin for 18 h prior to RNA extraction. The Tri-Reagent (Sigma 
Aldrich) was used to extract total RNA from the cells and quantified by measurement 
of absorbance at 260 nm. It was shown that the RNA was undegraded following 
electrophoresis of an aliquot in a 1% agarose gel containing 8% formaldehyde and 
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visualization of the RNA by ethidium bromide staining. The Titan (one-tube RT-PCR) 
system (Boehringer Mannheim, Mannheim, Germany) was used to prepare cDNA and 
PCR products for IL-4, TNFα, IFNγ, and β-actin from 2 mg of RNA, using PCR 
conditions and primer sequences as published elsewhere240,241.  
 
The vector pGEM7Zf (Promega U.K.), was digested with SmaI (Boehringer 
Mannheim) and the PCR products were blunted and cloned into this vector. Sequencing 
the clones confirmed the DNA sequence (Table 5) and ascertained the orientation of the 
PCR product in order to synthesize sense and antisense riboprobes.  
Table 5: Sequences of cytokine riboprobes used in ISH 
 
Riboprobe 
 
Length (bp) 
 
Sequence (5′–3′) 
 
TNFα 
 
124 
 
TCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCT
GAGGGGCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAAT
GGTGTGGAGCTGAGAGATA 
 
IFNγ 
 
356 
 
AGTTATATCTTGGCTTTTGAGCTCTGCATCGTTTTGGGTTCTCTTGGCTGTTACT
GCCAGGACCCATATGTACAAGAAGCAGAAAACCTTAAGAAATATTTTAATG
CAGGTCATTCAGATGTAGCGGATAATGGAACTCTTTTCTTAGGCATTTTGAA
GAATTGGAAAGAGGAGAGTGACAGAAAAATAATGCAGAGCCAAATTGTCT
CCTTTTACTTCAAACTTTTTAAAAACTTTAAAGATGACCAGAGCATCCAAAA
GAGTGTGGAGACCATCAAGGAAGACATGAATGTCAAGTTTTTCAATAGCAA
CAAAAAGAAACGAGATGACTTCGAAAAGCTGACTAATTATTCGGT 
 
IL-4 
 
317 
 
CTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAACTTTGTCCACGGACACA
AGTGCGATATCACCTTACAGGAGATCATCAAAACTTTGAACAGCCTCACAG
AGCAGAAGACTTGTGCACCGAGTTGACCGTAACAGACATCTTTGCTGCCTC
CAAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCG
GCAGTTCTACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGC
ACAGCAGTTCCACAGGCACAAGCAGCTGATCCGATTCCTGAAACGGCTCGA
CAGGAA 
  
 
 
IL-12 
 
301 
 
CCAACAACTTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGGAGTACCC
TGACACCTGGAGTACTCCACATTCCTACTTCTCCCTGACAGGTCCAGGGCAA
GAGCAAGAGAGAAAAGAAAGATAGAGTCTTCACCGACCACGGTCATCTGC
CGCAAAAATGCCAGCATTAGCGTGCGGGCCCAGGACCTCATCTTGGAGCGA
ATGGGCATCTGTGCCCTGCAGTTAGGTTCTGATCTTTGGAGGAAAAGTGGA
AGATATTAAGCAAAATGTTTAAAAGACACAACGGAATAGACCCA   
 
The fragments were separated by electrophoresis on 1% low-melting-point temperature 
agarose gels and isolated from the gel by using the Boehringer Mannheim DNA 
extraction protocol, after digestion with PvuI. T7 and SP6 RNA polymerases were used 
to transcribe antisense and sense digoxigenin-labeled RNA as instructed by the 
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manufacturer (Boehringer Mannheim).  In addition to preparing cDNA and PCR 
product for TNFα, IFNγ and IL-4, it was also prepared for IL-12p40. The IL-12 PCR 
product was then cloned into the vector pGEMTeasy (Promega, Southampton, UK) and 
sequenced. A 600-base pair fragment containing the IL-12 cDNA was obtained. 
Labelling of the probes was subsequently confirmed by Northern blot analysis, by first 
incubating filters with antidigoxigenin alkaline phosphatase-conjugated F(ab9)2 
fragments (Boehringer Mannheim), washing, and then incubating with BCIP-NBT-INT 
(5-bromo-4-chloro-3-indolylphosphate –nitroblue tetrazolium–iodonitrotetrazolium 
violet; Dako, Glostrup, Denmark)242 .  
 
 
3.1.3 RNA-RNA In Situ Hybridisation   
Paraffin-embedded lung tissue was cut into 5-mm sections using a microtome. As 
previously described1,243, consecutive sections were applied to RNase-free slides that 
were previously coated with aminopropyltriethoxysilane (5 mg/ml; Sigma Aldrich). 
Deparaffinisation in xylene, rehydration through graded ethanols and diethyl 
pyrocarbonate-treated water, and finally incubation in phosphate-buffered saline (PBS) 
of the sections followed. To facilitate antigen retrieval, the sections were treated with 1 
mg of proteinase K per ml in 10 mM Tris-HCl (pH 7.5)–5 mM EDTA for 45 min at 
37°C.  Sections were washed with PBS, refixed in 0.4% paraformaldehyde and 
acetylated in a 400:1 (vol/vol) solution of triethanolamine-acetic anhydride for 10 min. 
Subsequently the slides were then rinsed in PBS, dehydrated in graded ethanols, and air 
dried.  
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Hybridisation followed after drying of the slides. The first step was to incubate sections 
for 30 min at 50°C in a prehybridisation mixture containing 25% dextran sulfate, 25 
mM Tris-HCl (pH 8.0), 2.53 Denhardt’s solution, 2.5 mM EDTA, 25 mM 
dithiothreitol, 1.25 mg of herring sperm DNA per ml, 0.06 mg of tRNA per ml, and 
50% deionized formamide. Digoxigenin-labeled riboprobes (5 ng/ml) were added to a 
hybridisation mixture made up of 20% dextran sulfate, 12.5 mM Tris-HCl (pH 8.0), 
2.53 Denhardt’s solution, 2.5 mM EDTA, 12.5 mM dithiothreitol, 0.01 mg of herring 
sperm DNA per ml, 0.002 mg of tRNA per ml, and 50% deionized formamide. This 
mixture was added to the sections and  the sections were hybridised for 18 hours at 
50°C in a humidified chamber.  Afterwards the slides were twice washed at room 
temperature in 23 SSC (saline sodium citrate; 13 SSC is 0.15 M NaCl plus 0.015 M 
sodium citrate) for 15 min at a time and then twice at 43°C with 0.13 SSC for 15 min at 
a time. The slides were then incubated for 5 min in 100 mM Tris-HCl (pH 7.5)–150 
mM NaCl (buffer A). After incubation it was placed in buffer A containing 2% normal 
sheep serum, and washed in buffer A plus 0.05% Tween 20.  
 
The final steps were incubation of the sections with antidigoxigenin antibody 
conjugated to alkaline phosphatase (Boehringer Mannheim) for 30 min at room 
temperature, and detection of the signal by BCIP-NBT-INT (Dako). A psotive reaction 
was demonstrated by the appearance of a brown colour (up to 60 min), and the slides 
were then counterstained with Mayer’s hematoxylin (Sigma Aldrich) for 15 s, rinsed in 
distilled water, and mounted with Dako Faramount. After proper drying of the 
coverslips, the slides were viewed under a light microscope. 
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3.1.4 Assessment of Slides 
A map of each section was created by photographing the slides at x25 magnification 
and printing out a copy of the photograph (fig. 8). Each granuloma was numbered.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: An example of the granuloma map for one of the cases. Each granuloma is circled, 
numbered and scored according to the number of positive cells present. 
 
The slides were then examined under the light microscope and the cytokine profile of 
each numbered granuloma was recorded (at x400 magnification) on the photographic 
map as follows:  
• >75% of cells in a granuloma positive: documented as a score of 3 
• <75% but >25% of cells in a granuloma positive: documented as a score of 2 
• <25% of cells in a granuloma positive: documented as a score of 1 
• no cells positive: documented as a score of 0  
 
Gr. 1 
IL-12=3
IFN=3 
TNF=3 
IL-4=0
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3.1.5 Statistical Analysis 
All granulomas were regarded as independent parameters.  
Statistical analysis was performed to investigate the following, applying Pearson Chi 
square and Spearman rank R tests: 
• The association between HIV serology and presence of necrosis. 
• The association between HIV and individual cytokines 
• Comparisons in association patterns between various cytokines were compared 
between HIV negative and HIV positive granulomas. 
• The association between necrosis and individual cytokines. 
• Comparisons in association patterns between various cytokines were compared 
between necrotic and non-necrotic granulomas. 
• Comparisons in association patterns between various cytokines, HIV serology and 
necrosis were compared between the various cytokines at a given percentage. 
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3.2 Sarcoidosis  
To investigate the cytokine profile of patients with sarcoidosis, open lung biopsies from 
a group of 15 patients with sarcoidosis were examined. The clinical information 
available on these patients are summarised in Table 6. The diagnosis of sarcoidosis was 
made in consultation with the pulmonologists and radiologists, based on the clinical, 
radiological and histological appearance of the disease and other possible causes of 
granulomatous lung disease had been excluded.  
  
Table 6: Clinical information and radiological staging of patients 
Age in years F = female, M = Male RX = treatment   
 
 
3.2.1 Tissue Specimens 
Lung tissue for histological examination was obtained from 15 patients at Tygerberg 
Hospital, with the clinico-radiological appearance of pulmonary sarcoidosis. The 
Patient Age/Sex Previous TB 
Rx at 
diagnosis 
Radiological 
staging Follow up 
S1 35/F No None 2 2 years, healthy 
S2 21/F No None 3 2 years, healthy 
S3 27/F No  None 2 6 years, healthy 
S4 36/F No None 2 3 years, respiratory 
failure 
S5 35/F No None 2 12 years, healthy 
S6 27/F No None 3 1,5yrs 
S7 26/F No None 2 6 years, Grade I 
dyspnoea 
S8 54/M No None 2 2 years, died 
S9 36/F No None 3 5 years, grade II 
dyspnoea 
S10 29/F No None 2 1 year, healthy 
S11 37/F No  None 2 1,5 years, died 
S12 25/M No None 2 5 years 
S13 36/F No None 2 1 year, healthy 
S14 23/F No None 2 2yrs 
S15 45/F No None 3            2 years, healthy 
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biopsies were performed for diagnostic purposes. Tissue biopsies were routinely 
processed in the department of anatomical pathology and after clinico-pathological 
consultation and exclusion of other possible causes of pulmonary granulomatous 
disease, the diagnosis of sarcoidosis was confirmed and the patients were put on 
treatment. Follow-up on these patients was available (table 6).   There were two male 
and thirteen female patients.   
 
 
3.2.2 Histological Grading 
The histological grading as discussed in the introduction was applied to these 15 cases.  
 
 
3.2.3 Preparation of the Riboprobes, RNA-RNA In Situ Hybridisation and Assessment of 
Slides 
The methodology used for the preparation of the riboprobes, performance of in situ 
hybridisation and assessment of slides was identical to that described for the pleural 
tuberculosis case above, except for the following additions and changes1,2,238.  
 
TNFα, IFNγ, IL-4 and IL-12 PCR product was cloned into the vector pGEMTeasy 
(Promega, Southampton, UK) and sequenced. To synthesize sense and antisense 
biotinylated, labelled riboprobes, T7 or SP6 RNA polymerases were then added 
according to the manufacturers' instructions (Gibco BRL, Basel, Switzerland).  
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Northern blot analysis using streptavidin-conjugated alkaline-phosphatase (Gibco BRL) 
and the substrate nitroblue tetrazolium chloride/5-bromo-4-chloro-3 indolyl- phosphate 
p-toluidine salt (NBT/BCIP) (Gibco BRL) confirmed labelling of the probes.  
 
 
3.2.4 RNA: RNA in situ hybridisation  
Proteinase K treatment, prehybridisation and hybridisation protocols were as previously 
described. After hybridisation, the slides were washed in 2x saline sodium citrate for 15 
min at room temperature and repeated once, after which the sections were blocked with 
100 μl blocking reagent (Gibco BRL) for 15 min at room temperature, followed by 100 
μl streptavidin-conjugated alkaline phosphatase diluted 1:10 in conjugate buffer for 30 
min also at room temperature. Slides were then washed twice in 100 mM Tris-HCl (pH 
7-5), 150 mM NaCI for 15 min at room temperature and the signal was then detected 
using NBT/BCIP. A blue/purple colour appeared when positive and the sections were 
counterstained with methyl green (Dako) for 10 seconds, rinsed in distilled water and 
mounted with Dako faramount. After proper drying of the coverslips, the slides were 
viewed under a light microscope.  
 
β-Actin was used as a positive control for the presence of mRNA within the tissue 
sections. β-Actin mRNA is ubiquitous in cells and therefore both a perfect positive 
control for the technique (but not for the specific probe) and also an indication of the 
immunoreactivity of the tissue.  Pretreatment of the sections by ribonuclease (RNase) 
before hybridisations further confirmed the specificity of the hybridisation signal.  
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3.2.5 Assessment of the slides 
The same principal described in the section on pleural tuberculosis was applied in 
sarcoidosis.  
 
3.2.6 Statistical Analysis 
Due to the uniform nature of the sarcoidosis results as can be seen in Chapter    
5, there was no requirement to perform any statistical analysis on the results. 
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3.3 Pulmonary Tuberculosis 
To investigate the cytokine profile of patients with pulmonary tuberculosis, two groups 
of patients were examined.  Two different patient groups had to be tested, as there was 
an insufficient amount of tissue available to perform the complete set of investigations 
on one group alone.  Additional ISH, as well as immunohistochemistry had to be 
performed on sections from the new group of patients with a similar clinical 
presentation to the first group. The 2 groups will be discussed separately and are 
labelled “first group of patients” and “second group of patients”.  
 
3.3.1 First Group of Patients 
3.3.1.1 Tissue Specimens  
Adult lung tissue obtained from five patients undergoing surgery for haemoptysis at 
Tygerberg Hospital was examined. There were four males and one female with TB and 
all had upper lobe cavitation. All five had received treatment for between 2 and 3 
months prior to surgery (Table 7). Diagnosis was confirmed by Ziehl-Neelsen staining, 
all patients had been culture positive for drug-sensitive M. tuberculosis and sero-
negative for HIV by ELISA.  
 
Table 7:Clinical details of first group of patients with pulmonary tuberculosis  
Patient Age  / sex Time since previous TB 
(years) 
Preoperative treatment 
duration (months)  
Chest 
radiograph 
A1 39/M 3 2 RUL cavity 
A2 35/M 15 3 RUL cavity 
A3 26/F 3.4 2 LUL cavity 
A4 23/M 3 2 LUL cavity 
A5 31/M 5 3 LUL cavity 
Age in years M = male, F = female RUL = Right upper lobe; LUL = Left upper lobe 
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The patients had recurrent disease, as they had all been successfully treated for 
tuberculosis between 3 and 15 years previously (Table 7). Directly after surgery, tissue 
was selectively dissected for formaldehyde fixation. All patients successfully 
completed their anti-TB therapy, but were lost for follow-up thereafter.  
 
 
3.3.1.2 Preparation of the Riboprobes, RNA-RNA In Situ Hybridisation and Assessment 
of Slides 
Preparation of the probes and ISH were performed according to the methods described 
earlier. BCIP-NBTINT (Dako) was used for detection.  The slides were examined 
under the light microscope and the results were recorded as positive (1) or negative (0) 
at x400 magnification.  The number of granulomas present in each biopsy was counted 
and the presence or absence of cytokines was noted in each of the granulomas.  
 
3.3.1.3 Statistical Analysis 
Statistical analysis was not originally performed on these cases, but as part of this thesis 
Pearson Chi square and Spearman rank R tests were performed.   
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3.3.2 Second Group of Patients 
 
Adult lung tissue was obtained from seven patients undergoing surgery for haemoptysis 
at Tygerberg Hospital (Table 8). Diagnosis was confirmed by Ziehl-Neelsen staining, 
all patients were culture positive for drug-sensitive M. tuberculosis, and sero-negative 
for HIV by ELISA. All patients completed their anti-tuberculosis therapy and follow-
up varied from none to 8 years.  
Table 8:Clinical details of patients of 2nd group of patients with pulmonary tuberculosis 
Patient Age/Sex Extent of disease Time since 
previous TB 
Pre-
operative 
treatment  
Follow-up 
B1 23/M RUL collapse 2 years 1 month 8 years, 
healthy 
B2 43/M LUL cavitation with active 
TB 
3 years 1 month 1 years, 
healthy 
B3 33/F LUL large cavity, RUL 
and LLL infiltration 
11 years 3 months 9 years, 
chronic 
asthma 
B4 31/F Mediastinal shift left, 
pleural effusion, scarring 
RUL 
3 years 3 months 4 years, 
healthy 
B5 22/M Cavitations RUL and 
RML, coughing up ascaris 
2.5 years 3 months None 
B6 21/F Total destruction RUL, 
cystic lesions in LUL 
17 years 2 months 1 month, 
healthy 
B7 41/M R lung collapse, fibrosis. L 
lung unaffected 
6 years 3 months 5 years, 
chronic 
empyema 
Age in years M = male, F = female RUL = Right upper lobe; LUL = Left upper lobe;  
LLL = Left lower lobe; RML = Right middle lobe 
 
 
3.3.2.1 Immunohistochemistry  
Sections were dewaxed, rehydrated through graded alcohols and washed in distilled 
water. Endogenous peroxidases were blocked and antigen retrieval performed by 
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microwaving of the sections in 0.01M citrate buffer pH 6-0 for 20 min.  Care was taken 
not to allow the citrate buffer to evaporate and after 5 min the citrate buffer was topped 
up. Sections were left in the microwave for 15 min and then placed into phosphate-
buffered saline (PBS) for 5 min. Five percent rabbit serum for 10 minutes was used to 
block non-specific proteins. Goat anti-human IFNγ, IL-4 and TNFα antibodies (R & D 
Systems, Oxford, UK) were diluted 1:400 in rabbit serum (final concentration 250 
ng/ml) and incubated on the sections overnight at 4°C.  
 
The following day the sections were then washed for 15 min in PBS. This was followed 
by incubation of the section with a  secondary antibody, biotinylated rabbit anti-goat 
immunoglobulin G (IgG; R & D Systems), diluted 1:100 for 1 hr at 4°. The sections 
were again washed for 15 min in PBS and incubated with streptavidin-horse radish 
peroxidase (Dako, Cambridge, UK) for 30 min. The 3'3-diaminobenzedine substrate 
(Dako) was then added to the sections (according to the manufacturer's instructions),  
counterstained with haematoxylin (Dako), washed in running tap water and mounted 
with Paramount (Dako).  
 
A control antibody (protein G-purified goat IgG, Santa Cruz, CA) was included, which 
was diluted to a final concentration of 250 ng/ml. As an additional control the primary 
antibody was also excluded from the overnight incubation step and these sections were 
only incubated with the secondary antibody. The specificity of the polyclonal 
antibodies was also tested. Preincubation of the primary antibody with the relevant 
recombinant cytokine established specificity. The antibodies (250 ng/ml) and the 
respective antigens (IFNγ, TNFα and IL-4 all at 50 μg/ml, all from R & D Systems) 
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were incubated together in for 30 min at room temperature. Antibodies were also 
incubated without their respective recombinant cytokine. Staining was performed as 
described above on sections from one IL-4-positive patient. 
 
3.3.2.2 Preparation of the Riboprobes, RNA-RNA In Situ Hybridisation and Assessment 
of Slides 
Preparation of the riboprobes, RNA-RNA in situ hybridisation and assessment of slides 
were performed as described earlier. Signal was detected using NBT/BCIP.  
 
3.3.2.3 Assessment of slides  
The sections were examined to determine to the presence or absence of the relevant 
colour reaction. The individual granulomas from all of the patients were scored as 
either positive or negative for each cytokine and caseous necrosis. 
 
3.3.2.4 Statistical analysis  
To test for association between pairs of cytokines and necrosis a two-tailed Fisher's 
exact test was used. Comparisons of association patterns between IL-4-positive and IL-
4-negative patients were made using a Mantel Haenszel x2 test. Comparisons between 
those granulomas staining alike with those staining differently for two cytokines were 
compared between IL-4-positive and IL-4-negative patients using Fisher's exact test.  
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3.4 Controls 
Lung tissue specimens were obtained from 2 patients undergoing surgery for 
pulmonary malignancies. Tissue samples were routinely processed and ISH for mRNA 
of all 4 cytokines was performed on the sections. Consecutive tissue sections of these 
cases were used as negative controls and the antisense probe was omitted. 
 
As negative controls, consecutive tissue sections of the cases studied were used and the 
antisense probe was omitted.  
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4. Results: Pleural Tuberculosis 
Pleural tuberculosis in HIV-negative subjects has been taken to represent a protective 
immune response to Mycobacterium tuberculosis because a high proportion of 
individuals recover without antibiotic therapy 120. A tuberculous pleural effusion in 
HIV-negative subjects is usually associated with a prominent cell-mediated immune 
response, represented by an infiltration of CD4+ T cells121 and high levels of pro-
inflammatory cytokines, including IFNγ and TNFα 122, suggesting a predominantly 
Th1 response.   
 
This appears to indicate a key role for these responses in protective immunity against 
tuberculosis in humans, in keeping with evidence that IFNγ and TNFα are necessary 
for protective immunity to tuberculosis in animals123,124,125, and that abnormalities of 
the IFNγ receptor are associated with susceptibility to mycobacterial disease in 
humans126,127. 
 
In HIV-positive patients, it has been hypothesized that qualitative T-helper-type 
responses may also impact on AIDS pathogenesis. A switch in the predominant 
response from a Th1 to a Th2 response and the production of associated cytokines may 
facilitate disease progression147,148,149. Numerous studies have shown that during the 
progression of HIV-1 disease, mononuclear cells lose their ability to secrete Th1 
cytokines and instead produce increased levels of the Th2 cytokines178.  
 
A Th phenotype switch in HIV positive patients should also be reflected in the 
granulomatous response to M.tb and differences in cytokine gene expression at the site 
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of disease in HIV positive and negative patients might offer important insights into 
appropriate antituberculous responses.    
 
4.1 Experimental Design 
To investigate the cytokine profile of patients with pleural tuberculosis, two groups of 
patients presenting with pleural effusions were examined, one group of 6 patients sero-
negative for HIV and the second group sero-positive for HIV. Pleural biopsy tissue was 
obtained, the diagnosis of tuberculosis was confirmed, and ISH was performed for IL-
12-, IFNγ-, TNFα- and IL-4-mRNA on all 12 cases.  
 
The cytokine profile of each granuloma was recorded on the photographic map as 
follows:  
• >75% of cells in a granuloma positive: documented as a score of 3 
• <75% but >25% of cells in a granuloma positive: documented as a score of 2 
• <25% of cells in a granuloma positive: documented as a score of 1 
• no cells positive: documented as a score of 0  
 
Statistical analysis was performed to test for the association between:  
• HIV serology and presence of necrosis. 
• Necrosis and individual cytokines. 
• HIV and individual cytokines. 
• Comparisons in association patterns between various cytokines were 
compared between necrotic and non-necrotic granulomas. 
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• Comparisons of association patterns between various cytokines were 
compared between HIV negative and HIV positive granulomas. 
• Comparisons of association patterns between various cytokines, HIV 
serology and necrosis were compared between the various cytokines at a 
given percentage. 
 
4.2 Results 
Throughout the results and the subsequent discussion the following are used as synonyms:  
For > 75% positive cells: majority of cells, high number of cells, Grade3.   
For 25-75% positive cells: a moderate number, intermediate, Grade 2 
For < 25% positive cells:  few cells, Grade 1 
Negative: a score of 0,no positive cells 
Equal distribution: no significant difference between the three groups i.e.:  75% positive cells, 
25-75% positive cells, < 25% positive cells. 
 
Pleural biopsy tissue from two groups of patients presenting with pleural effusions was 
examined, one group of 6 patients sero-negative for HIV and the second group sero-
positive for HIV. The number of necrotic and non-necrotic granulomas was determined 
on H + E stain and the cytokine mRNA profile was determined by ISH for IL-12-, 
IFNγ-, TNFα- and IL-4-mRNA on all 12 cases.   
 
All patients with pleural tuberculosis presented with symptoms of pleuritis and had a 
CXR to confirm the effusion before a pleural biopsy was performed as a diagnostic 
procedure (table 9). Histological and microbiological confirmation of the diagnosis of 
tuberculosis resulted in initiation of treatment and discharge with referral to primary 
health clinics where the patients were further treated and followed up.  No follow-up of 
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the patients was available in our records.  An HIV ELISA test was performed on all 
these patients, as part of the routine work-up of possible tuberculosis cases. 
 
The patients’ age ranged from 21 years to 71 years with 9 of the patients in their 4th or 
5th decade. Five patients were female and seven were male. None had any additional 
medical history of any significance.    
 
Table 9: Demographic and clinical information on patients with pleural tuberculosis.  
The table shows the basic demographic and clinical characteristics of 12 patients with TB pleuritis who 
were recruited for the histological study of closed Abrams needle pleural biopsy samples.   
Patient Age /sex previous TB  Current RX Clinical presentation HIV serology 
1 39 / F No None (L) pleural effusion positive 
2 21 / F No None (R) pleural effusion positive 
3 31 / M No None (R) pleural effusion positive 
4 39 / F No None (R) pleural effusion positive 
5 43 / F No None (L) pleural effusion positive 
6 34 / M No None (L) pleural effusion positive 
7 71 / M No None (L) pleural effusion negative 
8 38 / M No None Bilateral pleural effusions negative 
9 41 / F No None (L) pleural effusion negative 
10 40 / M No None (L) pleural effusion negative 
11 42 / M No None (R) pleural effusion negative 
12 23 / M No None Bilateral pleural effusions negative 
Age in years F = female, M = Male RX = treatment (L) = left, (R) = right     
 
 
4.2.1 Interpretation of the slides 
Representative examples of the light microscopic appearance of the ISH can be seen in 
figs. 9-16. For complete scoring please see Appendix A. Positivity is represented by 
brown staining of the cytoplasm as described in the methods and indicates the presence 
of mRNA. Cells staining brown therefore contain mRNA for the specific cytokine 
tested. Counterstaining is blue, as described in the methods. Cells that stain negative do 
not contain the specific RNA and will therefore stain blue. These photographs were 
selected to illustrate the quality of staining for the various cytokine mRNAs. No 
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difference was seen between the staining quality of sections in HIV negative versus 
HIV positive patients or necrotic versus non-necrotic granulomas.    
 
The focus of the study was on the number of cells that are positive for a specific 
cytokine within the granuloma and the sources of the cytokines were not determined. 
This does not however, detract from the fact that the cytokine mRNA was present. 
Documented sources of these cytokines were discussed in chapter 1.  
 
Thick irregular dark lines on the photographs represent folds in tissue sections, which 
often occur during sectioning.   
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Figure 9: Pleural tuberculosis: anti-sense for β-actin diffusely positive (x100 magnification). 
A representative section of a pleural needle biopsy from an HIV- patient is shown. ISH with the anti-
sense β-actin probe was performed after appropriate preparation of paraffin-embedded tissue.  The β-
actin probes were used to determine the presence of non-degraded mRNA in sections. The brown 
staining represents positive signal and intact mRNA. Granulomas are outlined in black. 100 times 
magnification was used for this photograph. Caseous necrosis = CN.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Pleural tuberculosis: sense probes and negative controls show no staining (x40 
magnification).   
A representative section of a pleural needle biopsy from an HIV- patient is shown. ISH with the sense 
probes for β-actin, IL-12, IFN and IL-4 was performed after appropriate preparation of paraffin-
embedded tissue.  No brown staining represents positive signal was observed.   
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Figure 11: Pleural tuberculosis: anti-sense for IL-12, > 75% cells positive (x100 magnification). 
A representative section of a pleural needle biopsy from an HIV- patient is shown. ISH with the anti-
sense IL-12 probe was performed after appropriate preparation of paraffin-embedded tissue. The brown 
staining represents positive signal and intact mRNA. Granulomas are outlined in black. A 40 times 
magnification was used and a 400 times magnification for the insert, which shows that the signal is 
concentrated in lymphocytes. Caseous necrosis = CN.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Pleural tuberculosis: anti-sense probe for IFNγ, > 75% cells positive positive  
A representative section of a pleural needle biopsy from an HIV- patient is shown. ISH with the anti-
sense IFNγ probe was performed after appropriate preparation of paraffin-embedded tissue.  The brown 
staining represents positive signal. Granulomas are outlined in black.  A 40 times magnification was used 
and a 400 times magnification for the insert, which shows that the signal is concentrated in lymphocytes. 
Caseous necrosis = CN. 
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Figure 13: Pleural tuberculosis: anti-sense probe for TNFα, > 75% cells positive positive 
A representative section of a pleural needle biopsy from an HIV- patient is shown. ISH with the anti-
sense TNFα probe was performed after appropriate preparation of paraffin-embedded tissue.  The brown 
staining represents positive signal. Granulomas are outlined in black.   A 40 times magnification was 
used and a 400 times magnification for the insert, which shows that the signal is concentrated in 
lymphocytes. Caseous necrosis = CN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Pleural tuberculosis: anti-sense probe for IL-4, > 75% cells positive positive  
A representative section of a pleural needle biopsy from an HIV- patient is shown. ISH with the anti-
sense IL-4 probe was performed after appropriate preparation of paraffin-embedded tissue.  The brown 
staining represents positive signal. Granulomas are outlined in black.    A 40 times magnification was 
used and a 400 times magnification for the insert, which shows that the signal is concentrated in 
lymphocytes. Caseous necrosis = CN.  
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Figure 15: Pleural tuberculosis: anti-sense probe for TNFα, 25-75% cells positive 
A representative section of a pleural needle biopsy from an HIV+ patient is shown. ISH with the anti-
sense TNFα probe was performed after appropriate preparation of paraffin-embedded tissue. Granuloma 
outlined in black. No necrosis present. Although there is prominent positivity, it is clear that there is 
between 25-75% of the cells that are positive. The brown staining represents positive signal (200x 
magnification). Most negativity is seen in the lymphocyte cuff.    
 
 
 
 
 
 
 
 
 
Figure 16:  Pleural tuberculosis: anti-sense probe for IL-12,  <25% cells positive 
A representative section of a pleural needle biopsy from an HIV+ patient is shown. ISH with the anti-
sense IL-12 probe was performed after appropriate preparation of paraffin-embedded tissue. Granuloma 
outlined in black. No necrosis present. The brown staining represents positive signal (200x 
magnification) identified by arrows.  Very few cells are positive, clearly indicating <25% positivity.  
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4.2.2 HIV and Necrosis 
Pleural biopsy tissue from two groups of patients presenting with pleural effusions was 
examined, one group of 6 patients sero-negative for HIV and the second group sero-
positive for HIV. The number of necrotic and non-necrotic granulomas was determined 
on H and E stain and the cytokine mRNA profile was determined by ISH for IL-12-, 
IFNγ-, TNFα- and IL-4-mRNA on all 12 cases. A total of 166 granulomas was counted 
in these patients. In the HIV negative patients a total of 125 granulomas was counted, 
of which 104 were not necrotic and 21 had signs of caseous necrosis.   In the HIV 
positive group 41 granulomas were counted, of which 34% (n = 14) were not necrotic 
and 66% (n = 27) showed signs of caseous necrosis (fig. 17). 
Figure 17:A comparison between HIV status and necrosis in 166 granulomas.  
Pleural biopsies from 6 HIV negative and 6 HIV positive patients were examined. There were 166 
granulomas in total and the HIV negative patients had a total number of 125 granulomas (represented in 
green) of which 104 were non-necrotic and 21 necrotic. The HIV positive patients (represented in blue) 
had 41 granulomas of which 14 were non-necrotic and 27 necrotic (Chi-square test   p = <0.01). 
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On the other hand in the HIV negative group 83% of granulomas were non-necrotic 
and 17% showed signs of necrosis. There was a clear association between HIV 
positivity and necrotic granulomas as well as HIV negativity and non-necrotic 
granulomas (Chi-square test: p <0.01).    
 
4.2.3 Necrosis and Individual Cytokines 
In an analysis of the relation between the individual cytokines and necrosis in the 
granulomas, the tendency was for the necrotic granulomas to have more positive cells 
in comparison to the non-necrotic granulomas (figs. 18-21). This was applicable for 
cytokines, except IL-12, where there was a more equal distribution of the percentage of 
positive cells between necrotic and non-necrotic granulomas (fig. 18 and table 10).  
 
Forty percent of necrotic granulomas have >75% IFNγ-positive cells (fig. 19), which is 
more than IL-4, but less than TNFα.   With TNFα especially (fig. 20), a dramatic 
increase in the number of granulomas with a Grade 3 (>75%) distribution could be seen 
in necrotic granulomas. The percentage of IL-4 positive cells are illustrated in fig. 21. 
Fifty three percent of non-necrotic granulomas had either no IL-4 positive cells (3%) or 
less than 25% positive cells (50%).  On the other hand in necrotic granulomas 77% 
were either Grade 2 (42%) or Grade 3 (35%).  
 
Table 10:The % of granulomas positive for specific cytokines in the necrotic and non-necrotic 
groups of granulomas. 
 This table represents a summary of the data presented in figs. 16-19. An increase in the percentage of 
positive cells is noted in necrotic granulomas, especially TNFα, where 64% of granulomas have > 
75% positive cells.   
 Non-necrotic granulomas Necrotic granulomas Chi-square  
 0 1 2 3 0 1 2 3    test 
IL-12 0 31% 44% 25% 0 23% 54% 23% p = 0.50 
IFNγ 0 48% 35% 17% 0 35% 25% 40% p = 0.01 
TNFα 0 35% 42% 24% 0 17% 19% 64% p < 0.01 
IL-4 3% 50% 26% 21% 6% 17% 42% 35% P < 0.01 
  105
Figure 18:Distribution of IL-12 positive cells in necrotic and non-necrotic granulomas 
 
 
 
 
Figure 19: Distribution of IFNγ positive cells in necrotic and non-necrotic granulomas 
The presence of IFNγ positive cells was assessed by ISH in the same 166 granulomas as presented in 
figure 17. Positivity was graded according to the total number of cells staining positive in a specific 
granuloma (<25%, 25-75% and >75%). The percentage of necrotic and non-necrotic granulomas in each 
of these categories was calculated and is represented in this graph. More necrotic granulomas contain > 
75% positive of positive cells than non-necrotic granulomas (Chi-square test   p = 0.01).  
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The presence of IL-12 positive cells was assessed by ISH in the same 166 granulomas as presented in 
figure 17. Positivity was graded according to the total number of cells staining positive in a specific 
granuloma (<25%, 25-75% and >75%). The percentage of necrotic and non-necrotic granulomas in 
each of these categories was calculated and is represented in this graph. The presence of necrosis did 
not significantly influence the percentage of IL-12 positive cells (Chi-square test p = 0.47).
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Figure 20: Necrotic granulomas are associated with increased TNFα positivity.  
 The presence of TNFα positive cells was assessed by ISH in the same 166 granulomas as presented in 
figure 17.Positivity was graded according to the total number of cells staining positive in a specific 
granuloma (<25%, 25-75% and >75%). The percentage of necrotic and non-necrotic granulomas in each 
of these categories was calculated and is represented in this graph. Necrotic granulomas had a 
significantly higher percentage of granulomas where > 75% of cells expressed TNFα (Chi-square test    
p < 0.01). 
Figure 21: Distribution of IL-4 positive cells in necrotic and non-necrotic granulomas.  
 The presence of IL-4 positive cells was assessed by ISH in the same 166 granulomas as presented in 
figure 17.Positivity was graded according to the total number of cells staining positive in a specific 
granuloma (<25%, 25-75% and >75%). The percentage of necrotic and non-necrotic granulomas in each 
of these categories was calculated and is represented in this graph. Necrotic granulomas had a 
significantly higher percentage of granulomas where > 75% of cells were positive for IL-4 mRNA (Chi-
square test   p < 0.01). 
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4.2.4 HIV and Individual Cytokines 
It is clear from these results presented in fig. 22 that there was also a strong association 
between > 75% TNFα positive cells and HIV positivity, while there was a more equal 
distribution of the percentage of TNFα positive cells in HIV negative granulomas (Fig. 
22).  In HIV negative granulomas IL-4  (Fig. 23) followed a similar pattern to the 
pattern in necrosis, with an almost equal distribution between Grade 1 (46%) on the one 
hand and Grade 2 (26%) plus Grade 3 (26%) on the other.   
 
Figure 22: Distribution of TNFα positive cells in HIV positive and negative granulomas.   
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TNFα expression was examined by ISH of 166 granulomas as presented in fig 17. Positivity was graded 
according to the total number of cells staining positive in a specific granuloma (<25%, 25-75% and >75%). 
The percentage of HIV positive and negative granulomas in each of these categories was calculated and is 
represented in this graph. HIV positive granulomas had a significantly higher percentage of granulomas 
where the majority of cells expressed TNFα (Chi-square test   p < 0.01) 
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Figure 23:Distribution of IL-4 positive cells in HIV positive and negative granulomas.  
 
In HIV positive granulomas the picture changed with most granulomas either Grade 2 
(46%) or 3 (22%).  A similar picture could be seen with IFNγ (Fig. 24), while the IL-12 
(fig. 25) picture was not as absolute, but favoured Grades 1 (31%) and 2 (46%) in HIV 
negative granulomas and Grades 2(49%) and 3 (31%) in HIV positive granulomas. A 
summary of this data can be seen in Table 11.  
 
Table 11: The % of granulomas positive for specific cytokines in the HIV negative and HIV 
positive groups of granulomas.  
This table represents as summary of the data presented in figs. 20-23. An increase in the number of 
positive cells is noted in HIV positive granulomas, and especially TNFα.   
 
 
 HIV negative granulomas HIV positive granulomas Chi-square  
 0 1 2 3 0 1 2 3    test 
IL-12 0 31% 46% 23% 0 20% 49% 31% p = 0.03 
IFNγ 0 50% 30% 20% 0 26% 37% 37% p = 0.02 
TNFα 0 31% 42% 27% 0 24% 15% 61% p < 0.01 
IL-4 2% 46% 26% 26% 7% 24% 46% 23% p = 0.02 
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IL-4 expression was examined by ISH on 166 granulomas as presented in fig 17. Positivity was graded 
according to the total number of cells staining positive in a specific granuloma (<25%, 25-75% and 
>75%). The percentage of HIV positive and negative granulomas in each of these categories was 
calculated and is represented in this graph. HIV negative granulomas had a significantly higher 
percentage of granulomas where the minority of cells expressed IL-4 (Chi-square test   p = 0.02) 
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Figure 24: Distribution of IFNγ positive cells in HIV positive and negative granulomas. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Distribution of IL-12 positive cells in HIV positive and negative granulomas.  
IL-12 expression was examined by ISH on 166 granulomas as presented in fig 17. Positivity was graded 
according to the total number of cells staining positive in a specific granuloma (<25%, 25-75% and 
>75%). The percentage of HIV positive and negative granulomas in each of these categories was 
calculated and is represented in this graph. A fairly even distribution of IL-12 positive cells was seen, 
with almost 50% of granulomas containing 25 – 75% positive cells. (Chi-square test   p = 0.027). 
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IFNγ expression was examined by ISH on 166 granulomas as presented in fig 17. Positivity was graded 
according to the total number of cells staining positive in a specific granuloma (<25%, 25-75% and >75%). 
The percentage of HIV positive and negative granulomas in each of these categories was calculated and is 
represented in this graph. HIV positive granulomas had a significantly higher percentage of granulomas 
where the majority of cells expressed IFNγ (Chi-square test   p = 0.016). 
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4.2.5 Necrosis in Granulomas   
For the purpose of this section the HIV status of the patients was excluded and 
granulomas were only assessed on the presence of necrosis, to establish whether there 
was any correlation between necrosis and the cytokines, independent of HIV status. 
Further discussion on the relationship between HIV status, necrosis and cytokines will 
follow in subsequent sections. 
 
4.2.5.1 Non-necrotic granulomas 
There were 118 non-necrotic granulomas in total, 115 of which were IL-4 positive, 
while all 118 were TNFα, IFNγ and IL-12 positive.  There were however differences in 
the number of positive cells in the various circumstances.   
 
It was clear that a significant number of non-necrotic granulomas had low quantities of 
IL-4 and TNFα  positive cells (Tables 12 and 13).  Less than 25% of all the non-
necrotic granulomas had a high number of either TNF, IL-4 and of these only 12% had 
high numbers of both. On the other hand 50% of all non-necrotic granulomas had 
<25% IL-4 positive cells (27% of these also <25% TNF positive cells). However, there 
was a clear association between the number of IL-4 positive and TNFα cells in non-
necrotic granulomas. Granulomas with high numbers of IL-4 positive cells, tended also 
to have high numbers of TNFα positive cells (Spearman rank R - positive correlation,   
r = 0.46). 
 
The relationship between IL-4 and IFNγ was a little less strong (r = 0.33), but 34% of 
the granulomas had low numbers of positive cells for both cytokines (Table 12 and 13). 
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In fact, this was a higher number of granulomas than those with a low number of IL-4 
and TNF positive cells.  Only 8 non-necrotic granulomas (7%) had high numbers of IL-
4 and IFNγ positive cells. 
 
A positive correlation also exists between IL-4 and IL-12 (r = 0.39), but there was a 
more even distribution of cells than in the previous two groups. There were less 
granulomas with low numbers of cells for both cytokines (20%), as opposed to the two 
previous groups with 27% and 34% respectively. 
 
Table 12: Correlation of the various cytokines in necrotic and non-necrotic granulomas.  
Strong positive correlations exist between most of the cytokines. See text for detailed discussion of table.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlations are expressed as % of the total number of granulomas counted, while the figures in the total columns 
represent the actual number of granulomas. Percentages in italics indicate statistically significant correlations.  
0 = no positive cells 1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75%positive cells  
 
 
IL-4 vs IFNγ 
Non-necrotic granulomas p < 0.01 
IL-4  IFN   
 1 2 3 Total 
0 0 0.85 1.69 3 
1 33.9 11.86 4.24 59 
2 11.02 11.02 4.24 31 
3 3.39 11.02 6.78 25 
Total 57 41 20 118 
Necrotic granulomas p = 0.1 
0 6.25 0 0 3 
1 14.58 2.08 0 8 
2 14.58 10.42 16.67 20 
3 0 12.5 22.92 17 
Total 17 12 19 48 
IL-4 vs IL-12 
Non-necrotic granulomas p < 0.01 
IL-4  IL-12   
 1 2 3 Total 
0 0.85 0.85 0.85 3 
1 20.34 26.27 3.39 59 
2 4.24 15.25 6.78 31 
3 5.08 1.69 14.41 25 
Total 36 52 30 118 
Necrotic granulomas p < 0.01 
0 20.8 4.17 0 3 
1 12.5 2.08 2.08 8 
2 2.08 25 14.58 20 
3 6.25 22.92 6.25 17 
Total 11 26 11 48
IL-4 vs TNFα 
Non-necrotic granulomas p < 0.01 
IL-4  TNF   
 1 2 3 Total 
0 0 1.69 0.85 3 
1 27.12 20.34 2.54 59 
2 5.08 12.71 8.47 31 
3 2.54 6.78 11.86 25 
Total 41 49 28 118 
Necrotic granulomas p = 0.1 
0 2.08 0 4.17 3 
1 4.17 6.25 6.25 8 
2 8.33 10.42 22.92 20 
3 2.08 2.08 31.25 17 
Total 8 9 31 48 
IL-12 vs IFNγ 
Non-necrotic granulomas p < 0.01 
IL -12 IFN  
 1 2 3 Total 
1 21.19 5.9 3.39 36 
2 27.12 13.5  3.39 52 
3 0 15.25 10.17 30 
Total 57 41 20 118 
Necrotic granulomas p = 0.1 
1 12.5 4.17 6.25 11 
2 14.58 10.42 29.17 26 
3 8.33 10.42 4.17 11 
Total 17 12 19 48 
TNFα vs IFNγ 
Non-necrotic granulomas p < 0.01 
IFN TNF  
 1 2 3 Total 
1 27.12 19.49 1.69 57 
2 6.78 17.8 10.17 41 
3 0.85 4.24 11.86 20 
Total 41 49 28 118 
Necrotic granulomas p = 0.003 
1 12.5 14.58 8.33 17 
2 4.17 2.08 18.75 12 
3 0 2.08 37.5 19 
Total 8 9 31 48 
IL-12 vs TNFα                 
Non-necrotic granulomas p < 0.01 
IL -12 TNF  l 
 1 2 3 Tota 
1 14.41 14.41 1.69 36 
2 17.8 20.34 5.93 52 
3 2.54 6.78 16.1 30 
Total 41 49 28 118 
Necrotic granulomas p = 0.05 
1 2.08 8.33 12.5 11 
2 6.25 4.17 43.75 26 
3 8.33 6.25 8.33 11 
Total 8 9 31 48 
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Table 13: Spearman rank R- correlation for cytokines in non-necrotic granulomas.  
This correlation confirms the positive correlations noted for non-necrotic granulomas. All correlations 
are statistically significant.   
 
 IL-12 IFN TNF IL-4 
IL-12 1 0.49 0.44 0.39 
IFN 0.49 1 0.58 0.33 
TNF 0.44 0.58 1 0.46 
IL-4 0.39 0.33 0.46 1 
 
A similar positive correlation to the previous ones exists between IL-12 and IFNγ  (r = 
0.49).  There were still many more granulomas where low numbers of IL-12 and IFNγ 
positive cells (table 12) were present (Grade 3=10%).  The previous pattern of cytokine 
correlation was also followed by IL-12 and TNFα (r = 0.44) and IFNγ and TNFα (r = 
0.58) as seen in table 13. This strong positive correlation between IFNγ and TNFα was 
significantly more than the association between IL-4 and IFNγ (p = 0.016).  None of 
the other correlations were significantly less than IFNγ vs TNFα.   
 
4.2.5.2 Necrotic granulomas 
The most noticeable difference between the 48 necrotic and 118 non-necrotic 
granulomas was that many more cells per granuloma were positive for a specific 
cytokine in the necrotic granulomas. Due to the smaller number of necrotic 
granulomas, the differences in the results were often not statistically significant.  There 
was however, a clearly positive correlation between IL-4 and TNFα (r = 0.34), with 
31% of necrotic granulomas containing high numbers of cells of these 2 cytokines 
(table 14).  IL-4 vs IFNγ showed a Spearman rank R - positive correlation of 0.65 (table 
14), with 23% of granulomas having high numbers of positive cells for both cytokines. 
The correlation between IL-4 and IL-12 was not so strong  (r = 0.21) and indeed most 
granulomas were in the grade 2 or grade 2/3 group.   
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Table 14: Spearman rank R- correlation of cytokines in necrotic granulomas.  
This correlation confirms the positive correlations noted in table 11. All correlations in italics are 
statistically significant. A negative correlation is observed for TNFα versus IL-12, but it not of 
significance.    
 
Necrotic granulomas 
 IL-12 IFN TNF IL-4 
IL-12 1 0.32 -0.17 0.21 
IFN 0.03 1 0.63 0.65 
TNF -0.17 0.63 1 0.34 
IL-4 0.21 0.65 0.34 1 
 
A similar picture could be seen for IL-12 vs IFNγ with virtually no relationship (r = 
0.03)between these two cytokines (table 14).   There was a slight negative correlation 
between IL-12 and TNFα (r = 0.17), with the only noticeable association that of Grade 
3 TNFα with Grade 2 IL-12 (44%) seen in table 12.  A very strong correlation (r = 
0.63)exists between IFNγ and TNFα (table 14).  Thirty eight percent of cells in necrotic 
granulomas had more than 75% of cells positive for IFNγ and for TNFα (table 12).   A 
positive correlation also exists between HIV positivity and IFNγ in non-necrotic 
granulomas, but no other correlations between HIV and cytokines were of significance, 
either on necrotic, or non-necrotic granulomas.  
 
4.2.6 HIV Status and Granulomas  
4.2.6.1 HIV negative 
In HIV negative granulomas (table 15) a positive correlation exists between IL-12 and 
IFNγ (r = 0.49). This was reflected by low numbers of positive cells for both these 
cytokines in table 16.  A positive correlation (r = 0.49) also exists between IL-12 and 
TNFα, but a  more even distribution of positive cells was seen. 
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Table 15: Spearman rank R- correlation for cytokines in HIV negative granulomas.  
A strong positive correlation is observed between all the cytokines. Significant correlations are 
highlighted in italics 
.   
HIV negative granulomas 
 IL-12 IFN TNF IL-4 
IL-12 1 0.49 0.49 0.47 
IFN 0.49 1 0.66 0.52 
TNF 0.49 0.66 1 0.59 
IL-4 0.47 0.52 0.59 1 
 
 
 
Table 16: Relationship between cytokines in HIV positive and negative granulomas.  
Strong positive correlations exist between most of the cytokines. See text for detailed discussion of table.   
 
 
 
 
 
 
 
 
 
 
 
 
Correlations are expressed as % of the total number of granulomas counted, while the figures in the total columns 
represent the actual number of granulomas. Percentages in italics indicate statistically significant correlations.  
0 = no positive cells 1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75% positive cells  
 
The positive correlation (table 15) between IL-12 and IL-4 was just as strong (r = 0.47),  
with most granulomas having lower numbers of positive cells for both cytokines.  The 
strongest positive correlations in HIV negative granulomas were between IFNγ and 
TNFα (r = 0.66) and IL-4 and TNFα (r = 0.59), while the positive correlation between 
IL-12 vs IFNγ 
HIV negative  p < 0.01 
IL -12 IFN  
 1 2 3 Total 
 1 23.2 5.6 2.4 39 
2 27.2 11.2 8 58 
3 0 12.7 9.02 28 
Total 63 38 24 125 
HIV positive  p = 073 
1 4.8 4.8 9.6 8 
2 12.2 17 19.5 20 
3 9.7 14.6 7.3 13 
Total 11 15 15 41 
IL-12 vs TNFα 
HIV negative  p < 0.01 
IL -12 TNF  
 1 2 3 Total 
1 14.4 16 0.8 39 
2 16 19.2 11.2 58 
3 0.8 6.4 15.2 28 
Total 39 52 34 125 
HIV positive  p = 0.06 
1 0 2.4 17 8 
2 9.7 4.8 34.1 20 
3 14.6 7.3 9.7 13 
Total 10 6 25 41 
TNF vs IFNγ 
HIV negative  p < 0.01 
IFN TNF  
 1 2 3 Total 
1 26.4 22.4 1.6 63 
2 4.8 16 9.6 38 
3 0 3.2 16 24 
Total 39 52 34 125 
HIV positive  p = 0.2 
1 12.2 4.8 9.7 11 
2 9.7 4.8 21.9 15 
3 2.4 4.8 29.7 15 
Total 10 6 25 41
IL-4 vs IL-12 
HIV negative  p < 0.01 
IL -4 IL-12  
 1 2 3 Total 
0 1.6 0.8 0 3 
1 20.8 23.2 1.6 57 
2 4 15.2 6.4 32 
3 4.8 7.2 14.4 33 
Total 39 58 28 125 
HIV positive  p = 0.3 
0 0 4.8 2.4 3 
1 9.7 7.3 7.3 10 
2 2.4 26.8 17 19 
3 7.3 9.7 4.4 9 
Total 8 20 13 41 
IL-4 vs IFNγ 
HIV negative  p < 0.01 
IL -4 IFN  
 1 2 3 Total 
0 0.8 0.8 0.8 3 
1 34.4 9.6 1.6 57 
2 12 9.6 4 32 
3 3.2 10.4 12.8 33 
Total 63 38 24 125 
HIV positive  p = 0.2 
0 4.8 0 2.4 3 
1 9.7 7.3 7.3 10 
2 12.2 14.6 19.5 19 
3 0 14.6 7.3 9 
Total 11 15 15 41 
IL-4 vs TNFα 
HIV negative  p < 0.01 
IL -4 TNFα  
 1 2 3 Total 
0 0.8 1.6 0 3 
1 24 20.8 0.8 57 
2 15.6 12.8 8.8 32 
3 2.4 6.4 17.6 33 
Total 39 52 34 125 
HIV positive  p = 0.15 
0 0 0 7.3 3 
1 9.7 2.4 12.2 10 
2 12.2 9.7 24.3 19 
3 2.4 2.4 18.18 9 
Total 10 6 25 41 
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IL-4 and IFNγ was r = 0.52 (table 15).  In all of these there were more granulomas with 
less positive cells for both cytokines.  In the HIV negative group a positive correlation 
also exists between necrosis and IFNγ (r = 0.23) (data not shown), as well as necrosis 
and TNF (r = 0.39) (data not shown), but not as much between necrosis and IL-4 (r = 
0.2) (data not shown). This difference was however not statistically significant 
(p=0.09).  
 
4.2.6.2 HIV positive 
Due to the smaller number of granulomas in HIV positive patients, correlations 
between the various cytokines were not of statistical significance, except for the 
negative correlation between IL-12 and TNFα of –0.45 (table 17), where high numbers 
of TNFα positive cells were associated with an intermediate number of IL-12 positive 
cells. 
Table 17: Spearman rank R- correlation for cytokines in HIV positive granulomas.   
A negative correlation is noted between IL-12 and TNFα. 
 
HIV positive granulomas 
 IL-12 IFN TNF IL-4 
IL-12 1 -0.16 -0.45 -0.04 
IFN -0.16 1 0.38 0.22 
TNF -0.45 0.38 1 0.08 
IL-4 -0.04 0.22 0.08 1 
 
 
There were however, certain trends that were identifiable: namely, a higher number of 
cells positive in these granulomas as illustrated earlier (section 4.2.4), as well as a 
positive correlation between the various cytokines (not statistically significant).   
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4.2.7 Correlation Between HIV Status, Necrosis and the Various Cytokines when one of 
the Cytokines is a Constant 
In the following section the relationship between the variables are discussed relative to 
a constant. The relationship between a specific cytokine and the other variables was 
examined when granulomas contained either < 25% positive cells, 25-75% positive 
cells or > 75% positive cells of a specific cytokine. 
 
 
4.2.7.1 IL-12 as a constant 
There was a significant positive correlation between all the variables when IL-12 = 1 
(Table 18). The results in italics indicate statistically significant correlations (Spearman 
rank R-correlation) and this is further illustrated by the data in Table 19 
(crosstabulation), where IL-12 positivity =1. Most of the granulomas have <25% 
positive cells per granuloma when the HIV-status is negative and there is no necrosis.  
 
Table 18:  Spearman rank R- correlation between variables when IL-12 is a constant.  
A negative correlation is observed between HIV and cytokines when IL-12 positivity = 3, with more 
IFNγ, TNFα and IL-4 positive cells in HIV negative granulomas. All other significant correlations (in 
italics) are positive.  
IL-12 = 1 
 HIV necrosis IFN TNF IL-4 
HIV 1 0.55 0.43 0.64 0.2 
necrosis 0.55 1 0.15 0.49 0.03 
IFN 0.43 0.15 1 0.61 0.24 
TNF 0.64 0.49 0.61 1 0.2 
IL-4 0.2 0.03 0.24 0.3 1 
IL-12 = 2 
HIV 1 0.39 0.3 0.32 0.16 
necrosis 0.39 1 0.44 0.56 0.51 
IFN 0.3 0.44 1 0.57 0.51 
TNF 0.32 0.56 0.57 1 0.59 
IL-4 0.16 0.51 0.51 0.59 1 
IL-12 = 3 
HIV 1 0.53 -0.31 -0.44 -0.48 
necrosis 0.53 1 -0.37 -0.29 -0.17 
IFN -0.31 -0.37 1 0.52 0.18 
TNF -0.44 -0.29 0.52 1 0.25 
IL-4 -0.48 -0.17 0.18 0.25 1 
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Table 19: Crosstabulation between HIV and necrosis when IL-12=1.  
When IL-12 positivity = 1, most granulomas are non-necrotic and HIV negative (p=0.01).  
 
HIV Necrosis 0 Necrosis 1 Total 
0 34 5 39 
 72.3% 10.6% 82.9% 
1 2 6 8 
 4.2% 12.7% 17% 
Total 36 11 47 
Correlation expressed as actual number and as percentage of the total number of granulomas counted 
0 = negative 1 = positive  
 
 
This trend illustrated in Tables 18 and 19 is also applicable to the other positive 
correlations highlighted in italics in tables 21 to 27, which directly follows in 
discussions on the specific cytokines. 
 
A typical example of the statistically significant negative correlation is that of IL-4 
versus HIV when IL-12 positivity = 3 (table 20).  The largest number of granulomas 
have >75% IL-4 positive cells when IL-12 is also high and HIV negative. The presence 
of numerous IL-12 positive cells appears to have an impact on the presence of other 
cytokine positive cells in the granuloma. More IFNγ, TNFα and IL-4 positive cells can 
be seen in the presence of high numbers of IL-12 positive cells, when the patients are 
HIV negative (table 18). There is also a clear negative correlation between IFNγ and 
necrosis when IL-12 =3 (table 18).     
 
Table 20: Crosstabulation between HIV and IL-4 when IL-12 = 3.  
The largest number of granulomas have >75% IL-4 positive cells in an environment with the majority of 
cells IL-12 positive, in HIV negative patients (p < 0.01).  
 
HIV IL-4 0 IL-4 1 IL-4 2 IL-4 3 Total 
negative 0 2 8 18 28 
 0.00% 4.8% 19.5% 43.9% 68.2% 
positive 1 3 7 2 13 
 2.44% 7.32% 17.07% 4.8% 31.7% 
Total 1 5 15 20 41 
Correlation expressed as actual number and as percentage of the total number of granulomas counted 
0 = no positive cells 1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75%positive cells  
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4.2.7.2 IFNγ as a constant 
When IFNγ = 1, 90% of granulomas in HIV negative patients were non-necrotic, while 
100% of granulomas in HIV positive patients were necrotic(p < 0.01). The rest of these 
results follow a similar pattern, with the only negative correlation being between IL-12 
and necrosis as well as IL-4 and HIV (table 21). 
Table 21: Correlation between variables when IFNγ is a constant.  
When IFNγ positivity = 3, a negative correlation was observed between necrosis and IL-12 and IL-4 and 
HIV status. All other significant correlations (in italics) are positive.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, when IFNγ was high, fewer granulomas with >75% IL-12 positive cells 
tended to have necrosis. When IFNγ positivity was 3, the trend was for HIV positive 
granulomas to have a moderate amount of IL-4 positive cells. These granulomas tended 
to be necrotic, but the numbers were too low to be of statistical significance.  
 
On the other hand in HIV negative granulomas, high numbers of IL-4 cells were 
present in granulomas that had high numbers of IFNγ positive cells and there was an 
equal distribution between necrotic and non-necrotic granulomas.   
 
IFNγ = 1 
 HIV necrosis IL-12 TNF IL-4 
HIV 1 0.76 0.33 0.15 0.00 
necrosis 0.76 1 0.17 0.23 -0.03 
IL-12 0.33 0.17 1 0.1 0.14 
TNF 0.15 0.23 0.1 1 0.08 
IL-4 0.00 -0.03 0.14 0.08 1 
IFNγ = 2 
HIV 1 0.46 0.00 0.13 0.11 
necrosis 0.46 1 -0.01 0.3 0.23 
IL-12 0.00 -0.01 1 0.07 0.36 
TNF 0.13 0.30 0.07 1 0.49 
IL-4 0.11 0.23 0.36 0.49 1 
IFNγ=3 
HIV 1 0.07 -0.27 -0.05 -0.4 
necrosis 0.07 1 -0.35 0.32 0.30 
IL-12 -0.27 -0.35 1 0.19 0.15 
TNF -0.05 0.32 0.19 1 0.17 
IL-4 -0.4 0.30 0.15 0.17 1 
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4.2.7.3 TNFα as a constant 
Seventy seven percent of granulomas with <25% TNFα positive cells also did not show 
signs of necrosis and are found in HIV negative patients (table 22), as also 
demonstrated by the strong positive correlation between HIV and necrosis in table 23.  
A negative correlation can be seen between HIV and IL-12 and HIV and IL-4 when 
there is >75% TNFα positive cells, with less granulomas containing >75% positive 
cells of either IL-12 or IL-4 in HIV positive granulomas (table 23).   
 
Table 22; Crosstabulation between HIV and necrosis when TNFα positivity =1. 
 Seventy seven percent of granulomas with <25% TNF positive cells also did not show signs of necrosis 
and were found in HIV negative patients (p < 0.01). 
 
necrosis HIV 0 HIV 1 Row 
0 38 3 41 
 77.5% 6.1% 83.67% 
1 1 7 8 
 2% 14.2% 16.33% 
Total 39 10 49 
Correlation expressed as actual number and as percentage of the total number of granulomas counted 
0 = negative 1 = positive  
 
 
 
Table 23: Correlation between variables when TNFα is a constant.  
Most granulomas with a < 25% TNFα positive cells (TNFα = 1) were not necrotic and HIV negative, 
with a very strong correlation.  In granulomas with >75% TNFα positive cells there was a negative 
correlation between HIV and IL-4 and HIV and IL-12.   
TNFα = 1 
 HIV necrosis IL-12 IFN IL-4 
HIV 1 0.73 0.58 0.34 0.32 
necrosis 0.73 1 0.36 0.02 0.22 
IL-12 0.58 0.36 1 0.51 0.22 
IFN 0.34 0.02 0.51 1 0.18 
IL-4 0.32 0.22 0.22 0.18 1 
TNFα = 2 
HIV 1 0.32 0.22 0.18 0.18 
necrosis 0.32 1 0.01 -0.19 0.10 
IL-12 0.22 0.01 1 0.13 0.35 
IFN 0.18 -0.19 0.13 1 0.20 
IL-4 0.18 0.10 0.35 0.20 1 
TNFα = 3 
HIV 1 0.26 -0.46 -0.13 -0.43 
necrosis 0.26 1 -0.52 0.04 -0.02 
IL-12 -0.46 -0.52 1 0.06 0.18 
IFN -0.13 0.04 0.06 1 0.16 
IL-4 -0.43 -0.02 0.18 0.16 1 
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In non-necrotic granulomas where TNFα positivity = 1, IL-12 numbers were also lower 
than in the necrotic granulomas (table 24), while non-necrotic granulomas with > 75% 
TNFα positive cells, also had >75% IL-12 positive cells (table 25). As in the case with 
IFNγ, there were also statistically significant less IL-4 positive cells in HIV positive 
granulomas when TNFα is 3. 
 
Table 24: Crosstabulation between IL-12 and necrosis when TNFα positivity = 1 
 In non-necrotic granulomas where TNFα positivity = 1, IL-12 numbers were also lower than in the 
necrotic granulomas (p < 0.01).  
 
Necrosis IL-12=1 IL-12=2 IL-12=3 Total 
present 17 21 3 41 
 34.69% 42.86% 6.12% 83.67%
absent 1 3 4 8 
 2.04% 6.12% 8.16% 16.33%
Total 18 24 7 49 
Correlation expressed as actual number and as percentage of the total number of granulomas counted 
1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75% positive cells  
 
 
Table 25: Crosstabulation between IL-12 and necrosis when TNFα positivity = 3 
 Non-necrotic granulomas with a high number of TNFα positive cells, also had a high number of IL-12 
positive cells (p < 0.01). 
 
Necrosis IL-12=1 IL-12=2 IL-12=3 Total 
absent 2 7 19 28 
 3.39% 11.86% 32.20% 47.46% 
present 6 21 4 31 
 10.17% 35.59% 6.78% 52.54% 
Total 8 28 23 59 
Correlation expressed as actual number and as percentage of the total number of granulomas counted 
1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75% positive cells  
 
 
4.2.7.4 IL-4 as a constant 
Although there was a strong correlation between TNFα and HIV as well as IFNγ and 
necrosis when IL-4 was negative, only 6 granulomas in total were negative for IL-4 and 
therefore no conclusions could be drawn from these results. There was a strong 
correlation between HIV and necrosis when IL-4 positivity was 2 and more granulomas 
were HIV positive and necrotic than when IL-4 was negative (table 26).  
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Table 26: Spearman rank R- correlation between variables when IL-4 is a constant.  
A negative correlation existed between IFNγ and necrosis when low numbers of IL-4 were observed and 
therefore fewer granulomas were necrotic. The opposite is true for TNFα. All other correlations were 
positive, except for IL-12 in the presence of high numbers of IL-4, where negative correlation with HIV 
status and necrosis was noted. 
IL-4 = 0 
 HIV necrosis IL-12 IFN TNF 
HIV 1 0.33 0.73 -0.21 0.94 
necrosis 0.33 1 -0.21 -0.94 0.10 
IL-12 0.73 -0.21 1 0.18 0.78 
IFN -0.21 -0.94 0.18 1 -0.01 
TNF 0.94 0.10 0.78 -0.01 1 
IL-4 = 1 
HIV 1 0.49 0.13 0.31 0.24 
necrosis 0.49 1 -0.17 -0.14 0.26 
IL-12 0.13 -0.17 1 0.19 -0.11 
IFN 0.31 -0.14 0.19 1 0.32 
TNF 0.24 0.26 -0.11 0.32 1 
IL-4 = 2 
HIV 1 0.46 0.16 0.28 0.07 
necrosis 0.46 1 0.15 0.17 0.16 
IL-12 0.16 0.15 1 0.18 0.10 
IFN 0.28 0.17 0.18 1 0.59 
TNF 0.07 0.16 0.10 0.59 1 
IL-4 = 3 
 HIV necrosis IL-12 IFN TNF 
HIV 1 0.39 -0.25 -0.05 0.08 
necrosis 0.39 1 -0.33 0.36 0.32 
IL-12 -0.25 -0.33 1 0.12 0.14 
IFN -0.05 0.36 0.12 1 0.45 
TNF 0.08 0.32 0.14 0.45 1 
 
When IL-4 positivity = 1 there was also a strong positive correlation between HIV and 
necrosis with 80% of all granulomas being negative for both (table 27). 
 
Table 27: Crosstabulation between HIV and necrosis when IL-4 is a constant. 
In the presence of low numbers of IL-4 positive cells, few granulomas were necrotic, while in the 
presence of higher numbers, more necrosis was observed.    
 
 
 
 
 
Correlation expressed as actual number and as percentage of the total number of granulomas counted 
0 = negative 1 = positive  
 
Other significant correlations included a positive correlation of 0.31 between HIV and 
IFNγ when IL-4 positivity was 1 (table 26), with 64% percent of HIV negative 
 
HIV 
IL-4=2 
0  necrosis  1 
p < 0.01
Total 
0 25 7 32 
 49% 13.7%  
1 6 13 19 
 11.7% 25.5%  
Total 31 20 51
 
HIV 
IL-4=3 
  0  necrosis  1 
p=0.01 
Total 
0 23 10 33 
 69.7% 30.3%  
1 2 7 9 
 4.7% 16.7%  
Total 25 17 42
 
HIV 
IL-4=1 
 0   necrosis  1   
P=0.00 
Total 
0 54 3 57 
 80.6% 4.5%  
1 5 5 10 
 7.5% 7.5%  
Total 59 8 67 
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granulomas containing low numbers of INFγ positive cells when IL-4 was 1 (data not 
shown). Forty percent of granulomas contained high numbers of IL-12 in non-necrotic 
granulomas when IL-4 positivity was 3 (data nor shown), with a negative Spearman 
rank R-correlation of 0.33.  
 
 
 
 
4.2.8 Correlation Between the Various Cytokines when HIV Status and Necrosis are 
Constants 
 
In the group of HIV negative granulomas with no necrosis, there was always a strong 
positive correlation between the various cytokines (tables 28, 29 and 30).  In the HIV 
negative group without necrosis granulomas tended to have a lower number of positive 
cells for all the cytokines than in any of the other groups, but there still was a fairly 
even distribution between the various groups.     
 
Table 28: Correlation between the various cytokines when HIV and necrosis are constants.  
In the group of HIV negative granulomas with no necrosis, there was always a strong positive correlation 
between the various cytokines. In both groups with necrosis there was a very strong positive correlation 
between TNFα and IFNγ, as well as IFNγ and IL-4, but a strong negative correlation between IL-12 and 
TNFα.    
 
 
 
 
 
 
 
 
 
 
HIV negative no necrosis 
 IL-12 IFN TNF IL-4 
IL-12 1 0.53 0.52 0.47 
IFN 0.53 1 0.57 0.39 
TNF 0.52 0.57 1 0.49 
IL-4 0.47 0.39 0.49 1 
HIV positive no necrosis 
IL-12 1 -0.52 -0.38 -0.35 
IFN -0.52 1 0.27 -0.26 
TNF -0.38 0.27 1 0.2 
IL-4 -0.35 -0.26 0.2 1 
HIV negative with necrosis 
IL-12 1 0.27 0.43 0.41 
IFN 0.27 1 0.86 0.81 
TNF 0.43 0.86 1 0.79 
IL-4 0.41 0.81 0.79 1 
HIV positive with necrosis 
IL-12 1 -0.11 -0.47 0.12 
IFN -0.11 1 0.47 0.51 
TNF -0.47 0.47 1 0.01 
IL-4 0.12 0.51 0.01 1 
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Table 29: Correlation between HIV negative granulomas, necrosis and specific cytokines.  
In this group IL-12 positivity was evenly spread, while IFNγ and TNFα were low in non-necrotic and 
high in necrotic granulomas. IL-4 was also less positive in non-necrotic granulomas, but more evenly 
spread in necrotic granulomas, with no statistically significant differences.  
 
 
 
 
 
 
 
 
 
 
 
 
Correlations are expressed as % of the total number of granulomas counted, while the figures in the total columns 
represent the actual number of granulomas. Percentages in italics indicate statistically significant correlations.  
0 = no positive cells 1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75% positive cells 
 
In the HIV negative group with necrosis, there was a very strong positive correlation 
between TNFα and IFNγ, with most granulomas containing high numbers of cells for 
both cytokines (tables 28 and 29).  IL-4 and IFNγ, as well as IL-4 and TNFα showed a 
similar trend.  In the group of HIV positive granulomas with necrosis (tables 28 and 
30), there was also a strong positive correlation between IFNγ and TNFα, as well as 
IFNγ and IL-4, but a strong negative correlation between IL-12 and TNFα. On 
examining individual cytokines a similar picture could be seen, but in the case of HIV 
positive granulomas, only the association with IFNγ was statistically significant.   
 
Table 30: Correlation between HIV positive granulomas, necrosis and specific cytokines.  
IFNγ was the only cytokine with a statistically significant relationship with HIV and necrosis, with less 
positivity in the necrotic group. The other cytokines showed a more even distribution.   
 
 
 
 
 
 
 
 
 
 
 
 
Correlations are expressed as % of the total number of granulomas counted, while the figures in the total columns 
represent the actual number of granulomas. Percentages in italics indicate statistically significant correlations.  
0 = no positive cells 1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75% positive cells 
necrosis IL-12                p = 0.2
 1 2 3 Total 
absent 33% 43% 24% 104 
present 24% 62% 14% 21 
Total 39 58 28 125 
necrosis TNFα                p < 0.01
 1 2 3 Total 
absent 36% 44% 19% 104 
present 5% 29% 66% 21 
Total 39 52 34 125 
necrosis                     IL-4                     p=0.01 
 0 1 2 3 Total 
absent 2% 52% 24% 22% 104 
present 5% 14% 33% 48% 21 
Total 3 57 32 33 125 
 
necrosis IFNγ                  p < 0.01
 1 2 3 Total 
absent 55% 37% 13% 104 
present 29% 19% 52% 21 
Total 63 38 24 125 
 
necrosis                   IL-12 
 1 2 3 Total 
absent 14.29% 50.00% 35.71 14 
present 22.22% 48.15% 29.63% 27 
Total 8 20 13 41 
necrosis                   TNFα                 
 1 2 3 Total 
absent 7.32% 7.32% 19.51% 14 
present 17.07% 7.32% 41.46% 27 
Total 10 6 25 41 
necrosis                           IL-4                                      
 0 1 2 3 Total 
absent 2.44% 12.20% 14.63% 4.88% 14 
present 4.88% 12.20% 31.71% 17.07% 27 
Total 3 10 19 9 41 
necrosis IFNγ                  p = 0.02
 1 2 3 Total 
absent 0.00% 17.07% 17.07% 14 
present 26.83% 19.51% 19.51% 27 
Total 11 15 15 41 
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4.2.9 Correlation Between IL-4 and Necrosis when one Cytokine is a Constant 
 
The only significant correlations between necrosis and IL-4 when one cytokine was a 
constant can be seen in table 31. It is apparent that necrotic granulomas that contain 
high numbers of IL-4 positive cells were seen when high numbers of IFNγ positive 
cells were also present. A similar picture can be seen for TNFα (table 31). In the IL-12 
group, high numbers of IL-4 positive cells in necrotic granulomas were seen when a 
moderate number of IL-12 cells were positive (table 31). Although not significant, 41% 
of granulomas were non-necrotic and had high numbers of IL-4 positive cells when IL-
12 positivity = 3 (data not shown). 
 
Table 31: Crosstabulation between necrosis and IL-4 when one cytokine is a constant.  
The correlation between IL-4 and necrosis under specific conditions is only statistically significant when 
IFNγ positivity = 1 or 3, TNFα positivity = 1 or IL-12 positivity = 2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlations are expressed as actual numbers and % of the total number of granulomas counted, while the figures in 
the total columns represent the actual number of granulomas. Percentages in italics indicate statistically significant 
correlations.  
0 = no positive cells 1 = <25% positive cells 2 = 25 - 75% positive cells 3 = >75% positive cells 
 
 
 
 IFNγ=1   p < 0.01  
necrosis IL-4  
0 
IL-4 
 1 
IL-4  
2 
IL-4 
3 
Total 
 
absent 0 40 13 4 57 
 0.00% 54% 17.5% 5.4%  
present 3 7 7 0 17 
 4% 9.4% 9.4% 0.00%  
Total 3 47 20 4 74 
 IFNγ=3   p=0.04  
necrosis IL-4 
 0 
IL-4  
1 
IL-4  
2 
IL-4  
3 
Total
absent 2 5 5 8 20 
 5.13% 12.82% 12.82% 20.51%  
present 0 0 8 11 19 
 0.00% 0.00% 20.51% 28.21%  
Total 2 5 13 19  
 TNFα=1   p < 0.01  
necrosis IL-4  
0 
IL-4  
1 
IL-4 
 2 
IL-4 
3 
Total 
absent 0 32 6 3 41 
 0.00% 65.31% 12.24% 6.12%  
present 1 2 4 1 8 
 2.04% 4.08% 8.16% 2.04%  
Total 1 34 10 4 49 
 IL-12 =2   p < 0.01  
necrosis IL-4  
0 
IL-4  
1 
IL-4  
2 
IL-4  
3 
Total
absent 1 31 18 2 52 
 1.28% 39.74% 23.08% 2.56%  
present 2 1 12 11 26 
 2.56% 1.28% 15.38% 14.10%  
Total 3 32 30 13 78 
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5. Results: Sarcoidosis 
Sarcoidosis is a multi-system granulomatous disease of unknown cause, although 
several organisms have been investigated as possible causes, amongst these M. 
tuberculosis192,193,194,195.  The disease is characterised by non-caseating granulomas, 
which either resolve or progress to fibrosis.  The histological grading is as follows203:  
 
 
 
 
 
 
 
 
 
 
 
 
 
In patients with sarcoidosis, the hypersensitivity reaction is viewed as the consequence 
of a chronic, exaggerated immunological response against an unidentified antigen that 
persists at the sites of disease involvement204. Initial granuloma formation has the same 
pathogenesis as previously described. The accumulation of CD4+ Th1 cells and 
macrophages at the site of inflammation is the earliest step in the events that lead to 
granuloma formation. According to several studies, the net effect of the Th1 response is 
Pulmonary involvement 
Extent of specific pathological change  
Granulomas 
Minimal:  a few scattered granulomas 
Moderate:  more than a few, but occupying less than two thirds of the  
area 
Extensive:  numerous granulomas, often conglomerated and 
occupying more than two thirds of the area 
Interstitial pneumonitis (nongranulomatous inflammation of the alveolar 
walls, predominantely lymphocytic) 
Minimal:  lesions occupying less than one third of the area 
Moderate:  lesions occupying one to two thirds of the area 
Extensive:  lesions occupying more than two thirds of the area 
Granulomatous angiitis (granulomas within the walls of veins and/or 
arteries)   
Absent:  no granulomatous angiitis 
Minimal:  one to two foci 
Moderate:  more than two foci 
Fibrosis (fibrosis of alveolar wall or interstitium) 
Absent:  no fibrosis 
Focal:  focal and scattered fibrosis 
Diffuse:  diffuse and extensive fibrosis 
Evaluation of overall pathologic change 
Mild:  no fibrosis; granulomas and interstitial pneumonitis minimal and 
granulomatous angiitis absent or minimal 
Moderate:   by exclusion from mild and severe categories 
Severe:  diffuse fibrosis; granulomatous and interstitial pneumonitis both 
extensive; granulomatous angiitis moderate 
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the organization of the local inflammatory process into the granuloma and the 
inhibition of the fibrogenetic process208,209,210. Some studies suggest that a switch to 
Th2 cells occurs in patients with progressive disease, evolving towards lung fibrosis207. 
 
5.1 Experimental Design 
To investigate the cytokine profile of patients with sarcoidosis, open lung biopsies from 
a group of 15 patients with sarcoidosis were examined. Open lung biopsy tissue was 
obtained for routine diagnostic purpose: the diagnosis of sarcoidosis was confirmed; 
and biopsies were graded according to the histological grading system. ISH was 
performed for IL-12-, IFNγ-, TNFα- and IL-4-mRNA on all 15 cases. The cytokine 
profile of each granuloma was recorded on the photographic map as described 
previously.  
 
5.2 Results 
The clinical information on the patients can be seen in table 32. None of the patients 
had a previous history of tuberculosis. The ages ranged between 21 and 54 years and 13 
of the 15 patients were female. Follow-up varied from 1 year to 12 years, and although 
one of the patients died after 1,5 years, none developed tuberculosis.  
 
A spectrum of changes can be seen in the histological grading (table 33). Most of the 
cases (10) showed changes in keeping with moderate overall severity. Only one case 
showed minimal disease and 4 severe disease. Diffuse fibrosis was present in 8 cases 
and focal fibrosis in 3.  Four cases had no fibrotic change.   
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Table 32: Demographic, clinical and radiological information on patients with pleural tuberculosis.  
The table shows the basic demographic and clinical characteristics of 15 patients with sarcoidosis who 
were recruited for the histological study of open lung biopsy samples.   
 
Age in years F = female; M =male Rx = treatment at time of diagnosis 
 
 
 
Table 33: Histological grading of severity of disease.  
A spectrum of changes can be seen, with most cases either in the overall moderate or severe categories. 
Fibrosis was absent in four cases.  
 
Case Granuloma Pneumonitis Angiitis Fibrosis Overall 
+ ++ +++ + ++ +++ Min Mod Foc Dif Min Mod Sev 
S1  x   x  x  no no  x  
S2   x  x   x x   x  
S3  x   x  no no no no  x  
S4   x   x  x  x   x 
S5   x   x  x  x   x 
S6   x   x  x  x   x 
S7   x   x  x  x   x 
S8  x   x  x  x   x  
S9  x  x   x  no no  x  
S10  x   x   x  x  x  
S11 x   x   x  no no x   
S12  x    x  x  x  x  
S13  x    x  x  x  x  
S14  x   x  x  x   x  
S15  x    x no no  x  x  
+ = minimal numbers;  ++ = moderate numbers;  +++ = extensive;  min = minimal;  mod = moderate;  sev = severe 
 
 
 
 
Patient Age/Sex Previous TB Rx at diagnosis 
Radiological staging
Follow up 
S1 35/F No None 2 2 years, healthy 
S2 21/F No None 3 2 years, healthy 
S3 27/F No  None 2 6 years, healthy 
S4 36/F No None 2 3 years, respiratory 
failure 
S5 35/F No None 2 12 years, healthy 
S6 27/F No None 3 1,5yrs 
S7 26/F No None 2 6 years, Grade I 
dyspnoea 
S8 54/M No None 2 2 years, died 
S9 36/F No None 3 5 years, grade II 
dyspnoea 
S10 29/F No None 2 1 year, healthy 
S11 37/F No  None 2 1,5 years, died 
S12 25/M No None 2 4 years 
S13 36/F No None 2 1 year, healthy 
S14 23/F No None 2 2yrs 
S15 45/F No None 3                  2 years, healthy 
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5.2.1 Interpretation of the slides 
Representative examples of the light microscopic appearance of the ISH can be seen in 
figs. 26-31. For complete scoring please see Appendix A. Positivity is represented by 
blue staining (see methods) of the cytoplasm and indicates the presence of mRNA.  
Counterstaining is green as described in methods.  Cells that stain negative do not 
contain the specific RNA and will therefore stain green. A high concentration of 
positive cells in the lymphocyte cuff of the granulomas resulted in intense staining of 
this zone. These photographs were selected to illustrate the quality of staining for the 
various cytokine mRNAs.  
 
The focus of the study was on the number of cells that are positive for a specific 
cytokine within the granuloma and the sources of the cytokines were not determined. 
This does not however, detract from the fact that the cytokine mRNA was present. 
Documented sources of these cytokines were discussed in chapter 1.  
 
5.2.2 Cytokine profile 
The cytokine profile of the 15 cases was identical (table 34). Numerous granulomas 
were present in the biopsies, ranging from 103 to 1677 granulomas per section. In all 
the cases diffuse positivity in the granulomas could be seen for IL-12, IFNγ and TNFα.  
The mRNA expression was predominantly present in the lymphocytes. On the other 
hand no IL-4 mRNA expression could be found in any of the cases. These results 
indicate the presence of a pure Th1 response in sarcoidosis.  
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Table 34: Cytokine profile of the granulomas in sarcoidosis. All granulomas had the same profile.  
 All fifteen had had the same cytokine profile, showing strong positivity for IL-12, IFNγ and TNFα, but 
no IL-4 positivity. 
 
Case Number of granulomas IL-12 IFNγ TNFα IL-4 
S1 103 100% 100% 100% 0% 
S2 1212 100% 100% 100% 0% 
S3 145 100% 100% 100% 0% 
S4 209 100% 100% 100% 0% 
S5 426 100% 100% 100% 0% 
S6 537 100% 100% 100% 0% 
S7 1677 100% 100% 100% 0% 
S8 452 100% 100% 100% 0% 
S9 379 100% 100% 100% 0% 
S10 488 100% 100% 100% 0% 
S11 261 100% 100% 100% 0% 
S12 604 100% 100% 100% 0% 
S13 535 100% 100% 100% 0% 
S14 234 100% 100% 100% 0% 
S15 608 100% 100% 100% 0% 
+ = positive - = negative 
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Figure 26: Both negative control and sense probes consistently negative (x40) 
A representative section of an open lung biopsy from sarcoidosis patient is shown. ISH with the sense 
probe for all cytokines was performed after appropriate preparation of paraffin-embedded tissue.  No 
blue staining which will indicate positive signal was noted. A 40 times magnification was used for this 
photograph. 
 
 
 
 
 
 
 
 
 
 
Figure 27: anti-sense probe for β-actin strongly positive (x200)  
A representative section of an open lung biopsy from sarcoidosis patient is shown. ISH with the anti-
sense β-actin probe was performed after appropriate preparation of paraffin-embedded tissue.  The β-
actin probes were used to determine the presence of non-degraded mRNA in sections. The blue staining 
represents positive signal and intact mRNA. A 200 times magnification was used for this photograph. 
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Figure 28: anti-sense probe for IL-12 strongly positive (x200)  
A representative section of an open lung biopsy from a sarcoidosis patient is shown. ISH with the anti-
sense IL-12 probe was performed after appropriate preparation of paraffin-embedded tissue.  The blue 
staining represents positive signal.  Granuloma outlined in white. A 200 times magnification was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: anti-sense probe for IFNγ strongly positive (x200, insert x400) 
A representative section of an open lung biopsy from a sarcoidosis patient is shown. ISH with the anti-
sense IFNγ probe was performed after appropriate preparation of paraffin-embedded tissue.  The blue 
staining represents positive signal. Granuloma outlined in white.  A 200 times magnification was used 
and a 400 times magnification for the insert, which shown that the signal is concentrated in lymphocytes. 
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Figure 30: anti-sense probe for TNF strongly positive (x200)  
A representative section of an open lung biopsy from a sarcoidosis patient is shown. ISH with the anti-
sense TNFα probe was performed after appropriate preparation of paraffin-embedded tissue.  The blue 
staining represents positive signal. Granuloma outlined in white.  A 200 times magnification was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: anti-sense probe for IL-4 negative (x200)  
A representative section of an open lung biopsy from a sarcoidosis patient is shown. ISH with the anti-
sense IL-4 probe was performed after appropriate preparation of paraffin-embedded tissue.  A complete 
absence of blue staining representing positive signal is noted.  Granuloma outlined in black. A 200 times 
magnification was used.  
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 All the patients had radiological evidence of pulmonary involvement and all but one 
had at least a moderate degree of overall disease severity. Although four of the patients 
had no signs of fibrosis, there was no difference in the cytokine profile between these 
four and the remainder of the patients, as prominent IL-12, IFNγ and TNFα signals 
were observed, but a complete absence of IL-4 was noted in all 15 patients. 
Furthermore no difference in cytokine profile was found between those patients with a 
favourable and those with an unfavourable clinical course.  Despite the spectrum of 
changes observed in the histological grading, none of these differences in the 
histological grading were reflected in the cytokine mRNA profile of these cases.  
 
The investigations performed in the current study confirm the presence of a very strong 
Th1 response in all the cases of sarcoidosis as has been described in other 
studies205,206,207. Due to the uniformity of the results, no statistical analysis was could be 
performed. The presence of a pure Th response is in itself statistically significant. A 
comparison with the Th responses in pleural and pulmonary tuberculosis was 
performed and will be discussed in chapter 7.  
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6. Results: Pulmonary Tuberculosis 
This section is based on original work initiated by Philip Bardin and myself and 
carried on by Gael Fenhalls et al in collaboration with the abovementioned (Appendix 
B: copies of the published articles). This work formed the basis of the subsequent work 
on sarcoidosis and pleural tuberculosis. Individual granuloma results are not included 
and only the relevant results for comparison with pleural TB and sarcoidosis are 
presented.  
 
 
It has become quite apparent that T cells and cytokines play a major role in the host 
response against M.tuberculosis 70. During the last few years a substantial body of 
evidence has emerged that IFNγ, the hallmark cytokine of the Th1 response, plays a 
key role in the defence against tuberculosis 71,72. On the other hand, it is suggested that 
a persistently high IFNγ is responsible for the damage caused by granulomatous disease 
and that moderating cytokines are necessary to down-regulate the IFNγ response to 
more appropriate levels later in the disease process, after the organisms have been 
effectively contained. Thus, in tuberculosis a dual role for INFγ in both protection and 
pathology is suggested, where an appropriate CMI is responsible for containment, but a 
hyper-reactive CMI is responsible for tissue destruction.   
 
Some studies suggest however, that an increase in IL-4 and IL-10 production is 
responsible for the pathology of tuberculosis 68,69. It is suggested that an increase in IL-
4 suppresses IFNγ production, followed by reduced killing of organisms78.  
 
Another cytokine that is of key importance is IL-12. It has been demonstrated that IL-
12 production is essential for the initiation of the Th1-response and that persistent IL-
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12 production is necessary to sustain it. In mice, enhanced protection was noted in the 
group where IL-12 was used as an adjuvant to bacille Calmette-Guérin (BCG) 
immunisation81. There is also however, evidence for the destructive effect of IL-12. In 
a murine study 84 demonstrated that granuloma disintegration and death was dependant 
on T cells and IL-12 production, while depletion of T cells subsets and IL-12 led to 
well-formed compact granulomas and prolonged survival.                                                                    
 
Several studies in mice have demonstrated the importance of TNFα for the early 
expression of mRNA encoding chemokines and leukocyte recruitment88, the ability of 
macrophages to phagocytose and kill mycobacteria 86,87, granuloma formation, 
prevention of necrosis 90,91 and induction of apoptosis93,94.  
 
Although enough evidence exist to support a protective role for TNFα, excessive 
production of TNFα and an increased sensitivity to the cytokine have been implicated 
in the immunopathology of tuberculosis, for example caseous necrosis96. While TNFα 
is an essential component of the host immune response against mycobacterial infection, 
high levels of the cytokine at the site of infection induce an excessive inflammatory 
response that overrides the beneficial effects of the cytokine.        
 
It is also possible that the Th2 cytokines may mediate local tissue inflammation and 
necrosis through their effect on TNFα mediated cytotoxicity97,98. The role of cytokines 
such as TNFα may be to modulate and fine-tune this process, depending on the 
spectrum of cytokines already present.  It may be of particular importance in TB where 
TNFα superimposed on a Th1 cytokine profile may lead to a protective granulomatous 
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response, whereas a Th2 background may result in tissue necrosis and breakdown with 
cavitation, thus favouring spread of organisms.   
 
6.1 Experimental Design 
To investigate the cytokine profile of patients with pulmonary tuberculosis, two groups 
of patients were examined, due to limited availability of appropriate tissue samples as 
previously discussed. The 2 groups will be discussed separately, and are labelled “first 
group of patients” and “second group of patients”. Adult lung tissue was obtained, the 
diagnosis of tuberculosis was confirmed, and ISH was performed for IFNγ-, TNFα- 
and IL-4-mRNA on the first group of 5 patients, while ISH for IL-12 mRNA and 
immunohistochemistry for TNFα, IFNγ and IL-4 were performed on the second group 
of patients.  
 
6.2 Results 
6.2.1 The First Group of Patients 
The first five patients presented with massive haemoptysis and on CXR all had cavity 
formation (Table 35). On histology, granuloma formation with caseating necrosis could 
be demonstrated.  Ziehl-Neelsen staining revealed low levels of acid-fast bacilli in the 
lungs of all patients, even though all had received at least two months of multidrug 
therapy, which included rifampicin, isoniazid and pyrazinamide, prior to surgery. 
 
 
  137
Table 35:  Clinical details of patients.  
The table shows the basic demographic and clinical characteristics of 5 patients with pulmonary 
tuberculosis who were recruited for the histological study of lobectomy (surgical removal of one or more 
lobes of a lung) or pneumonectomy (surgical removal of a whole lung) specimens.   
 
Patient Age/sex Time since previous TB 
(years) 
Preoperative treatment 
duration (months)  
Chest 
radiograph 
A1 39/M 3 2 RUL cavity 
A2 35/M 15 3 RUL cavity 
A3 26/F 3.4 2 LUL cavity 
A4 23/M 3 2 LUL cavity 
A5 31/M   3 LUL cavity 
Age in years; M=male; F=female; RUL = Right upper lobe of the lung; LUL = Left upper lobe of the lung 
 
 
 
6.2.1.1 In Situ Hybridisation 
6.2.1.1.1 General assessment of granulomas   
A summary of the results can be seen in table 36.  Granulomas from three patients (A1, 
A2 and A5) stained positive for IL-4 and IFNγ.  Granulomas from two patients (A3 and 
A4) stained positive for IFNγ and negative for IL-4 mRNA.  Granulomas from all 
patients were positive for TNFα mRNA. 
 
Table 36:  Summary of ISH of granulomas.  
Two of the five patients have a pure Th1 profile, with no IL-4 positivity, while the remaining 3 have Th0 
profile.  
 
Patient TNFα IFNγ IL-4 βactin 
A1 ++ +++ + +++ 
A2 +++ +++ ++ +++ 
A3 +++ +++ - +++ 
A4 ++ ++ - +++ 
A5 +++ ++ ++ +++ 
+++ strong positivity; ++ intermediate positivity; + weak positivity; - no positivity 
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6.2.1.1.2 Analysis of granulomas 
The presence of cytokine mRNA and caseous necrosis was determined for the 
individual granulomas in each patient. (table 37).  The number of granulomas ranged 
from 6 to 12 and most stained positive for IFNγ and TNFα mRNA.  The IL-4 staining 
was negative in two patients (A3 and A4).   
 
Table 37:  Cytokine patterns of individual granulomas from five patients.  
The majority of granulomas stained positive for IFNγ and TNFα mRNA. The number of TNFα mRNA 
positive granulomas was highest in those patients with IL-4 positive granulomas.  
 
Granulomas/section (% of total) Patient Total no. of    
granulomas IFNγ   TNFα  IL-4  + necrosis Th2 Th1 Th0 
A1 6 100% 83% 33% 33% 0 67% 33% 
A2 7 86% 71% 43% 29% 0 43% 43% 
A3 12 75% 58% 0 50% 0 75% 0 
A4 11 82% 64% 0 45% 0 82% 0 
A5 9 67% 78% 44% 33% 0 22% 44% 
 
 
The number of TNFα mRNA positive granulomas was highest in those patients with 
some IL-4 positive granulomas, but did not necessarily overlap with the IL-4 
granulomas. No granulomas which stained positive for IL-4 and negative for IFNγ were 
observed; in fact, IL-4 mRNA was always detected in granulomas with low levels of 
IFNγ staining.  Granulomas with caseous necrosis were generally larger than those 
without central necrosis and were either negative or only weakly positive for IFNγ and 
IL-4 mRNA. 
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Due to the relatively small number of granulomas, statistical analysis was not always 
viable, but significant differences were still present.  Necrotic granulomas were more 
abundant in those patients with no evidence of IL-4 staining (fig. 32) and non-necrotic 
granulomas were positive for IL-4.  One hundred percent of non-necrotic granulomas 
were positive for IFNγ (fig. 33), and 61% of necrotic granulomas were positive for 
IFNγ. However, these necrotic granulomas were all IL-4 negative.  In general, necrotic 
granulomas were also negative to intermediately positive for TNFα mRNA.  Cytokine 
mRNA staining, where present, was generally in the periphery of the granulomas and 
not in or around the necrotic centre, despite the periphery being positive for β-actin 
mRNA.   
 
In summary, the two patients with IFNγ positive, IL-4 negative patterns of cytokine 
production expressed lower levels of TNFα mRNA and had more necrotic granulomas 
than the three patients whose granulomas were positive for both IFNγ and IL-4. In the 
IL-4 positive patients none of the IL-4 positive/IFNγ positive granulomas were 
necrotic.  
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Figure 32:Correlation between necrosis in granulomas and IL-4. 
 
No necrotic granulomas showed any IL-4 mRNA positivity, while 67% of non-necrotic granulomas had 
some IL-4 mRNA positivity (Chi-square test p = 0.0006). 
 
 
Figure 33:Correlation between necrosis in granulomas and IFNγ. 
All non-necrotic granulomas had some IFNγ presence, but only 61% of necrotic granulomas showed any 
IFNγ positivity (Chi-square test p = 0.0004). 
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6.2.2 The Second Group of Patients 
The seven patients in the second group of tuberculosis patients again presented with 
massive haemoptysis and on chest X-ray (CXR) all had cavity formation (Table 38). 
On histology, granuloma formation with caseating necrosis could be demonstrated.  
Ziehl-Neelsen staining revealed low numbers of acid-fast bacilli in the lungs of all 
patients, even though all had received at least one month of multidrug therapy, which 
included rifampicin, isoniazid and pyrazinamide, prior to surgery. 
 
Table 38:  Clinical details of patients.  
The table shows the basic demographic and clinical characteristics of 5 patients with pulmonary 
tuberculosis who were recruited for the histological study of lobectomy or pneumonectomy specimens.  
  
 Age/Sex Extent of disease Time since 
previous TB 
Pre-operative 
treatment  
Follow-up 
B1 23/M RUL collapse 2 years 1 month 8 years 
B2 43/M LUL cavitation with active TB 3 years 1 month 1 years 
B3 33/F LUL large cavity, RUL and 
LLL infiltration 
11 years 3 months 9 years  
B4 31/F Mediastinal shift left, pleural 
effusion, scarring RUL 
3 years 3 months 4 years 
B5 22/M Cavitations RUL and RML, 
coughing up ascaris 
2.5 years 3 months None 
B6 21/F Total destruction RUL, cystic 
lesions in LUL 
17 years 2 months 1 month 
B7 41/M R lung collapse, fibrosis. L lung 
unaffected 
6 years 3 months 5 years  
Age = years RUL = Right upper lobe; LUL = Left upper lobe; LLL = Left lower lobe;  
 RML = Right middle lobe 
 
 
6.2.2.1 In Situ Hybridisation and Immunohistochemistry 
6.2.2.1.1 Scoring of individual granulomas for cytokine patterns and 
immunophenotype 
 
Individual granulomas from the seven patients were scored for the presence of  
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cytokines, phenotypic markers, and caseous necrosis and the data are summarised in 
Table 39.  Each case contained 10 and 40 granulomas. All seven patients had some 
granulomas positive for IFNγ, TNFα, IL-12p40 and central necrosis.  However, only 
four of the seven patients had any granulomas staining positive for IL-4 (Table 39: 
patients B3, B4, B5 and B7).  These patients tended to have the highest percentage of 
necrotic granulomas and the lowest percentage of TNFα positive granulomas.  Staining 
intensity did not necessarily correlate with protein levels, being dependent also on the 
affinity of the primary antibody for the antigen.   
 
Table 39: Cytokine patterns and immunophenotyping of the individual granulomas for seven 
patients.  
All 7 patients had some granulomas positive for IFNγ, TNFα, IL-12 and central necrosis.  Only 4 of the 
7 patients had any granulomas staining positive for IL-4 and these patients tended to have the highest 
percentage of necrotic granulomas and the lowest percentage of TNFα positive granulomas.   
 
 Total no. 
granulomas 
Caseous 
necrosis 
IFNγ TNFα IL-4 IL-12p40 
mRNA 
B1 10 2 (20%) 9 (90%) 10 (100%) 0 (0%) 9 (90%) 
B2 40 9 (23%) 37 (93%) 30 (75%) 0 (0%) 29 (73%) 
B3 12 4 (33%) 11(92%) 4 (33%) 4 (33%) 9 (75%) 
B4 15 8 (53%) 10 (67%) 8 (53%) 6 (40%) 11 (73%) 
B5 23 9 (39%) 17 (74%) 15 (65%) 5 (22%) 17 (74%) 
B6 29 7 (24%) 26 (90%) 21 (72%) 0 (0%) 25(86%) 
B7 12 4 (33%) 9 (75%) 4 (33%) 5 (42%) 8 (67%) 
Percentage of total granulomas indicated in brackets 
 
 
6.2.2.1.2 Association between IFNγ, IL-4, TNFα proteins, IL-12p40 mRNA and 
caseous necrosis in individual granulomas  
 
The data were further analysed for associations between cytokines and necrosis and the 
results were expressed in contingency tables using Fisher’s exact and Mantel Haenszel 
x2 tests.  Fisher’s exact test is designed to give robust estimates of significance when 
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frequencies in the contingency table are low, i.e. scores of zero for some cytokines.  
The patients were also divided into two groups, those expressing IL-4 in some of their 
granulomas (patients B3, B4, B5 and B7) and those not expressing IL-4 in any of their 
granulomas (patients B1, B2 and B6). Dual-parameter associations in the IL-4 positive 
and negative patients were considered separately. 
 
6.2.2.1.2.1 IFNγ AND IL-12P40 
Seventy six percent (107 out of 141) of all granulomas were positive for both IFNγ and 
IL-12.  Almost all granulomas staining positive for IL-12p40 were also expressing 
IFNγ (107 out of 108 granulomas) with only one granuloma positive for IL-12p40 and 
negative for IFNγ (Table 40).  The probability of a granuloma producing IFNγ was 
significantly greater if the granuloma was also positive for IL-12p40  (fig. 34).  
However, 12 granulomas were identified which were negative for IL-12p40 but IFNγ 
positive.  Granulomas that were positive for either IFNγ or IL-12 were more likely to 
be IFNγ positive rather than IL-12p40 positive (P=0.002 McNemar’s test).  No 
significant differences between IL-4 positive or negative patients were found with 
respect to these associations.  
 
Table 40: Correlation between IFNγ protein and IL-12 mRNA in all granulomas  
Almost all granulomas staining positive for IL-12p40 were also expressing IFNγ (107 out of 108 
granulomas) with only one granuloma positive for IL-12p40 and negative for IFNγ (Chi-square test p = 
0.001). 
 
 
 
 
 
 IFNγ 
IL-12p40 0 
(negative) 
1 
(positive) 
Total 
0 (negative) 219 12 33 
1 (positive) 1 107 108 
Total 22 119 141 
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Figure 34: IFNγ and IL-12p40 
The probability of a granuloma producing IFNγ was significantly greater if the granuloma was also IL-12 
positive; only 12 IFNγ positive granulomas were IL-12 negative (Chi-square test   p=0.001).  
6.2.2.1.2.2 IFNγ AND IL-4  
In table 41 the correlation between IFNγ and IL-4 in patients with IL-4 positive 
granulomas demonstrates that no IL-4 positive granulomas were negative for IFNγ, 
although not all IFNγ positive granulomas were IL-4 positive. IL-4-negative patients 
also tended to have a higher percentage of IFNγ positive granulomas than the IL-4 
positive group (Chi-square test p = 0.001).     
 
Table 41: Correlation between IFNγ and IL-4 in IL-4 positive patients  
 
All granulomas that were IL-4 positive were also IFNγ positive. However, 15 IFNγ positive granulomas 
were IL-4 negative.   
 
 
 
 
 
 
219
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IL-12 negative granulomas IL-12 positive granulomas
 IFNγ 
IL-4 0 
(negative) 
1 (positive) Total 
0 (negative) 15 27 42 
1 (positive) 0 20 20 
Total 15 47 62 
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6.2.2.1.3 TNFα and caseous necrosis and TNFα and IL-4 
It is quite apparent from table 42 that all granulomas with caseous necrosis were TNFα 
positive. However, in IL-4 negative patients, non-necrotic granulomas were more likely 
to be TNFα positive than negative.  The opposite was true for IL-4 positive patients. In 
IL-4 positive patients, half of the granulomas were TNFα positive, but only 5 
granulomas showed positivity for both IL-4 and TNFα (Table 43).  
 
Table 42: Patients separated into two groups on the basis of the presence or absence of 
IL-4 and their granulomas scored for TNFα and caseous necrosis.  
All granulomas with caseous necrosis were TNFα positive, from both IL-4 positive and negative 
patients.  (P<0.001: Mantel Haenszel).  
 
 Caseous necrosis 
TNFα 0 (negative) 1 (positive) Total 
IL-4 negative patients    
0 (negative) 18 0 18 
1 (positive) 43 18 61 
Total 61 18 79 
IL-4 positive patients    
0 (negative) 31 0 31 
1 (positive) 8 25 31 
Total 37 25 62 
 
 
 
Table 43:  Contingency table of TNFα and IL-4 (IL-4 positive patients only).  
Half of the granulomas in IL-4 positive patients (B3,B4,B5 and B7) were TNFα positive.  However, 
these TNFα positive granulomas tended to be negative for IL-4.  TNFα negative granulomas were 
equally likely to be IL-4 positive or negative.  
 
 TNFα 
IL-4 0 (negative) 1 (positive) Total 
0 (negative) 16 26 42 
1 (positive) 15 5 20 
Total 31 31 62 
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6.3 Controls 
Tissue sections taken from 2 patients who underwent surgery for pulmonary 
malignancies were examined and a histological diagnosis of squamous carcinoma was 
made in both instances.  Sections from the carcinoma were subjected to ISH for IL-12, 
IL-4, TNFα and IFNγ. The carcinoma cells showed no signs of positivity for any of 
these cytokines.  Due to subsequent technical difficulties photographic records of these 
controls no longer exist and could not be included in the thesis.  
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7. Results: A Comparison Between Pleural Tuberculosis, 
Sarcoidosis and Pulmonary Tuberculosis.  
A summary of the results of the various groups in this study can be seen in table 44. 
Necrotic granulomas were seen in most of the patients with tuberculosis, while no 
necrosis was present in the sarcoid granulomas. Most granulomas in the pleural 
tuberculosis group had a Th0 profile, while in sarcoidosis all had a Th1 profile. The 
pulmonary granulomas had a mixed response.      
Table 44: Summary of the cytokine profile of individual patients in the pleural tuberculosis, 
sarcoidosis and pulmonary tuberculosis groups.  
The granulomas positive for a specific parameter are expressed as a percentage of the total number of 
granulomas. All patients with pulmonary tuberculosis had necrotic granulomas, while most of the 
patients with pleural tuberculosis and none with sarcoidosis had necrotic granulomas. There were clear 
differences in the Th profile of the various groups.   
Group Nr. of granulomas Necrosis IL-12 IFNγ TNFα IL-4 Th1 Th0 
Pleura +  5 88% 100% 100% 100% 100% 0% 100% 
Pleura +  9 30% 100% 100% 100% 67% 33% 67% 
Pleura + 10 100% 100% 100% 100% 100% 0% 100% 
Pleura + 3 100% 100% 100% 100% 100% 0% 100% 
Pleura + 6 63% 100% 100% 100% 100% 0% 100% 
Pleura + 8 20% 100% 100% 100% 100% 0% 100% 
Pleura - 24 68% 100% 100% 100% 88% 13% 87% 
Pleura - 16 6% 100% 100% 100% 100% 0% 100% 
Pleura - 16 25% 100% 100% 100% 100% 0% 100% 
Pleura - 8 80% 100% 100% 100% 100% 0% 100% 
Pleura - 10 0% 100% 100% 100% 100% 0% 100% 
Pleura - 51 0% 100% 100% 100% 100% 0% 100% 
Sarcoid 103 0% 100% 100% 100% 0% 98% 0% 
 Sarcoid 1212 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 145 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 209 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 426 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 537 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 1677 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 452 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 379 0% 100% 100% 100% 0% 100% 0% 
 Sarcoid 488 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 261 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 604 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 535 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 234 0% 100% 100% 100% 0% 100% 0% 
Sarcoid 608 0% 100% 100% 100% 0% 100% 0% 
Lung 6 33% N/A 100% 83% 33% 67% 33% 
Lung 7 29% N/A 86% 71% 43% 43% 43% 
Lung 12 50% N/A 75% 58% 0% 75% 0% 
Lung 11 45% N/A 82% 64% 0% 82% 0% 
Lung 9 33% N/A 67% 78% 44% 22% 44% 
Lung 10  20% 90% 90% 100% 0% 90% 0% 
Lung 40  23% 73% 93% 75% 0% 93% 0% 
Lung 12 33% 75% 92% 33% 33% 58% 44% 
Lung 15 53% 73% 67% 53% 40% 27% 55% 
Lung 23 39% 74% 74% 65% 22% 52% 29% 
Lung 29  24% 86% 90% 72% 0% 90% 0% 
Lung 40 33% 67% 75% 33% 42% 33% 63% 
Pleura+ = HIV positive group; pleura - - HIV negative group N/A = not applicable 
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The tissue destruction in granulomatous disease is ascribed to necrosis and in the 
instance of tuberculosis specifically caseous necrosis.  It is clear from the comparison 
between necrosis in the various groups (fig. 35) that HIV positive pleural tuberculosis 
is the group with the highest percentage of necrotic granulomas (66%), followed by 
pulmonary tuberculosis (33%), HIV negative pleural tuberculosis (21%) and 
sarcoidosis (0%).   
Figure 35: A comparison between necrosis in pleural tuberculosis, pulmonary tuberculosis and 
sarcoidosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A comparison of the Th profiles of the four groups (fig. 36) indicates that sarcoidosis 
has the strongest Th1 response (100%), followed by pulmonary tuberculosis, with a 
60% Th1 response and lastly pleural tuberculosis as a combined group of HIV positive 
and HIV negative (average 4,5%). There is a statistically significant difference between 
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Results are expressed as the % granulomas with necrosis.  A bootstrap means analysis indicates a 
statistically significant difference of p < 0.01 between the percentage of necrotic granulomas in 
sarcoidosis and pulmonary tuberculosis, sarcoidosis and pleural (HIV +) tuberculosis, pleural (HIV-) 
tuberculosis and pulmonary tuberculosis, and between HIV positive and HIV negative granulomas in 
pleural tuberculosis. A bootstrap analysis illustrates differences by allocating different letters of the 
alphabet, while similarities are illustrated by allocating the same letter, therefore an A for HIV 
positive pleural tuberculosis, a C for HIV negative pleural tuberculosis, a B for pulmonary 
tuberculosis and a D for sarcoidosis indicates a statistically significant difference between each of the 
individual parameters.      
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the percentages of Th1 positive granulomas in each of these 3 groups respectively. No 
statistically significant difference can however be seen between the HIV positive and 
negative groups of pleural tuberculosis.   
Figure 36: A comparison between the Th1 response in pleural tuberculosis, pulmonary 
tuberculosis and sarcoidosis in the top graph and Th0 in the bottom graph.  
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There is however, no statistical difference between the Th1 response in HIV positive 
(2%) and HIV negative patients (7%). The exact reverse applies to a comparison of the 
Th0 profiles in the various groups, with sarcoidosis clearly having no Th0 response, 
pulmonary tuberculosis with a 40% response and pleural tuberculosis with a 98% Th0  
response in HIV positive and a 93% Th0 response in HIV negative patients. 
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8. Discussion 
8.1 Pleural Tuberculosis 
 
It has been proposed that pleural tuberculosis in HIV negative patients is characterised 
by Th1 predominance 244.  This data is usually based on the measurement of cytokine 
levels in body fluids, or examining cytokine production by immune cells in vitro.   
 
This study is the first description of in situ hybridisation of cytokine mRNA in pleural 
biopsies of HIV sero-negative and sero-positive patients. In both groups of patients a 
Th0 response, characterised by the presence of both Th1 and Th2 cytokines, was noted.  
Of the 166 granulomas counted in total, only 6 had a Th1 profile, while the remainder 
all had a Th0 profile. There were however, significant differences in the cytokine 
profiles between the 2 groups.  
 
All 12 patients with pleural tuberculosis presented with symptoms of pleural effusion, 
which was confirmed by CXR and a pleural biopsy was performed as a diagnostic 
procedure. HIV ELISA tests showed that 6 patients were infected with this virus.  ISH 
for IL-12, IFNγ, TNFα and IL-4 was carried out on a total of 166 granulomas in these 
patients. 
 
It is quite apparent from the results that granulomas in HIV positive patients have a 
higher incidence of necrosis, as 66% of these granulomas showed necrosis as opposed 
to 17% in granulomas of HIV negative patients, in keeping with the histological 
appearance of granulomas in HIV positive patients as described by Lucas161.   
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The necrotic granulomas have a tendency towards more IFNγ, TNFα and IL-4 positive 
cells per granuloma in comparison to the non-necrotic granulomas. TNFα presence in 
granulomas, especially a Grade 3 (> 75% positive cells) distribution, was associated 
with a dramatic increase in necrosis. In addition, granulomas with a high number of 
TNFα positive cells also tend to have a high number of IFNγ positive cells.  In the case 
of IL-12 there is a more equal distribution of the number of cells throughout the 
granulomas. 
 
In non-necrotic granulomas a significant number have low numbers of cells positive for 
all of the cytokines tested, and less than 25% of all the non-necrotic granulomas have a 
high presence of either TNFα or IL-4 mRNA. The granulomas that do have a high 
number of IL-4 positive cells also have a high number of TNFα positive cells. In the 
HIV negative group these granulomas tend not to be necrotic. A similar picture can be 
seen for IL-4 and IFNγ  where only 8 non-necrotic granulomas (7%) had high numbers 
of IL-4 and IFNγ positive cells. 
 
Substantial evidence exists that IFNγ, the hallmark cytokine of the Th1 response, plays 
a key role in the defence against tuberculosis. IFNγ is a pro-inflammatory cytokine 
promoting macrophage activation and an inflammatory rich environment that is 
beneficial for the inhibition and killing of mycobacteria. It is apparent from the 
literature that IFNγ is crucial in the defence against mycobacteria71,72. However, it is 
also suggested that persistently elevated IFNγ is responsible for the damage caused by 
granulomatous disease and that moderating cytokines like IL-4 are necessary to down-
regulate the IFNγ response to more appropriate levels after effective containment of the 
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organisms.  It is therefore suggested that a dual role exists for IFNγ, where early 
containment requires sufficient IFNγ levels, but similar levels, without modulation by 
other cytokines later in disease may lead to tissue destruction.   
 
Recently a virtual model to predict cell mediated immune regulatory mechanisms 
during human infection with M tuberculosis was designed by Wigginton et al245. 
According to this model a high production of IL-4 by Th0 cells is associated with a 
shift from latency to active disease. On the other hand, a high level of IFNγ is 
protective and prevents reactivation.   
 
If reactivation does occur, patients may or may not incur tissue damage as a 
consequence of the immune response. It is not only desirable to suppress bacterial 
infection, but also to do so in the most efficient and least damaging manner. According 
to this virtual model245, an increase in IFNγ beyond the lower limit needed to control 
infection after reactivation, exacerbates infection. In addition, if the rate of IL-4 decay 
increases or the production of IL-10 decreases, greater damage will occur.     
 
In the pleural tuberculosis cases, non-necrotic granulomas tend to have lower numbers 
of IFNγ positive cells in the presence of low numbers of IL-4 positive cells, while the 
inverse is true for necrotic granulomas. This pattern is in keeping with the virtual model 
described. An increase in IFNγ correlates with an increase in necrosis, while a decrease 
of IFNγ positive cells is seen in non-necrotic granulomas.     
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It is apparent that an intricate balance exists between down-and-up-regulatory immune 
components.  Immune activation is essential for suppression of infection, but once 
bacterial load is controlled, down-regulation is required to minimise tissue damage. 
Unfortunately the role of TNFα is not addressed in the model designed by 
Wigginton245. My data suggests, however, together with other studies of TNFα-induced 
immunopathology84,85,86,87,88 that this cytokine plays an important role in this balance 
between essential immune activation on the one hand and immunopathology on the 
other. The correct timing and amount of TNF production might have a very narrow 
limit to offer a benefit to the M. tuberculosis infected host.  
  
There is a definite correlation between TNFα and necrosis in the pleural tuberculosis 
granulomas. Although a causative relationship between TNFα and necrosis cannot be 
deduced from this evidence, it appears likely that TNFα may be involved in necrosis 
development277. The caseous necrosis is a consequence of apoptosis of infected 
macrophages and activated T cells within the granuloma278 and TNFα is a known 
inducer of apoptosis279.   
 
A strong positive correlation exists between high numbers of TNFα positive cells and 
HIV positivity. This finding supports the fact that TNF regulates HIV transcription and 
that higher TNF levels are expected in HIV positive patients246. Further support of this 
finding is the fact that there is a more even distribution of the numbers of TNFα 
positive cells in HIV negative granulomas.  The IL-4 and IFNγ profiles follow a similar 
pattern to that in necrotic granulomas, with more cells positive for these cytokines in 
HIV positive than in HIV negative granulomas.  IL-12 positivity is once again more 
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evenly distributed, with 31% granulomas containing <25% positive cells in HIV 
negative granulomas and 31% containing >75% positive granulomas in HIV positive 
granulomas. 
  
When exploring the relationship between the various cytokines in HIV negative 
granulomas it is found that there is a very strong relationship between  IFNγ and TNF,  
IL-4 and TNFα, IL-12 and IFNγ as well as between IL-12 and IL-4, with a 
predominantly low number of positive cells for these cytokines in HIV negative 
granulomas. IL-12 and TNFα positivity is also linked, but a  more even distribution of 
the number of  positive cells is observed. 
 
On the other hand, the higher number of cytokine positive cells in HIV positive 
granulomas is reflected in the relationship between all the various cytokines, except for 
the relationship between IL-12 and TNFα, where most granulomas have a very high 
number of TNFα positive cells and an intermediate number of IL-12 positive cells.    
 
The observation that more cytokine positive cells are seen in HIV positive granulomas 
supports the theory that an overproduction of cytokines may be seen in HIV positive 
patients as a mechanism to compensate for the failure of another immune effector 
mechanism122.  The presence of mRNA of course does not assure that the cytokines are 
produced, secreted or effective. It is therefore possible that the high number of positive 
cells is an indication of a failed attempt to induce cytokine production.     
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On exploring the association between HIV status and necrosis in more depth it is found 
that in HIV negative granulomas without necrosis, a strong positive correlation exists 
between all the cytokines. Granulomas in this group have a tendency towards fewer 
positive cells per granuloma than in any of the other groups. The inference from this is 
that fewer cells positive for cytokines, and possibly therefore less cytokines produced, 
are beneficial to the patient, as destruction does not occur. The inverse appears to be 
true for necrotic granulomas in the HIV negative group of patients.  
 
Although the association between the various cytokines in the HIV negative 
granulomas with necrosis is rarely statistically significant, there is a very clear 
association between IFNγ and TNFα, with 52% of all granulomas in this group 
containing high numbers of positive cells for both these cytokines. The trend followed 
by the other cytokines is similar.  On examination of individual cytokines, a statistically 
significant relationship can be identified between necrotic granulomas and IFNγ as well 
as necrotic granulomas and TNFα. In both instances more than half of the necrotic 
granulomas have more than 75% positive cells of each cytokine.  
 
In the group of HIV positive granulomas with necrosis, there is also a strong positive 
correlation between IFNγ and TNFα, as well as IFNγ and IL-4, but a strong negative 
correlation between IL-12 and TNFα. On investigation of the HIV positive granulomas 
the only individual cytokine with a statistically significant result is IFNγ with a low 
number of positive cells in necrotic granulomas. This is in direct contrast to the HIV 
negative group where necrotic granulomas contained a high number of IFNγ positive 
cells. Overall the IFNγ presence is however still higher in HIV positive granulomas 
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than HIV negative granulomas. This finding concurs with several studies confirming an 
increase of IFNγ in HIV positive patients with tuberculosis247,248.     
 
TNFα has a central role to play both in the host immune response to M.tb and the 
immunopathology of tuberculosis85. The release of TNFα in response to M.tb has 
several beneficial effects86, and is required for granuloma formation, which is accepted 
to be protective and indicates a successful immune response. Other benefits include 
regulation of chemokines and leukocyte recruitment88.  
 
Excessive production of TNFα and an increased sensitivity to the cytokine have, 
however, been implicated in the immunopathology of tuberculosis, for example 
caseous necrosis96. Although TNFα is an essential component of the host immune 
response against mycobacterial infection, high levels of the cytokine at the site of 
infection may induce an excessive inflammatory response that overwhelms the 
beneficial effects of the cytokine.  
 
It may also be possible that Th2 cytokines mediate local tissue inflammation and 
necrosis through their effect on TNFα induced cytotoxicity97,98. The relationship 
between the various cytokines in the current study supports the theory that high IFNγ 
levels later in disease may be detrimental, and there is a suggestion that this may be 
especially important in the presence of high numbers of TNFα positive cells.  
 
Significant immune activation in HIV positive patients is demonstrated by the current 
findings, and both the Th1 and Th2 arms appear to be excessively stimulated.  The 
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present study and the virtual model by Wigginton suggest that such cytokine 
overproduction is detrimental to the patient245. 
 
The presence of numerous IL-12 positive cells appears to have an impact on the 
presence of other cytokine positive cells in the granuloma. More IFNγ, TNFα and IL-4 
positive cells can be seen in the presence of high numbers of IL-12 positive cells, when 
the patients are HIV negative. This relationship is of course interchangeable and the 
statement that IL-12 positive cells have an impact on the presence of other cytokine 
positive cells is just as applicable to any of the other cytokines.  
 
It is apparent that necrotic granulomas contain higher numbers positive cells, especially 
IL-4 and TNFα, but also IL-12 and IFNγ. On the other hand, high numbers of IL-12 
cells are less prevalent in necrotic granulomas. In the non-necrotic granulomas with 
high numbers of IL-12 positive cells, high numbers of IL-4 positive cells can also often 
be seen.  The high number of IL-4 positive cells does not appear to have an effect on 
necrosis.  It is possible that this may be due to the influence of the IL-12 positive cells. 
On the other hand, the presence of high numbers of IL-4 positive cells in these 
granulomas may in itself be a regulatory presence and prevent the development of 
necrosis by acting as opposition to necrosis inducing factors.    
 
The number of IFNγ positive cells appears to be higher in non-necrotic granulomas 
when numerous IL-12 cells are present, but lower when less IL-12 positive cells can be 
seen. This is of course in keeping with the function of IL-12 as an IFNγ regulatory 
cytokine16,23.  In necrotic granulomas the opposite is true, with more IFNγ positive cells 
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in necrotic granulomas where there are less IL-12 positive cells. Very few necrotic 
granulomas contain high numbers of IFNγ positive cells in the presence of high 
numbers of IL-12 positive cells. This finding may suggest some breakdown in the 
regulatory mechanism of IL-12.   
 
High numbers of IL-4 cells are also present in granulomas with a high number of IFN 
positive cells, but there is an equal distribution between necrotic and non-necrotic 
granulomas. This suggests that although IL-4 may have a regulatory effect on the 
possible detrimental impact of high levels of IFNγ at this stage of disease according to 
the virtual model by Wigginton, this definitely is not the only, or even the most 
important controlling factor.   
 
In tuberculosis, the first step in host defence is the ingestion and uptake of M. tb 
organisms by alveolar macrophages and other cells.  Apoptosis is an important host 
defence mechanism to contain mycobacterial survival and growth233,234.  By inducing 
apoptosis of macrophages containing organisms, the organism is deprived of its 
intracellular sanctuary and the process of apoptosis therefore favours the host233,234. It is 
possible that dissemination in tuberculosis depends at least in part on a paucity of 
apoptosis. Caseous necrosis in granulomas is also associated with an increase in 
apoptotic activity. Within the granuloma, apoptosis is prominent in the epithelioid cells 
as demonstrated by condensed chromatin viewed by light microscopy or with the in situ 
terminal transferase mediated nick end labelling (TUNEL) technique249. The effects of 
Fas L- mediated or TNFα-induced apoptosis on M. tuberculosis viability in human and 
mouse macrophages is controversial; some studies report reduced bacterial numbers 
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within macrophages after apoptosis250 while others indicate this mechanism has little 
antimycobacterial effect251. Insufficient T cell apoptosis may also interfere with clonal 
deletion and maintenance of tolerance, resulting in inappropriate T cell accumulation, 
contributing to chronic inflammation. This may lead to maintenance of the granulomas 
and to consequent fibrosis235.   
 
Detailed analysis of human tuberculous tissues revealed that apoptotic CD3+, 
CD45RO+ cells are present in productive tuberculous granulomas, particularly those 
containing a necrotic centre252. Studies carried out by Raja have demonstrated the 
ability of mycobacterial antigens to bring about apoptosis in animal models253. In 
addition, increased spontaneous apoptosis, which is further enhanced by mycobacterial 
antigens, has also been shown to occur in pleural fluid cells254. 
 
In the pleural tuberculosis cases in the current study, a definite increase in the number 
of TNFα mRNA positive cells was observed in necrotic granulomas. In the pulmonary 
tuberculosis patients all the necrotic granulomas stained positive for TNFα mRNA or 
protein. It is apparent that there is an association between TNFα and necrosis in 
tuberculous granulomas. This association may be ascribed to the increased apoptotic 
activity of TNFα. 
 
8.1.1 In summary   
This study is the first description of in situ hybridisation of cytokine mRNA in pleural 
biopsies of HIV sero-negative and sero-positive patients. In both groups of patients a 
Th0 response, characterised by the presence of both Th1 and Th2 cytokines, was noted.   
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Granulomas in HIV positive patients have a higher incidence of necrosis than 
granulomas in HIV negative patients.  There is a clear association between TNFα and 
necrosis in tuberculous granulomas that may possibly be ascribed to the increased 
apoptotic activity of TNFα.  
 
The cytokine pattern is in keeping with the virtual model described by Wigginton. An 
increase in IFNγ correlates with an increase in necrosis, while a decrease of IFNγ 
positive cells is seen in non-necrotic granulomas. This supports the theory that high 
IFNγ levels later in disease may be detrimental, and there is a suggestion that this may 
be especially important in the presence of high numbers of TNFα positive cells.  
 
A strong positive correlation exists between high numbers of TNFα positive cells and 
HIV positivity. This finding supports the fact that TNF regulates HIV transcription and 
that higher TNF levels are expected in HIV positive patients, as well as the theory that 
an overproduction of cytokines may be seen in HIV positive patients as a mechanism to 
compensate for the failure of another immune effector mechanism.   
 
In the non-necrotic granulomas with high numbers of IL-12 positive cells, high 
numbers of IL-4 positive cells can also often be seen.  The high number of IL-4 
positive cells does not appear to have an effect on necrosis.  It is possible that this may 
be due to the influence of the IL-12 positive cells. On the other hand, the presence of 
high numbers of IL-4 positive cells in these granulomas may in itself be a regulatory 
presence and prevent the development of necrosis by acting as opposition to necrosis 
inducing factors.    
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Very few necrotic granulomas contain high numbers of IFNγ positive cells in the 
presence of high numbers of IL-12 positive cells. There were also granulomas with 
high numbers of IFNγ positive cells in the presence of less IL-12 positive cells. This 
finding may suggest some breakdown in the regulatory mechanism of IL-12. 
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8.2 Sarcoidosis 
Sarcoidosis is a multi-system granulomatous disease of unknown cause, although 
several organisms have been investigated as a possible cause, amongst these M. 
tb192,193,194,195. The disease is characterised by non-caseating granulomas, which either 
resolve or progress to fibrosis.  The granulomas are well formed, consisting of tightly 
clustered epithelioid macrophages, usually with Langhans or foreign body-type giant 
cells, and often lacking significant surrounding inflammation.  Concentric fibrosis, 
surrounding the granuloma, is often a feature. 
 
This fibrosis represents the major cause of morbidity and mortality in pulmonary 
sarcoidosis. Histologically it would appear that granulomas act as a focus for fibrosis 
and that fibrosis is not an independent process. This leads to fibrosis becoming more 
diffuse255,256,257. Clinical support for this is found in the improvement of symptoms and 
organ function in patients with sarcoidosis receiving some form of immunosuppressive 
treatment257. It can be concluded therefore that propagation or preservation of 
granulomas eventually lead to fibrosis and severe disease.  
 
The investigations performed in the current study confirm the presence of a very strong 
Th1 response in all the cases of sarcoidosis as has been described in other 
studies208,209,210. A prominent IL-12, IFNγ and TNFα signal was observed, but a 
complete absence of IL-4 was noted. The patients all had at least stage II radiological 
disease and therefore fall in the group of those with chronic disease according to the 
findings by Möllers et al201. This stratification was based on comprehensive clinical 
data258,259 and may differentiate between patients with a high likelihood of spontaneous 
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remission and those with a more prolonged course of disease. One draws the 
conclusion that their differentiation between acute  (spontaneous remission) and 
chronic (prolonged disease) is analogous to the terms inactive and active disease in 
other publications.  
 
In the patients with acute disease and a good prognosis, described by Möllers et al201 
the level of expression of Th1 cytokines, specifically IFNγ, IL-2 and TNFα, were much 
higher than in the patients with chronic disease, while the Th2 cytokine expression 
level, including IL-4, IL-10 and IL-5 was very low in both groups.  Similar results were 
seen in other studies207,211.This suggests that a high level of Th1 cytokines is required 
for a good prognosis.  It has also been shown that patients with high serum levels of 
IFNγ have better chance of achieving complete resolution after corticosteroid 
treatment.  
 
The strong expression of IFNγ may be responsible for the absence or suppression of the 
Th2 cytokines as IFNγ is known to be a Th2 suppressor. In addition, however, IFNγ 
acts as a promoter for accessory macrophage function, which may lead to the 
production of more inflammatory cytokines. The result of the IFNγ associated 
promotion of macrophage activity is the production and release of additional TNFα. 
There is convincing evidence that overexpression of TNFα is associated with 
persistence of inflammation and the development of fibrotic lung disease260,261.  In 
addition, chronic sarcoidosis patients with corticosteroid resistant disease, studied by 
Ziegerhagen et al262, are characterised by a significantly increased release of TNFα by 
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cultured alveolar macrophages.  IFNγ also has a profibrotic effect under certain 
circumstances263.  
 
Supporting evidence for the adverse effect of the Th1 subset is provided by the high 
levels of TGFβ and the negative correlation between IL-2, a Th1 cytokine, and TGFβ 
found in patients with acute remitting disease264, where patients who have gone into 
remissions expressed high levels of TGFβ and low levels of IL-2. TGFβ is known to 
have a suppressive effect on the Th1 response and an increased release in TGFβ is 
associated with spontaneous remission. In addition IL-12 levels have been shown to be 
higher in sarcoid patients who worsened without therapy230. 
 
Although it appears that a pure Th1 response may have an adverse effect on the 
disease, primarily through TNFα, a shift to a predominant Th2 response promotes 
deposition of fibronectin and other collagen matrix products from recruited 
fibroblasts265.  It has been shown that IL-4 stimulates collagen production in fibrosing 
alveolitis, while INFγ inhibits fibrogenesis.  Evidence of increased TGFβ expression 
causing extracellular matrix deposition in fibrotic lung diseases has also been 
found266,267. On the one hand a pure Th1 response appears to be present in patients with 
with periods of recurrence and remission of disease, but on the other hand IFNγ is also 
a promoter of TNFα production, which is associated with fibrosis and progressive 
disease. Suppression of Th1 by TGFβ appears to have a positive effect, whereas a 
strong Th2 shift has a negative effect.  
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The critical question is whether the Th1 response is purely beneficial in sarcoidosis or 
whether the effect of Th1 cytokines depends on the stage of disease. An early pure Th1 
response may be beneficial to the patient if it effectively clears the granuloma-inducing 
antigen. In chronic disease where failure to remove the antigen has resulted in 
progression of granulomas with subsequent fibrosis, a pro-inflammatory Th1 response 
may be detrimental to the patient and minimising of this detrimental effect is needed. It 
therefore appears that a fine balance between excessive pro-inflammatory action (Th1) 
and a Th2 shift is essential for the best possible prognosis in sarcoidosis.  
 
In the current study strong evidence of a Th1 response and no evidence of a Th2 
response was found. All the patients had radiological evidence of pulmonary 
involvement and all but one had at least a moderate degree of overall disease severity. 
Although four of the patients had no signs of fibrosis, there was no difference in the 
cytokine profile between these four and the remainder of the patients. Furthermore no 
difference in cytokine profile was found between those patients with a favourable and 
those with an unfavourable clinical course.   
 
Apoptosis results from the activation of an internally encoded suicide program induced 
by a variety of extrinsic and intrinsic signals. It is a form of cell death that serves to 
eliminate cells that are no longer needed232. Apoptosis is the net result of the balance 
between pro-apoptotic and anti-apoptotic stimuli, including cytokines, death receptors, 
caspases, mitochondria bcl-2 proto-oncogenes and certain tumour-suppressor genes.  
TNFα is an established pro-apoptotic cytokine, released during the inflammatory 
process.   
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The composition of the subset of lymphocytes in sarcoidosis depends on the balance of 
immigration, local proliferation, apoptosis and migration (removal)268.  The removal of 
activated lymphocytes by apoptosis is one prerequisite for the resolution of 
inflammation269.  The balance of pro-inflammatory cytokines promoting granuloma 
growth and resolution of tissue inflammation via cell apoptosis in combination with 
immunosuppressive cytokines may be one of the reasons why spontaneous remission 
and aggravation occur in sarcoidosis. Failure of cells to die might be one mechanism 
contributing to the maintenance of immune granulomas, characterised by persistence of 
inflammation at the site of disease activity and resulting in fibrosis.  
 
It is interesting to note that in patients with chronic, fibrotic disease high levels of 
TNFα are found. As TNFα is a potent inducer of apoptosis one would expect it to be 
absent. However, dysregulation of the TNF receptor family may prevent TNFα induced 
apoptosis.  It may be possible that more TNF is produced in an effort to overcome this 
dysregulation and in the process fibrosis is induced.      
 
The strong presence of Th1 cytokines as well as TNFα in the sarcoidosis patients in 
this study supports the theory that a strong Th1 presence in conjunction with TNFα 
may induce fibrosis, as most of these cases showed signs of at least focal fibrosis.  
 
A spectrum of changes was observed in the histological grading. Most of the cases (10) 
showed changes in keeping with moderate overall severity. Only one cases showed 
minimal disease and 4 severe disease. Diffuse fibrosis was present in 8 cases and focal 
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fibrosis in 3.  Four cases had no fibrotic change. None of these differences in the 
histological grading are reflected in the cytokine mRNA profile of these cases.  
 
None of the differences in the histological grading are reflected in the cytokine mRNA 
profile of these cases. It is possible that the cytokine profile does not reflect the 
histological grade of disease or that the cytokine profiles may reflect various stages of 
the disease. Patients with little or focal fibrosis might possibly be in an earlier stage of 
disease, when a Th1 response is expected and possibly beneficial to the patients. Cases 
with more established and diffuse fibrosis may represent a much later stage of disease, 
where the presence of a pure Th1 response may be detrimental to the patient.     
 
8.2.1 In summary 
In the current study strong evidence of a Th1 response and no evidence of a Th2 
response was found. All the patients had radiological evidence of pulmonary 
involvement and all but one had at least a moderate degree of overall disease severity. 
Although four of the patients had no signs of fibrosis, there was no difference in the 
cytokine profile between these four and the remainder of the patients. Furthermore no 
difference in cytokine profile was found between those patients with a favourable and 
those with an unfavourable clinical course.   
 
The strong presence of Th1 cytokines as well as TNFα in the sarcoidosis patients in 
this study supports the theory that a strong Th1 presence in conjunction with TNFα 
may induce fibrosis, as most of these cases showed signs of at least focal fibrosis.  
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8.3 Pulmonary Tuberculosis 
The tissue sections of two of the patients contained granulomas staining positive for 
only for TNFα and IFNγ and negative for IL-4 mRNA. According to the dogma270, 
these patients are considered to be launching an appropriate Th1 response271,272.  In 
three of the patients the sections contained some granulomas staining positive for only 
TNFα and IFNγ and other granulomas staining positive for all three cytokine mRNAs.  
Accordingly these patients are regarded to have a  mixed, or Th0 response. The 
presence of both types of granulomas in one patient casts doubt on the precise 
distinction between Th1 and Th0 responses. It might be more suitable to assess 
individual granulomas and confine this classification to individual granulomas. 
  
Previously the presence of IL-4 in patients with TB has been has been regarded as an 
inappropriate immune response, indicative of a poor prognosis.  Based on this the 
patients with a Th0 pattern should be expected to have a poorer outcome than the 
patients with a Th1 cytokine pattern.  Despite this difference in cyokine patterns 
however, all five patients were successfully treated for TB and were disease free at last 
follow-up, which was at least two years post-surgery.  This implies a Th0 response may 
not be an indication of bad prognosis, but may be an important component of 
granuloma formation in tuberculosis. The possibility exists that it may have a function 
in the control of tissue damage.  
 
In the second group of patients, immunohistochemistry to determine the cytokine 
profile and mRNA ISH was performed on lung tissue sections of seven patients with 
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pulmonary tuberculosis.  All seven of the patients stained positive for IFNγ and TNFα 
protein as well as IL-12p40 mRNA. All patients had necrotic granulomas.  Despite a 
similar clinical and histological appearance, only four patients had granulomas staining 
positive for IL-4 protein, which is comparable to the results observed in the first group 
of patients where three of the five had granulomas positive for IL-4 mRNA.  It is 
apparent that two-thirds of the patients had granulomas positive for IL-4. This 
discrepancy in the cytokine profile was again not reflected in the clinical course of the 
patients. There was no difference in outcome between the IL-4 positive and IL-4 
negative patients. Unfortunately the patient numbers are very small and positive 
conclusions cannot be drawn from this observation.      
 
The patients with tuberculosis described in the second group can be divided into an IL-
4 positive and an IL-4 negative group. This is similar to the immune response described 
in the two extremes of leprosy, where tuberculoid leprosy, with a Th1 response is 
regarded as having an effective immune response and lepromatous leprosy with a Th2 
response being regarded as having an ineffective response. This is not reflected in the 
clinical follow-up of these patients. According to the available data these patients have 
been successfully treated for tuberculosis.    
 
The four patients who had granulomas positive for IL-4 also had a lower number of 
IFNγ and TNFα positive granulomas than patients who had no IL-4 positive 
granulomas.  This is in direct opposition to the result from the first group of patients, 
where the IL-4 positive patients had more IFNγ and TNFα positive granulomas than 
the IL-4 negative group. This phenomenon may serve as an indication that these 
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patients have less ability to launch an effective Th1 immune response. These 
granulomas were however always associated with IFNγ positivity in the same 
granulomas, as well as IL-12 mRNA positivity in most cases. Furthermore, none of 
these granulomas were necrotic. It is quite apparent that it is virtually impossible to fit 
the cytokine patterns in these patients into the existing dogma of Th1 versus Th2.  It 
has also been suggested in the literature that IL-4 knockout mice were more susceptible 
to M. tuberculosis, which suggests that IL-4 may have a protective role in 
tuberculosis273.   
 
There is a distinct difference in the overall picture between the first and the second 
group of patients, where in the first group IL-4 positive patients had more IFNγ and 
TNFα positive granulomas and less necrotic granulomas than the IL-4 negative group, 
while in the second group IL-4 positive patients had less IFNγ and TNFα positive 
granulomas and more necrotic granulomas than the IL-4 negative group. However, on 
an individual granuloma level, the cytokine profile is distinctly similar.  In both groups 
all IL-4 positive granulomas are also IFNγ positive and these granulomas tend to be 
non-necrotic, as most of the IL-4 positive granulomas are non-necrotic. On the other 
hand, most of the necrotic granulomas are TNFα positive and negative or weakly 
positive for IL-4 and IFNγ. 
 
Most adults with active tuberculosis have secondary disease due to reactivation of 
latent disease or re-infection. One of the burning questions in tuberculosis research 
concerns the nature of the initial event that triggers reactivation. The virtual model 
discussed earlier in the pleural tuberculosis section 245, postulates that a high production 
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of IL-4 by Th0 cells is associated with a shift from latency to active disease, while a 
high level of IFNγ is protective and prevents reactivation. If reactivation does occur, 
patients may or may not incur tissue damage as a consequence of the immune response. 
According to the virtual model, an increase in IFNγ beyond a lower limit that would 
control infection, exacerbates infection, and if the rate of IL-4 decay increases or the 
production of IL-10 decreases, greater damage will ensue.     
 
The predictions of this virtual model are supported by evidence in the literature as 
reviewed by Shelley Rhodes in 200274.  Several studies of mouse models suggest that 
IL-4 has a controlling effect on IFNγ and that this control may be at the level of 
dendritic cells. IFNγ appears to be crucial for protection against reactivation, but once 
this has occurred, IFNγ may be active in the immunopathology of tuberculosis.  
In comparing the current results with this virtual model, a similar picture emerges. A 
strong IFNγ response can be seen in smaller non-necrotic granulomas, while IL-4 is 
absent or weak. Larger granulomas still show an IFNγ presence, but IL-4 expression is 
now present or strongly positive.  In the necrotic granulomas TNFα is the predominant 
cytokine, with IL-4 and IFNγ either absent or weakly positive.    
 
In a study by Fuller et al 274 on Cynomolgus Macaques, it was found that there was 
abundant IFNγ and TNFα mRNA expression in both necrotic and non-necrotic 
granulomas, with no difference in expression between these two groups.  No IL-4 
mRNA expression was found.  This finding illustrate the importance of IFNγ and 
TNFα presence in driving granuloma formation.   
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It has been suggested in the literature that the effect of TNFα may be influenced by the 
cytokine environment in which TNFα is produced.275,276.  On the background of a Th1 
response TNFα may be advantageous to the patient and augment control of the 
organism.  However, when TNFα is produced on a background of in a site with a Th0 
or Th2 response it may cause significant damage to the tissue275,276.  In contrast to this 
dogma, all the patients described here had signs of major disease pathology. The 
patients produced TNFα against both aTh1 and a Th0 background.  When assessing 
individual granulomas, the circumstances may be more intricate. While TNFα is 
positive in most necrotic granulomas, IL-4 and IFNγ are generally negative or weakly 
positive. There appears to be an inverse relationship between IL-4 and IFNγ on the one 
side and TNFα on the other. In looking at the evolution of granulomas, the earliest 
granulomas appear to be predominantly Th1, with a very small amount of IL-4. Once 
the granuloma grows larger, an increase in IL-4 and TNFα is noted, while there is a 
decrease in IFNγ. In the necrotic granuloma however, very little IL-4 and IFNγ is 
present, whereas a strong TNFα presence can be noted.  
 
All necrotic granulomas from all the patients stained positive for TNFα.  Although this 
is not sufficient evidence to prove that there is a direct relationship between TNFα and 
necrosis, it seems possible that TNFα may be involved in the development of 
necrosis277.  The caseous necrosis is likely to be due to apoptosis of infected 
macrophages and activated T cells in the granuloma278 and TNFα is known to induce 
apoptosis279.  IL-4 positive patients had more necrotic granulomas than IL-4 negative 
patients and most of the non-necrotic granulomas were TNFα negative.  This suggests 
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that  IL-4 positive patients are more inclined to develop necrosis due to induction by 
TNFα than IL-4 negative patients. The relationship is however unclear, as most of the 
necrotic granulomas were IL-4 negative.   
 
 
8.3.1 In summary 
The presence of IL-4 may not be an indicator of poor prognosis in pulmonary 
tuberculosis patients but rather may be an integral feature of tuberculous granuloma 
formation with a role in controlling tissue damage.  
 
There is a distinct difference in the overall picture between the first and the second 
group of patients. However, on an individual granuloma level, the cytokine profile is 
distinctly similar.  In both groups all IL-4 positive granulomas are also IFNγ positive 
and these granulomas tend to be non-necrotic, as most of the IL-4 positive granulomas 
are non-necrotic. Conversely, most necrotic granulomas are TNFα positive and 
negative or weakly positive for IL-4 and IFNγ. These results support the virtual model 
described by Wigginton.  
 
All necrotic granulomas from all the patients stained positive for TNFα.  Although we 
cannot extrapolate from these findings to a causative relationship between TNFα and 
necrosis, it appears likely that TNFα may be involved in necrosis development.  The 
caseous necrosis appears to be a consequence of apoptosis of infected macrophages and 
activated T cells within the granuloma and TNFα is a known inducer of apoptosis.   
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IL-4 positive patients tended to have more necrotic granulomas than IL-4 negative 
patients and almost all non-necrotic granulomas were TNFα negative.  This may imply 
that in IL-4 positive patients it is more likely that TNFα will induce necrosis in the 
granuloma that in those patients who are IL-4 negative. However, most of the necrotic 
granulomas were IL-4 negative.   
 
An essential role for IL-12 and IFNγ in protective immunity to mycobacterial infection 
has been described.  Individuals who are susceptible to disseminated mycobacterial 
infection have been shown to have defects in their receptors for IL-12 or IFNγ.  Also, in 
patients with tuberculosis, decreased IFNγ production by peripheral blood mononuclear 
leucocytes has been shown to correlate with decreased IL-12 receptor subunits B1 and 
B2.  In the tuberculous granulomas studied here, 91% of the granulomas gave the same 
pattern of cytokine expression for IL-12p40 and IFNγ being either positive or negative 
for both cytokines, as expected from the literature.   
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8.4 A Comparison between Pleural Tuberculosis, 
Pulmonary Tuberculosis and Sarcoidosis 
 
A summarised schematic representation of the findings in this study can be seen in fig. 
37 at the end of this chapter. The formation of granulomas at the site of antigen 
presentation in both tuberculosis and sarcoidosis is an essential component of host 
immunity for controlling infection. This process is dependant on the activation of T 
lymphocytes, especially IFNγ secreting CD4+ cells. Granuloma formation however, is 
a complex process that not only requires the activation of lymphocytes, but also their 
recruitment with monocytes to the site of infection and arrangement into a granuloma.  
 
In tuberculosis the presence of macrophages and lymphocytes facilitate the activation 
of bactericidal mechanisms in infected macrophages by T-cell derived cytokines. Some 
bacteria unfortunately survive within the macrophages and persistent antigenic 
stimulation leads to chronic granuloma formation. These granulomas contain the 
infection and prevent dissemination to other organs, but they are also responsible for 
pulmonary immunopathology. In sarcoidosis similar events occur when the unknown 
antigen cannot be eliminated.  
 
TNF plays an important role in the regulation of granuloma formation. TNF is a highly 
potent cytokine with a wide range of activities. It is essential for the early induction of 
chemokines and the subsequent leukocyte recruitment. It is also essential for the 
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differentiation of macrophages into epithelioid cells and the maintenance of 
granulomas.  
 
It is apparent that granulomas are essential for the elimination or containment of 
intracellular antigens. The continuous propagation of granulomas is however, 
detrimental to the host as immunopathology ensues. In tuberculosis this manifests as 
caseous necrosis, with destruction of tissue and subsequent fibrosis, whereas in 
sarcoidosis fibrosis develops directly, without the intervention of necrosis.   
 
In the pleural tuberculosis cases, non-necrotic granulomas tend to have lower numbers 
of IFNγ positive cells in the presence of low numbers of IL-4 positive cells, while the 
converse is true for necrotic granulomas. This pattern is in keeping with the virtual 
model described by Wigginton. An increase in IFNγ correlates with an increase in 
necrosis, while a decrease of IFNγ positive cells is seen in non-necrotic granulomas.  
Although the association between the various cytokines in the HIV negative 
granulomas with necrosis is rarely statistically significant, there is a very clear 
association between IFNγ and TNFα, with 52% of all granulomas in this group 
containing high numbers of positive cells for both these cytokines.    
 
High numbers of IL-4 cells are also present in granulomas with a high number of IFN 
positive cells, but there is an equal distribution between necrotic and non-necrotic 
granulomas. This suggests that although IL-4 may have a regulatory effect on the 
possible detrimental impact of high levels of IFNγ at this stage of disease according to 
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the virtual model by Wigginton, this definitely is not the only, or even the most 
important controlling factor.   
 
In the pleural tuberculosis cases in the current study, a definite increase in the number 
of TNFα mRNA positive cells was observed in necrotic granulomas. It is apparent that 
there is an association between TNFα and necrosis in pleural tuberculous granulomas. 
This association may possibly be ascribed to the increased apoptotic activity of TNFα.   
 
As has been described earlier in the discussion, in pulmonary tuberculosis there appears 
to be an inverse relationship between IL-4 and IFNγ on the one side and TNFα on the 
other. In looking at the evolution of granulomas, the earliest granulomas appear to be 
predominantly IFNγ positive, with a very small amount of IL-4. Once the granuloma 
expands, an increase in IL-4 and TNFα is noted, while there is a decrease in IFNγ. In 
the necrotic granuloma however, very little IL-4 and IFNγ is present, whereas a strong 
TNFα presence can be noted.   
 
All necrotic granulomas from all the patients were positive for TNFα and it appears 
likely that TNFα may be involved in necrosis development, due to apoptosis of 
macrophages and T cells278. It also appears that TNFα is more likely to induce necrosis 
in IL-4 positive patients than in IL-4 negative patients, even though most of the 
necrotic granulomas were IL-4 negative. Supportive evidence for this phenomenon is 
also found in the fact that necrosis is not present in the absence of IL-4, as observed in 
sarcoidosis. It is therefore clear that TNFα, most probably through inducing apoptosis, 
may have a significant effect on the course of tuberculosis.   
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Although there are differences between the cytokine profile in pleural and pulmonary 
tuberculosis, the common thread is that of a high TNF presence in necrotic granulomas, 
associated with an IL-4 presence. The relationship between IFNγ, IL-4 and necrosis as 
described by Wigginton, is not as readily apparent in the current study.  In pleural 
tuberculosis this trend is evident, but in pulmonary tuberculosis the changes are more 
subtle, but still present.  
 
In sarcoidosis on the other hand, there is convincing evidence that overexpression of 
TNFα is associated with persistence of inflammation and the development of fibrotic 
lung disease260,261 as well as with corticosteroid resistant sarcoidosis262. From the 
literature it is clear that a raised TNFα is a strong indicator of poor prognosis in 
sarcoidosis.  
 
In contrast to the relationship between TNFα and necrosis in tuberculosis the 
relationship in sarcoidosis is between TNFα and fibrosis.  The common denominator in 
both is however, quite clearly TNFα. It is clear that TNF is needed for granuloma 
formation and the consequent removal or containment of the causal antigen. However, 
a continuous presence of TNFα results in the development of immunopathology with 
subsequent permanent damage to the lungs.         
 
It appears therefore, that the dogma of a pure Th1 response being beneficial is not 
entirely true in either tuberculosis or sarcoidosis. It is possible that the effect of Th1 
cytokines depends entirely on the stage of disease. An early pure Th1 response may be 
beneficial to the patient if effectively clearing the granuloma inducing antigen. At this 
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stage a Th2 presence will be harmful to the patients as clearing of the antigen will not 
be as effective. In chronic disease where failure to remove the antigen results in 
progression of granulomas with subsequent necrosis and/or fibrosis, a pro-
inflammatory Th1 response may be detrimental to the patient and minimising of this 
detrimental effect is needed. It therefore appears that a fine balance between excessive 
pro-inflammatory action (Th1) and a Th1/Th2 shift are essential for the best possible 
prognosis in both these granulomatous diseases.
   
Figure 37: SUMMARISED SCHEMATIC REPRESENTATION OF THE FINDINGS IN THIS STUDY
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9. Conclusions and Future Research 
My hypothesis proposed:  “Cytokine profiles determine clinical and histopathological 
phenotypes of disease. This thesis tests the hypothesis that this will be reflected by 
cytokine expression profiles in granulomas in different forms of tuberculosis and in 
sarcoidosis.” To investigate this, in situ hybridisation assessment of the cytokine 
profile of each of these diseases as well as a comparison between the various profiles 
was performed, with the following conclusions:  
 
In both HIV sero-negative and sero-positive patients with pleural tuberculosis, a Th0 
response, characterised by the presence of both Th1 and Th2 cytokines, was noted, 
while necrotic granulomas were more evident in HIV positive than HIV negative 
patients.  There was a clear association between TNFα and necrosis in tuberculous 
granulomas that may possibly be ascribed to the increased apoptotic activity of TNFα.  
An increase in IFNγ correlated with an increase in necrosis, supporting the theory that 
high IFNγ levels later in disease is detrimental. This effect may be enhanced by the 
presence of high numbers of TNFα positive cells.  
 
The strong positive correlation between high numbers of TNFα positive cells and HIV 
positivity supports the fact that TNF regulates HIV transcription and that higher TNF 
levels are expected in HIV positive patients. An increase in both Th1 and Th2 cytokine 
mRNA in HIV positive patients supports the theory that an overproduction of cytokines 
may be a mechanism to compensate for the failure of another immune effector 
mechanism.   
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In sarcoidosis strong evidence of a Th1 response and no evidence of a Th2 response 
was found. No difference in cytokine profile was found between those patients with a 
favourable and those with an unfavourable clinical course, neither between patients 
with severe diffuse fibrosis and those without.  The strong presence of Th1 cytokines as 
well as TNFα supports the theory that a strong Th1 presence in conjunction with TNFα 
may induce fibrosis, as most of these cases showed signs of at least focal fibrosis.  
 
The results in pulmonary tuberculosis patients also support the virtual model described 
by Wigginton. The presence of IL-4 may not be an indicator of poor prognosis in 
pulmonary tuberculosis patients but rather may be an integral feature of tuberculous 
granuloma formation with a role in controlling tissue damage. It again appears likely 
that TNFα may be involved in necrosis development.  The caseous necrosis appears to 
be a consequence of apoptosis of infected macrophages and activated T cells within the 
granuloma and TNFα is a known inducer of apoptosis.   
 
Numerous aspects are involved in granulomatous inflammation, of which the T helper 
response forms only a component. The earlier dogma of good (Th1) versus evil (Th2), 
stating that a pure Th1 response is beneficial, and that a Th2 response is detrimental, is 
an oversimplification of a very complex process. When investigating the contribution 
of the Th response to the disease process, it is clear that the effect of a cytokine 
depends at least partially on the stage of disease.  
 
The balance between the various cytokines and also the levels of these cytokines 
contribute to their role in resolution or disease progression.  An early pure Th1 
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response may be beneficial to the patient if effectively clearing the granuloma-inducing 
antigen. At this stage, a Th2 presence will be harmful to the patients as clearing of the 
antigen will not be as effective. In chronic disease where failure to remove the antigen 
results in progression of granulomas with subsequent necrosis and/or fibrosis, a pro-
inflammatory Th1 response may be detrimental to the patient and minimising of this 
detrimental effect is needed. A strong presence of the various cytokines may also be 
detrimental to the patient, while lower levels will be beneficial.  Numerous other 
cytokines are involved in the process and other representatives of the Th1 and Th2 
subsets also exist. An investigation into these cytokines will fill out some of the 
numerous blank spaces in this equation.     
 
The discrepancy between the presence of cytokines in circulation and at the site of 
disease is also of interest (Fig 35). This is best demonstrated by the high numbers of 
IFNγ mRNA positive cells in necrotising granulomas in pulmonary tuberculosis, while 
a virtual absence is noted in the peripheral blood.  Possible explanations for this 
occurrence include a selective anergy, and a redistribution of cells with preferential 
treatment of the disease site. It is also possible that the presence of mRNA does not 
reflect the production, secretion and/or effectiveness of a cytokine. An investigation 
into the distribution and quantities of cytokines in various compartments, including the 
site of the disease, will contribute greatly to our understanding if the inflammatory 
response.  
 
Another area of interest is the interaction between the causative organism and the 
granuloma. Work in this area by Fenhalls et al and has already resulted in 2 
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publications280,281.  Further investigations into the various factors of virulence, latency 
and other factors, by mRNA will provide invaluable information into the behaviour of 
both the host and the organism at the site of disease and in context of the cellular 
components.          
 
Possible areas of future research, some of which are already in progress include: 
• Investigation of additional cytokines and chemokines involved in granulomatous 
disease.  
• Investigation of other sites of disease in tuberculosis and a comparison with the 
sites already studied. 
• Investigation of the numerous receptors for organisms, cytokines and chemokines 
involved in tuberculosis and other granulomatous diseases.  
• Expansion of the study of HIV sero-negative and sero-positive tuberculosis 
• An investigation into the distribution and quantities of cytokines in various 
compartments, including the site of the disease. 
• Further investigations into the expression by Mycobacterium tuberculosis of factors 
of virulence, latency and other factors and its relationship to cytokine expression by 
the host. 
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